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Throughout history, ancient tribes and civilizations have displayed a clear understanding 
of the essential role the kidney plays in sustaining life. For instance, the Aborigines of 
Australia believe that the kidney houses the kurrunpa or spirit, and it is reported that they 
wore a piece of kidney as an amulet around the neck to protect themselves against 
harmful spells [1]. In ancient Egypt, the heart and kidney were the only organs not removed 
from the body during mummification, indicating that they were considered important, 
although it is still unclear what mythical significance was bestowed upon the kidney [2]. 
Moreover, in the Bible (i.e. the Christian Old Testament), the kidney is mentioned over 30 
times, often in conjunction with the heart, whereas the brain is never mentioned [1,3]. Of 
note, in the scriptures the kidney is regarded as the seat of conscience, emotions and 
wisdom [3]. And in the Talmud, the presence of two kidneys is explained as there being 
one to give good and the other bad advice [3]. Moreover, in the teachings from Saint 
Ephrem the Syrian (ca. 306 to 373 AD) it is stated that: “In the kidneys are seated reasonings, 
and there dwells in them the faculty of discernment; they distinguish truth from falsehood, 
and judge what is base and what is noble”. Eloquently summarizing the current 
understanding of normal renal functioning.    
Uremia
The main role of the kidney is recycling nutrients and removing endogenous and 
exogenous waste products, and for this seemingly easy task the kidney is equipped with 
an ingenious system of filters and smart plumbing, the so-called nephrons. When the 
kidneys fail, patients will develop uremia – a term generally used to describe the illness 
accompanying kidney failure – due to the accumulation of organic waste products 
normally cleared by the kidney [4]. Approximately 10% of the adult population in the 
developed countries suffers from chronic kidney disease (CKD) [5], and in half of these 
patients the diagnosis of CKD is based on the presence of a reduced kidney function 
defined by a reduction in estimated glomerular filtration rate (eGFR). Although features of 
uremic illness are most pronounced in patients with end-stage renal disease (ESRD; Stage 
5 CKD: eGFR < 15 ml/min/1.73 m2), symptoms associated with uremia may be present to a 
lesser extent in people with a GFR that is barely below 50% of the normal rate, which 
ranges between 100 – 120 ml/min/1.73 m2, at 30 years of age [4]. Uremic illness is a complex 
disorder illustrated by the diverse clinical signs and symptoms associated with the disease, 
such as fatigue, cognitive impairment, insulin resistance, bone disease and anemia [6-11]. 
Thus, it is not surprising that the quality of life is very low in CKD patients. Due to a lack of 
donor kidneys, uremia treatment is currently dominated by dialysis. The concept of dialysis 
was first devised by the Scottish chemist Thomas Graham who, in 1861, observed that by 
using vegetable parchment as a semipermeable membrane, colloid and crystalloid 
substances contained in fluids could be separated by diffusion [12]. In 1945, Kolff reported 
for the first time the successful implementation of hemodialysis to treat acute renal failure 
using the “rotating drum kidney” (developed in Kampen, the Netherlands) with cellophane 
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β2-microglobulin levels were associated with both all-cause mortality and infectious 
mortality in the studied patient population [26,27]. The third, and final group, are the 
protein-bound solutes, compounds in this class are very difficult to eliminate using 
standard dialysis modalities as well as high-flux dialysis [23,28]. Clearance of these 
compounds is not limited due to their size but because they bind to albumin or other 
plasma proteins, and as a result only the free, unbound fraction contributes to the gradient 
driving solutes across the dialysis membrane [4]. Indoxyl sulfate is probably the most 
studied solute belonging to this class, and recently also p-cresyl sulfate has gained much 
attention from the scientific community [29,30]. Of note, indoxyl sulfate is one of the 
solutes that has been almost exclusively studied in the context of uremic illness and while 
in 1990 no publication was devoted to this compound, since 2011 the number of papers 
exceeds 60 per year [29]. Indoxyl sulfate is a small organic aromatic polycyclic anion 
(average molecular weight: 213.21, chemical formula: C8H7NO4S, [31]) derived from dietary 
tryptophan that is mainly studied in conjunction with CKD-associated cardiovascular 
disease, and it is reported that this uremic solute can induce vascular calcification and 
correlates with coronary artery disease and mortality [32-34]. Furthermore, it has been 
shown that indoxyl sulfate can induce free radical formation in several cell types [35,36], 
disrupt adherens junctions of endothelial cells [37], promote smooth muscle cell 
proliferation [38], is toxic for renal tubular cells as well as osteoblasts [39,40], and stimulates 
renal and cardiac fibrosis [41,42]. Congruous effects have been reported for p-cresyl sulfate 
and it known that this solute is pro-inflammatory and is a predictor of mortality in dialysis 
patients [43-46]. Moreover, both indoxyl sulfate and  p-cresyl sulfate are associated with 
CKD progression [47].
Due to technical advances in analytical approaches the bewildering list of solutes 
implicated in uremic illness will only lengthen, yet novel therapeutics resulting in an 
improved removal of uremic retention solutes are lacking. Hopefully, better understanding 
of both the formation and the physiological clearance of these compounds will reveal 
new avenues to achieve a more effective therapy.       
Metabolism in CKD patients
A hallmark of uremic illness are changes in drug disposition, partially caused by a reduction 
in glomerular filtration and active tubular secretion of xenobiotics, as well as due to a 
direct effect of uremic solutes on the expression level and activity of drug metabolism 
enzymes [48,49]. During the process of drug metabolism, three phases can be 
distinguished: Phase I reactions, mainly occurring in the liver, are oxidation reactions 
mediated by cytochrome P450 enzymes. Phase II reactions are conjugation reactions 
encompassing methylation involving methyltransferase, acetylation by N-acetyltransfer-
ases, sulfation mediated by sulfotransferases and glucuronidation via UDP-glucuronosyl-
transferases, these reactions primarily take place in the liver, kidney and gastro-intestinal 
tract. Finally, Phase III is the active efflux of xenobiotics by a multitude of transport proteins 
as dialysis membrane [13], and in 1960, Scribner first described the use of hemodialysis for 
the treatment of ESRD [14,15]. Although hemodialysis treatment has been highly effective 
in relieving the symptoms of uremic illness, it has become increasingly clear that patients 
undergoing chronic dialysis treatment – either hemodialysis or peritoneal dialysis – have a 
markedly reduced survival attributable to accelerated cardiovascular disease and to 
progressive renal disease [16]. Due to the view that uremia is caused by small, dialyzable 
solutes, modifications of dialysis membranes, frequency of dialysis, and duration of dialysis 
treatments have been extensively studied. Although progress has been made regarding 
dialysis adequacy, there has been little impact on the renal and cardiovascular comorbities 
associated with dialysis treatment, often, incorrectly, termed “renal replacement “ therapy 
[17]. Regarding uremic illness, Homer Smith wrote in 1951 “Death, if not caused by 
intercurrent infection or other extrarenal disturbance, occurs from severe imbalance in the 
composition of body fluids (edema, acidosis, hyponatremia, hyperkalemia, hyperphos-
phatemia, etc.) complicated by anemia, circulatory disturbances, and other factors of 
unknown nature” [18]. Several years later, Kolff wrote “What uremic toxin is and what it 
really does is something which still worries a number of scientists … For a physician 
engaged in dialysis treatment such as is the writer, it is wise to assume that uremia is 
caused by an aggregate of many products that are normally excreted but which are now 
being retained, and it behooves him to remove them all” [19].     
Uremic solutes 
For a long time it was unclear whether the uremic syndrome and the associated alterations 
in biochemical and physiological functions could be attributed to one or more uremic 
retention solutes [20]. In 1999, the European Uremic Toxin Workgroup (EUTox; www.
uremic-toxins.org) was launched in order to find biomarkers for different stages of CKD as 
well as identifying solutes that accumulate during renal failure. At present, over 150 
compounds have been found at higher concentrations in the plasma of patients with 
uremia as compared to healthy individuals [21,22]. These uremic retention solutes 
compromise a heterogeneous multiplicity of compounds, and although many of these 
solutes can evoke symptoms seen in CKD patients, identifying responsible retention 
solutes remains problematic [4]. Currently, uremic solutes are divided into three classes 
based on the chemical properties that influence the capacity to clear these solutes during 
dialysis [23]. The first group consists of small water-soluble compounds (≤500 Da) with 
limited toxicity that are easily cleared by standard dialysis treatment. Urea, one of the 
earliest identified uremic solutes, is archetypical for this class and although dialysis is still 
adjusted to eliminate approximately two thirds of the total-body urea content [4], it has 
been long since recognized that urea contributes little to the pathophysiology of CKD 
[24]. The second group are the middle molecules (>500 Da) for which filtration during 
conventional dialysis is limited due to their size. β2-microglobulin is a prototype for this 
class of uremic solutes [25], and in an analysis from the Hemodialysis (HEMO) study, serum 
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depicted in Figure 2 [58-61]. However, the importance of these systems in uremic toxin 
removal is for a part still unknown. 
Already in the 1960’s it was demonstrated that serum isolated from uremic rats or patients 
could hamper accumulation of the prototypical organic anion substrate, p-aminohippurate 
(PAH), in rat renal cortical slices [62,63], implicating the classical organic anion transport 
system in the renal elimination of uremic toxins. Since then, OAT1 (SLC22A6), OAT2 
(SLC22A7), OAT3 (SLC22A8), OAT4 (SLC22A11) and URAT1 (SLC22A12) all have been shown to 
contribute, at least to some degree, to the renal handling of uremic solutes [39,64-71]. Up 
to now, OAT1 and OAT3 have been studied most extensively with regard to the transport 
of uremic solutes, and a multitude of uremic toxins have been shown to be either a 
substrate or inhibitor for these OATs, including 3-carboxy-4-methyl-5-propyl-2-furanpro-
panoic acid (CMPF), hippuric acid, indole-3-acetic acid, indoxyl sulfate and kynurenic acid 
[50], which will be described in more detail below. Next to drugs, uremic solutes are also 
subjected to enzymatic metabolism, and the most straight-forward example of uremic 
solute formation can be illustrated by the process of p-cresol metabolism. As depicted in 
Figure 1, p-cresol is formed by colonic bacteria from dietary tyrosine and this parent 
compound is either conjugated to sulfate or glucuronic acid giving rise to circulating 
p-cresyl sulfate (~95% of total p-cresol) or p-cresyl glucoronide (~5% of total p-cresol), 
respectively [51]. In an analogous fashion, tryptophan can give rise to a multitude of 
indolic uremic solutes, including indoxyl sulfate and indoxyl glucuronide [52,53]. Of note, 
one could argue that tryptophan is the kingpin of uremic toxin precursors, since this 
amino acid is also metabolized via the kynurenine pathway – responsible for ~99% of 
non-protein tryptophan metabolism – resulting in the formation of, amongst others, 
melatonin, kynurenic acid and quinolinic acid [54,55]. All compounds with distinct 
neuroactive properties as well as major contributors to immune responses [55]. For more 
information regarding the complex pathways of tryptophan metabolism and the 
biological responses elicited by endogenous kynurenines the interested reader is referred 
to the review by Stone and Darlington [55]. Taken together, there is a clear link between 
enzyme activity and uremic solutes, yet the repercussion of elevated metabolite levels on 
the functionality of drug metabolism enzymes is still unknown.      
Renal handling of uremic solutes
For a long time, renal function has been solely assessed by means of serum creatinine in 
order to calculate the eGFR, disregarding the important role of active tubular secretion in 
the clearance of waste products. Already in 1959, Homer Smith put forward that toxins 
might be secreted rather than filtered, this suggestion arose from his observation that 
prochordates living in osmotic equilibrium with their salt water habitat did not have 
glomeruli and disposed of wastes via tubules which drained into the coelomic cavity. He 
pointed out that though glomeruli evolved when life moved into fresh water in the 
Cambrian era 500 million years ago, aglomerular species of fish have persisted throughout 
evolution up to the present [56]. Micropuncture studies in glomerular teleosts have 
demonstrated that the importance of tubular secretion is not limited to aglomerular fish 
[57]. The renal proximal tubules are equipped with a range of transporters, consisting of 
multiple carriers with overlapping substrate specificities that cooperate in basolateral 
uptake and luminal excretion. We can distinguish the organic anion and the organic 
cation systems, each comprising transporters belonging to the organic cation/anion/
zwitterion solute carrier family (SLC; e.g. Organic Cation Transporter 2 (OCT2; SLC22A2), 
Organic Anion Transporter 1 and 3 (OAT1/3; SLC22A6 and SLC22A8), Organic Anion 
Transporting Polypeptide 4C1 (OATP4C1; SLCO4C1), the Multidrug and Toxin Extrusion 
proteins (MATEs; SLC47A1/2)) and the ATP-binding cassette transporter family (P-
glycoprotein (P-gp also termed MDR1; ABCB1) Multidrug Resistance Protein 2 and 4 
(MRP2/4; ABCC2/4), and Breast Cancer Resistance Protein (Bcrp; ABCG2)), as schematically 
Figure 1  Colonic formation of p-cresol and its metabolites. 
The dietary amino acid tyrosine is fermented by the intestinal flora resulting in the formation of 
p-cresol. Subsequently, this parent compound is metabolized into either p-cresyl sulfate or p-cresyl 
glucuronide which enter the systemic circulation. Chemical structures were obtained from the 
Human Metabolome Database (www.hmdb.ca). PAP, 3’-phosphoadenosine-5’-phosphate; PAPS, 
3’-phosphoadenosine-5’-phosphosulfate; SULT, sulfotransferase; UDP, Uridine 5’-diphosphate; 
UDPGA, UDP-glucuronic acid; UGT, UDP-glucuronosyltransferase
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spermidine, the polyamine breakdown product acrolein, and the guanidino compounds 
guanidine and methylguanidine inhibited substrate-specific transport by OCT2 [78,79]. In 
addition, two single nucleotide polymorphisms (SNPs) of OCT2, e.g. rs3127573 and 
rs316009, were associated with an increased risk for ESRD [80]. Thus, progress has been 
made in identifying the transport systems involved in the basolateral uptake of uremic 
toxins, yet, transport of uremic solutes over the apical membrane into urine remains to be 
elucidated. 
Various transporters expressed at the apical membrane of renal proximal tubule cells are 
suspected to play a role in the urinary efflux of uremic solutes (Figure 2). The multidrug 
and toxic compound extrusion (MATE) family of transporters is the latest addition to the 
pack of multidrug transporter families [81]. MATE1 and its isoforms (MATE2 and MATE2-K), 
are encoded by the SLC47A gene family and they function as secondary-active antiporters 
[58,82]. MATE1 is expressed throughout the body, but predominantly in the liver and 
kidney, whereas MATE2-K is exclusively located in renal proximal tubules [83]. Up to now, 
only a limited number of MATE substrates have been identified and their contribution to 
uremic solute clearance remains unknown. Another important congregate of efflux 
transporters is the family of ATP-binding cassette (ABC) transporters, a group of 
transmembrane proteins – including P-gp, MRP2, MRP4 and BCRP – that are involved in 
the urinary excretion of a multitude of endogenous compounds and drugs [84]. P-gp is 
the best characterized transporter, originally discovered in drug-resistant tumor cells, but 
now recognized as crucial component of tissues with a barrier function [85]. The efflux 
pump has a preference for uncharged and cationic compounds and was found to be 
differentially regulated in CKD rats [49], but evidence of its involvement in renal uremic 
toxin excretion are lacking. MRPs are highly promiscuous transporters and a multitude of 
substrates have been identified [59]. In addition, MRP2 expression was demonstrated to 
be elevated  in uremic conditions   suggesting a protective function for this transporter 
[49,86]. More importantly, both MRP4 and BCRP are known to transport the uremic solute 
urate [87,88], making them likely candidates involved in the tubular excretion of uremic 
solutes. 
AIMS OF THE THESIS
A key feature of CKD is the retention and subsequent accumulation of a great array of 
metabolites that are normally excreted by the healthy kidney. The chemical diversity of 
these uremic retention solutes likely contributes to the complex pathophysiology that 
defines uremic illness. In this thesis we strived to lift the uremic veil in order to gain more 
insight on the multiplicity of uremic retention solutes – by using and improving both 
untargeted and targeted analytical techniques – as well as the possible detrimental 
impact of these solutes on xenobiotic elimination pathways in renal proximal tubule cells. 
[64,72-74]. Another transporter suspected to aid in the renal clearance of uremic solutes is 
member 4C1 of the organic anion transporting polypeptide family (OATP4C1), classified 
within the SLCO solute carrier superfamily family. Members of the OATP/SLCO family are 
expressed in various organs and their substrates also range in a broad spectrum from 
endogenous compounds to xenobiotics [75,76]. Interestingly, OATP4C1 is the only OATP/
SLCO member expressed in the human kidney, where it is found at the basolateral side of 
proximal tubules [76]. Recently, Toyohara et al. demonstrated that OATP4C1 facilitates the 
removal of several uremic solutes, including guanidino succinate and asymmetric dimeth-
ylarginine [60]. Moreover, they reported that the promoter region of OATP4C1 contains 
xenobiotic responsive element motifs and that statins, via interplay with the aryl 
hydrocarbon receptor, can be used to increase the expression and thus activity of the 
uptake transporter [60]. This suggests that it might be feasible to directly influence renal 
handling of uremic solutes by medication. Next to the organic anion system, the human 
kidney is also equipped with transporters to handle organic cations, of which OCT2 
(SLC22A2) is the predominant transporter present in proximal tubules [77]. Recently, it was 
reported that the polyamine uremic toxins, cadaverine, putrescine, spermine and 
Figure 2  Renal tubular transport systems. 
Schematic presentation of transporters present in the renal proximal tubule and potentially relevant 
for tubular uremic toxin handling. See text for details. 
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In Chapter 2 we describe the successful use of 1H-nuclear magnetic resonance 
spectroscopy, an untargeted metabolomic approach, following different deproteinization 
techniques to detect both known and previously unidentified uremic retention solutes 
(e.g. dimethyl sulfone and 2-hydroxyisobutyric acid). Moreover, we tested the nephrotoxic 
potential of these two newly detected solutes using human conditionally immortalized 
renal proximal tubule epithelial cells (ciPTEC). 
Chapter 3 details the interaction between several uremic solutes, including indoxyl 
sulfate and kynurenic acid, and the renal efflux pumps BCRP and MRP4. These pumps 
were selected for scrutinization since they were known to transport urate, as described 
above, and because of the wide availability of models for these transporters in our lab. In 
this chapter, we demonstrated that uremic solutes can inhibit substrate-specific transport 
mediated by both transporters at clinically relevant concentrations, indicating that uremic 
solutes can augment retention of potential toxic metabolites in CKD patients.
The transporters involved in the renal handling of  p-cresyl sulfate and p-cresyl glucuronide 
are, as of yet, unknown. Moreover, due to a recent paradigm shift [30], both solutes have 
gained much attention as key uremic solutes. Therefore, Chapter 4 investigates the 
interaction between the two p-cresol metabolites and the ABC-transporters BCRP and 
MRP4. In addition, this chapter delineates the negative impact of both uremic solutes on 
ciPTEC, illustrating the nephrotoxic potential of both compounds.
It is still a debate whether uremic retention solutes are simply a result of CKD or if these 
compounds can also be a causative agent of uremia. Using a murine model of 
hyperuricemia, Chapter 5 shows that elevated levels of uric acid in lieu of kidney damage 
instigate accumulation of the tryptophan metabolites kynurenine and kynurenic acid. In 
addition, we identified the transporters involved in the renal clearance of kynurenic acid.  
A hallmark of CKD are the alterations in drug disposition and kinetics observed in dialysis 
patients. Chapter 6 describes the effect of a myriad of uremic retention solutes on a 
specific class of phase II drug metabolism enzymes present in renal tubule cells, namely 
UGTs, in addition to the mitochondria. Moreover, we studied the potential contribution of 
the proximal tubule in the formation of uremic solutes.  
Chapter 7 provides a general discussion of the findings described in this thesis, placing 
them in the framework of our current understanding of uremic illness and details the 
future perspectives. The results detailed in this thesis are summarized in Chapter 8. 
2
Optimized metabolomic approach 
to identify uremic solutes in plasma of stage 3-4 
chronic kidney disease patients  
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INTRODUCTION
The kidneys play an important role in maintaining total body homeostasis by facilitating the 
urinary secretion of both endogenous and exogenous waste products. Chronic kidney 
disease (CKD) affects approximately 10% of the adult population in developed countries. 
In half of these patients the diagnosis of CKD is based on the presence of a reduced kidney 
function (chronic renal failure; CRF). In CKD patients adequate renal clearance is compromised 
resulting in the accumulation of a plethora of uremic solutes [5]. Nowadays, over 140 uremic 
toxins have been reported, divided into three distinct classes based on their physico-chemical 
properties. It is well documented that uremic toxins accumulate in dialysis patients and 
several biomarkers of CKD have been identified [21,22,89,90]; yet, less is known about the 
retention of possible toxic solutes in other patients with a compromised kidney function. 
Herget-Rosenthal et al., reported that several uremic toxins are retained during acute kidney 
injury including β2-microglobulin, hippuric acid and 3-carboxyl-4-methyl-5-propyl-2-furan-
propionic acid [91]. Furthermore, our group previously demonstrated that plasma levels of 
hippuric acid, indole-3-acetic acid, indoxyl sulphate and kynurenic acid are elevated in 
non-dialysis CRF patients compared with healthy controls [89]. 
Although the retention of uremic toxins in dialysis patients is widely studied, there is a 
large variation in blood levels reported for uremic toxins. These discrepancies can be due 
to differences in the study population with respect to diet, colonic microbial metabolism 
and endogenous metabolism [92,93]. Moreover, precise determination of uremic toxin 
concentrations is cumbersome and dependent on the physico-chemical characteristics 
of these solutes, such as protein-binding, which can result in insufficient extraction of 
compounds from body fluids, leading to an underestimation of the true values [30,51]. In 
addition, plasma is a complex mixture of proteins, molecules and ions that together can 
undergo a myriad of molecular interactions [94]. During 1H-nuclear magnetic resonance 
(NMR) spectroscopy, the abundance of proteins in complete plasma results in broad 
overlapping signals that obscure resonances of low-molecular-weight metabolites and 
quantification of these compounds is hampered due to T2-relaxation processes [94]. 
Therefore, deproteinization is required when studying small organic molecules in plasma, 
and it is required to optimize analytical techniques and/or sample preparation methods to 
obtain a reliable overview of uremic toxin levels in CKD patients.
In metabolomics studies, generally two analytical approaches are used: mass spectrometry- 
based methods and NMR [95]. Recently, Shah et al., reported the plasma metabolite 
profiles of stage 2-4 CKD patients using gas and liquid chromatography coupled to mass 
spectrometry [96]. Therefore, we investigated whether NMR could be used as a 
complementary tool to elucidate novel biomarkers in kidney disease. The metabolic status 
of stage 3-4 CKD patients was determined using one-dimensional 1H-NMR spectroscopy 
following three previously described deproteinization strategies [94], namely ultrafiltration, 
protein precipitation via perchloric acid or via acetonitrile extraction. 
ABSTRACT
Chronic kidney disease (CKD) is characterized by the progressive accumulation of various 
potential toxic solutes. Furthermore, uremic plasma is a complex mixture hampering 
accurate determination of uremic toxin levels and the identification of novel uremic 
solutes. In this study, we applied 1H-nuclear magnetic resonance (NMR) spectroscopy, 
following three distinct deproteinization strategies, to determine differences in the plasma 
metabolic status of stage 3-4 CKD patients and healthy controls. Moreover, the human 
renal proximal tubule cell line (ciPTEC) was used to study the influence of newly indentified 
uremic solutes on renal phenotype and functionality. Protein removal via ultrafiltration 
and acetonitrile precipitation are complementary techniques and both are required to 
obtain a clear metabolome profile. This new approach, revealed that a total of 14 
metabolites were elevated in uremic plasma. In addition to confirming the retention of 
several previously identified uremic toxins, including p-cresyl sulphate, two novel uremic 
retentions solutes were detected, namely dimethyl sulphone (DMSO2) and 2-hydroxy-
isobutyric acid (2-HIBA). Our results show that these metabolites accumulate in non-dialysis 
CKD patients from 9 ± 7 µM (control) to 51 ± 29 µM and from 7 (0-9) µM (control) to 32 ± 
15 µM, respectively. Furthermore, exposure  of ciPTEC to clinically relevant concentrations 
of both solutes resulted in an increased protein expression of the mesenchymal marker 
vimentin with more than 10% (p<0.05). Moreover, the loss of epithelial characteristics 
significantly correlated with a loss of  glucuronidation activity (Pearson r = -0.63; p<0.05). 
In addition, both solutes did not affect cell viability nor mitochondrial activity. This study 
demonstrates the importance of sample preparation techniques in the identification 
of uremic retention solutes using 1H-NMR spectroscopy, and provide insight into the 
negative impact of DMSO2 and 2-HIBA on ciPTEC, which could aid in understanding the 
progressive nature of renal disease.     
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single-frequency irradiation during a relaxation delay of 10 s, and a 90° excitation was 
used. Automated tuning and matching (ATMA) and shimming (Topshim) was performed 
on all plasma samples. The resonances from the metabolites in Table 2 and the TSP singlet 
(nine equivalent protons) were fitted semi-automatically with Lorentzian line shapes. The 
concentration of the metabolites was calculated from the relative integrals of the fitted 
lineshapes using the known concentration of TSP.
Cell culture
The human conditionally immortalized proximal tubule epithelial cell (ciPTEC) line was 
generated as previously described by Wilmer et al. [98]. The cells were cultured in phenol 
red free DMEM/F12 medium (Gibco/Invitrogen, Breda, the Netherlands) containing 10% 
(v/v) fetal calf serum (MP Biomedicals, Uden, the Netherlands), insulin (5 µg/ml), transferrin 
(5 µg/ml), selenium (5 ng/ml), hydrocortisone (36 ng/ml), epithelial growth factor (10 ng/
ml), and tri-iodothyronine (40 pg/ml) at 33 ºC in a 5% (v/v) CO2 atmosphere. Propagation 
of cells was maintained by subculturing the cells at a dilution of 1:3 to 1:6 at 33 °C. For 
experiments, cells were cultured at 33 ºC to 40% confluency, followed by maturation for 7 
days at 37 ºC. Experiments were performed on the cells between passages 30 and 40, 
during which proximal tubule characteristics, such as albumin uptake and phosphate 
reabsorption, were maintained [98].
Flow cytometry
In this study, flow cytometry was used to study both cell viability and the expression of 
vimentin, a mesenchymal cell marker. ciPTEC were seeded at 40% confluence in 12-well 
MATRIALS AND METHODS
Ethics statement
The ethical committee of the Radboud University Nijmegen Medical Centre on research 
involving human subjects approved this study, and written informed consent was 
obtained from each patient and each healthy volunteer.
Chemicals
All chemicals were obtained from Sigma (Zwijndrecht, the Netherlands) unless stated 
otherwise. Stock solutions of uremic toxins were prepared in milli-Q and stored at -20 ºC. The 
reference standard of p-cresyl sulphate, kindly provided by Prof. R. Vanholder (University 
Hospital Ghent, Belgium), was synthesized as a potassium salt as described previously [97]. 
Patients and sample preparation
Blood samples were obtained from ten patients with CKD stage 3-4 (eGFR: 14-36 ml/
min/1.73 m2) during regular check-up and four adult controls. Clinical characteristics of 
study subjects are listed in Table 1. None of the subjects had been fasting at the time of 
blood sampling. Blood was collected in an Heparin Vacutainer and was immediately 
centrifuged at 3,000 x g for 10 min. Subsequently, plasma was collected and stored at -20 
°C. Before analysis, each patient sample was deproteinized via three distinct methods: (1) 
ultrafiltration; plasma samples were deproteinized using a 10 kD filter (Sartorius). Before 
use, the filter was washed twice by centrifugation of water to remove glycerol. (2) 
perchloric acid (PCA) extraction; 100 µl of 20% (v/v) PCA was added to 500 µl plasma, 
samples were then vortexed and placed on ice for 5 min. Next, samples were centrifuged 
at 12,000 x g for 3 min and the clear supernatant was used for spectroscopy. (3) acetonitrile 
extraction; 1.5 ml of acetonitrile was added to 0.5 ml plasma, mixed thoroughly, followed 
by centrifugation (3,000 x g for 5 min). Subsequently, the supernatant was dried by heating 
at 40 ºC under N2 flow and finally resuspended in 700 µl milli-Q. The control samples were 
deproteinized via ultrafiltration or acetonitrile extraction. Following protein removal via 
the different methods, 20 µl of 20.2 mM trimethylsilyl-2,2,3,3-tetradeuteropropionic acid 
(TSP, sodium salt) in 2H2O was added to the sample, providing a chemical shift reference 
(δ=0.00), a concentration reference and a deuterium lock signal. The pH of the ultrafiltrate 
was adjusted to 2.50 ± 0.05 with concentrated hydrogen chloride. Finally, 650 µl of the 
sample was placed in a 5 mm NMR tube (Wilmad Royal Imperial).
One-dimensional 1H-NMR spectroscopy
Plasma was measured at 500 MHz on a Bruker DRX 500 spectrometer equipped with a 
triple-resonance inverse (TXI) 1H [15N, 13C] probe head and equipped with x,y,z gradient 
coils. 1H spectra were acquired as 256 transients in 32K data points with a spectral width of 
6002 Hz. Sample temperature was 298 K and the H2O resonance was pre-saturated by 
Table 1  Characteristics of study subjects
Patients Controlsa
Number 10 4
Age (years) 55 ± 12 40 ± 12
Women (%) 33 50
Urea (mmol/l) 20 ± 9 ND
Creatinine (µmol/l) 227 ± 56 20-90
Albumin (g/l) 37 ± 4 ND
eGFR (ml/min/1.73 m2)b 26 ± 7 ND
Values are shown as mean ± SD. ND, not determined.
a   Control metabolite levels were similar as compared to an established database (n=50) from the Radboud 
University Nijmegen.
b   eGFR was calculated using the Modification of Diet in Renal Disease (MDRD) equation (www.nkdep.nih.gov).
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were considered to be statistically significant when p<0.05. The software was also used to 
perform linear regression analysis and correlation analysis (Spearman and Pearson). Raw 
data files are available upon request.
RESULTS
Influence of deproteinization on 1H-NMR spectra 
Figure 1 shows the deproteinized 1H-NMR plasma spectrum following ultrafiltration 
(Figure 1A), acetonitrile precipitation (Figure 1B) and PCA extraction (Figure 1C). Citric acid 
is clearly detected following ultrafiltration with a symmetrical quadruplet, generally 
referred to as an AB-system, at 2.94 ppm; whereas, resonance signals are low in the spectral 
region δ 7.00-8.00 (Figure 1A). In contrast, high-resonance signals were observed in this 
part of the 1H-NMR spectrum after acetonitrile treatment (Figure 1B). Hippuric acid showed 
a triplet at both 7.54 ppm and 7.62 ppm, and a doublet at 7.82 ppm. The other resonance 
signals were assigned to p-cresyl sulphate. Moreover, Figure 1B also shows that the citric 
acid peak observed following ultrafiltration is lost by acetonitrile deproteinization. 
Furthermore, PCA extraction resulted in an overall decreased sensitivity, a poor signal- 
to-noise ratio and shifts in peak position (Figure 1C), making this method unsuitable for 
metabolite identification and quantification. To our knowledge, this is the first report to 
demonstrate the presence of p-cresyl sulphate in plasma using 1H-NMR spectroscopy. 
Therefore, we aimed to verify the identity of the detected metabolite using a reference 
standard. 1H-NMR of the authentic compound p-cresyl sulphate in H2O at pH 2.5 (Figure 
2A) showed a singlet at 2.33 ppm (CH3 group) and a doublet at both 7.19 ppm and 7.27 
ppm (aromatic ring protons). A similar resonance profile was observed in acetonitrile- 
treated plasma from a CKD patient (Figure 2B), indicating that p-cresyl sulphate is indeed 
retained in patients with kidney failure. The absence of both hippuric acid and p-cresyl 
sulphate in plasma following ultrafiltration is most likely due to the strong protein binding 
of these solutes. Thus, ultrafiltration and acetonitrile extraction are complementary 
 deproteinization strategies and both methods are required to obtain a clear overview of 
the metabolic status of non-dialysis CKD patients.
Accumulation of uremic toxins in patients with CKD stage 3-4       
1H-NMR spectroscopy revealed that a plethora of uremic compounds are elevated in CKD 
patients as compared with healthy controls (Figure 3). Resonance assignments were based 
on previously recorded spectra and a total of 14 solutes could be assigned. As expected, 
creatinine was elevated in all patients. Moreover, the well-known toxins 3-methylhistidine, 
hippuric acid, p-cresyl sulphate, N,N-dimethylglycine, betaine and myo-inositol were 
detected in all patients. In all ten patient samples we also detected the hitherto unknown 
toxins DMSO2 and 2-HIBA. 1-methylhistidine was detected in nine patients, trigonelline 
plates and allowed to adhere over night at 33 ºC followed by maturation for 7 days at 37 
ºC, before being treated for 48 h with clinically relevant uremic toxin concentrations. In 
addition, ciPTEC were also exposed for 48 h to 1 mM 1-methylhistidine, 3-methylhistidine 
(both as negative control) or indoxyl sulphate as a positive control. After incubation, cells 
were harvested using trypsin-EDTA and centrifuged at 600 x g during 5 min. Subsequently, 
supernatant was removed and the cell pellet was resuspended in 100 µL PBS containing 
1 µL mouse-α-human Vimentin-PE (Abcam, Cambridge, UK) followed by 30 min incubation 
at RT. Samples were acquired with a BD FACSCalibur (Becton Dickinson, Breda, the 
Netherlands) using channel FL-2. Analysis was performed using Flow Jo software (TreeStar, 
Ashland, USA), gating on live cells. 
High-performance liquid chromatography (HPLC)
HPLC was used to measure UDP-glucuronosyltransferase (UGT) activity via the glucuroni-
dation of 7-hydroxycoumarin (7-OCH), as described previously [99,100]. Following 
exposure to uremic toxins at clinically relevant concentrations for 48 h, ciPTEC were 
incubated with 10 µM 7-OCH for 3 h at 37°C. Before chromatography, an aliquot of culture 
medium was collected and centrifuged at 12,000 x g for 3 min and 50 µl of the supernatant 
was injected into the HPLC-system (Spectra-Physics Analytical, Spectrasystem SCM400). 
To measure 7-OCH and 7-OCH glucuronide (7-OCHG) the HPLC was equipped with a C18 
HPLC column (GraceSmart RP 18 5u 150 x 4.6 mm; Grace, Breda, the Netherlands). 
Separation was performed at a flow rate of 1 ml/min with eluent A (95% (v/v) H2O, 5% (v/v) 
methanol and 0.2% (v/v) acetic acid) and eluent B (50% (v/v) H2O, 49% (v/v) acetonitrile and 
1% (v/v) tetrahydrofuran) under the following gradient conditions: 0-3 min, 80-50% eluent 
A; 3-8 min, 50% eluent A; 8-9 min, 50-80% eluent A; 9-14 min, 80% eluent A. The compounds 
were detected at a wavelength of 316/382 nm. Standards of the compounds were also run 
in order to quantify the amount of metabolites found in the samples. Acquired data were 
processed with PC1000 software (Spectrasystem).
3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) assay
Mitochondrial succinate dehydrogenase activity was assessed using the MTT assay. ciPTEC 
were cultured in a 96 well culture plate and exposed to DMSO2 or 2-HIBA for 48 h. Next, 
medium was removed and 40 μl preheated (37ºC) MTT-solution (5 mg 3-[4,5-dimethylth-
iazol-2-yl]-2,5-diphenyl tetrazolium bromide/ml ciPTEC medium) was added and 
incubated for 4 h at 37ºC. Afterwards, MTT-solution was removed, followed by the addition 
of 150 μl DMSO to dissolve produced formazan crystals. The extinction of the solution was 
measured at 570 nm using a Benchmark Plus Microplate Spectrophotometer (Bio-rad). 
Statistics
Statistics were performed using GraphPad Prism 5.02 via one-way analysis of variance 
(ANOVA) followed by Dunnett’s Multiple Comparison Test. Differences between groups 
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and trimethylamine N-oxide were found in six patients and pseudouridine was found in 
five patients; whereas, dimethylamine was only detected in one individual. Resonance 
assignments and concentrations of uremic toxins measured by 1H-NMR are summarized in 
Table 2 and chemical structures can be found in Figure S1.
Comparison with normal concentrations
To evaluate the relative solute retention in stage 3-4 CKD patients, the ratio of the mean of 
all uremic concentrations (M) determined were calculated to the normal concentration (N) 
reported in literature (M/N), as described previously [22]. The solute solely retained in one 
patient (i.e. dimethylamine), trigonelline (due to lack of reference value) and creatinine 
Figure 1  Comparison of deproteinization methods. 
500 MHz 1H-NMR spectrum of plasma from CKD patient following (A) ultrafiltration, (B) acetonitrile 
precipitation or (C) PCA extraction. 
Figure 2  500 MHz 1H-NMR spectra: region δ 7.00-7.80 and 3.00-2.00. 
(A) Authentic reference solution of p-cresyl sulphate with chemical structure and assignments. 
(B) Plasma (acetonitrile precipitation) from CKD patient. The spectrum shows resonances of p-cresyl 
sulphate. These resonances were not observed in plasma from controls. 
Figure 3  Accumulation of uremic solutes. 
500 MHz 1H-NMR spectrum of plasma (ultrafiltrate) from (A) a healthy control and (B) a CKD patient. 
Insets show 5 regions of interest in greater detail. Metabolite abnormalities: Creatinine (1 and 2), 
1-methylhistidine (3), 3-methylhistidine (4), myo-Inositol (5), trimethylamine N-oxide (6), dimethyl 
sulphone (7), N,N-dimethylglycine (8) and 2-hydroxyisobutyric acid (9). 
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Influence of uremic solutes on ciPTEC phenotype
The impact of the novel uremic retention solutes on proximal tubular epithelium was 
investigated using a unique human proximal tubule cell line, demonstrated to be a valid 
model to study nephrotoxicity and renal cell metabolism [100-102]. Exposure of ciPTEC to 
the Cmax of DMSO2 or 2-HIBA, determined in this study (Table 2), resulted in an increase in 
vimentin expression by 12% and 30%, respectively (Figure. 6A). Moreover, at the highest 
concentration tested (10x Cmax,) these toxins increased vimentin expression by 26% and 
55%, respectively. In comparison, both 1-methylhistidine and 3-methylhistidine did not 
were excluded from this analysis. The M/N ratio ranged from 2.3 for trimethylamine 
N-oxide to 44.7 for hippuric acid (Figure 4). In the case of five metabolites, the uremic 
concentration was more than 10 times higher than normal. A moderate degree of 
retention was observed for four solutes for which the M/N ratio ranged between 4 and 10. 
Correlation between eGFR and retention of DMSO2 and 2-HIBA
Next, we investigated whether the plasma concentration of DMSO2 and 2-HIBA in 
non-dialysis CKD patients correlated with a decline in kidney function as represented by 
the eGFR. As shown in both Figure 5 and Figure S2, there is no association between the 
parameters studied as concluded from a Spearman correlation analysis (r<0.2 for both 
solutes). 
Table 2   1H resonance assignments and plasma concentrations of uremic solutes in 
stage 3-4 CKD patients
Metabolite Peak 
no.a
Cu (µM) Cmaxb (µM) Control 
(µM) 
Literaturec 
(µM) 
1-Methylhistidine 3 34 ± 26 87 < 5 4 ± 8 
3-Methylhistidine 4 38 ± 25 89 ND 2.7 (0-6) 
Hippuric acid 134 ± 111 357 ND 3 (0-5) 
p-Cresyl sulphate 289 ± 132 552 ND 15 ± 9     
Creatinine 1,2 590 ± 276 1143 20-90 72 (57-93)  
Dimethyl sulphone 7 51 ± 29 108 < 30 9 ± 7 
2-Hydroxyisobutyric acid 9 32 ± 15 61 ND 7 (0-9)    
N,N-Dimethylglycine 8 23 ± 11 46 < 5 2.6 (1.8-3.7)  
trigonelline 28 ± 24 76 ND ND
Pseudouridine 48 ± 15 79 ND 3.2 ± 1  
Betaine 83 ± 34 150 < 50 34.6 (24-42)  
myo-Inositol 5 499 ± 170 838 ND 30 (21-49)  
Dimethylamine 17d NA ND 3.3 ± 1.5  
Trimethylamine N-oxide 6 88 ± 42 172 ND 38 ± 20  
Values are shown as mean (Cu) ± SD or range (µM) and maximal uremic concentration (Cmax,). ND, not 
detected; NA, not applicable.
aNumbers correspond to peaks in Figure 3.
bHypothetical Cmax calculated as Cmax = Cu + 2 SD, as previously described [21,89].
cData obtained from the Human Metabolome Database (www.hmdb.ca) [31].
dOnly detected in one patient. 
Figure 4  Relative retention of uremic solutes in stage 3-4 CKD patients. 
The M/N index is the ratio of the mean uremic concentration (M) found in the present study to the 
normal concentration (N) measured in healthy controls reported in literature. 
Figure 5  Correlation between plasma solute levels and eGFR. 
Dots represent the natural logarithm (LN) of individual concentrations of (A) DMSO2 and (B) 2-HIBA 
and the lines the best fit linear regression line with the 95% confidence interval. 
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affect vimentin expression; whereas the positive control (indoxyl sulphate) increased 
vimentin expression by 55% (Figure 6B). Flow cytometry revealed that exposure to the 
highest concentration of both solutes did not affect cell morphology nor the percentage 
of living cells as compared to untreated cells (Figure 6C). Furthermore, when ciPTEC were 
exposed to the Cmax, UGT activity was reduced by 8% and 13%, respectively. And we 
observed a clear correlation between vimentin expression and UGT activity with a 
calculated Pearson r of -0.63 (p<0.05; Figure 6D). In addition, DMSO2 and 2-HIBA did not 
impede mitochondrial succinate dehydrogenase activity as demonstrated with the MTT 
assay (Figure 6E). Taken together, our findings suggest that both solutes induce a loss of 
epithelial characteristics and reduce renal glucuronide formation, indicating changes in 
cell metabolism without affecting cell viability.   
DISCUSSION
Accumulation of uremic toxins due to inadequate renal clearance is a hallmark of CKD. 
Uremic retention solutes are associated with disease progression and the myriad of 
pathologies observed in dialysis patients. In this study, 1H-NMR spectroscopy was 
successfully used to indentify multiple uremic toxins in the plasma of stage 3-4 CKD 
patients. 
Our results revealed that ultrafiltration and acetonitrile extraction are complementary 
deproteinization techniques and both are required as sample preparation methods for 
the proper detection of uremic retention solutes using 1H-NMR spectroscopy. In the study 
of Tiziani et al., it was demonstrated that ultrafiltration was the best deproteinization 
strategy to remove proteins from serum samples resulting in a high metabolite retainment 
and reproducibility [103]. Furthermore, they reported that following acetonitrile extraction 
most of the metabolites were maintained, although with a reduced signal intensity 
compared to ultrafiltration [103]. In contrast, Daykin et al., demonstrated that deproteiniza-
tion using acetonitrile at physiological pH resulted in an increased detection of low-mo-
Figure 6  Impact of DMSO2 and 2-HIBA on ciPTEC. 
Cells were exposed for 48 h to ciPTEC medium (gray bar), DMSO2 or 2-HIBA (concentration range: ½ 
Cmax – 10x Cmax). (A) Following treatment, cells were harvested and stained with mouse-α-human 
Vimentin-PE. Quantification of staining was done with a BD FACSCalibur flow cytometer using 
channel FL-2, and analyzed with FlowJo software, gating on live cells. Statistical analysis was 
performed via a One-way ANOVA followed by the Dunnett’s Multiple Comparison Test for each 
toxin. Results are presented as mean ± SEM of three independent experiments performed in 
duplicate or triplicate. * indicates p<0.05 compared with control. (B) Vimentin expression following 
exposure to 1 mM 1-methylhistidine (1-MH), 3-methylhistidine (3-MH; both negative control) or 
indoxyl sulphate (IS; positive control) for 48 h. Results are presented as mean ± SEM of three 
independent experiments performed in duplicate or triplicate. * indicates p<0.05 compared with 
control.  (C) Cells were exposed for 48 h to ciPTEC medium, DMSO2 or 2-HIBA (both 10x Cmax).  
Representative density plots with percentage of gated (i.e. living) cells of three independent 
experiments, performed in duplicate or triplicate 
(D) Following treatment, ciPTEC were incubated for 3 h with 10 µM 7-OHC. Afterwards, an aliquot of 
culture medium was collected and injected into the HPLC-system. Standards of 7-OHCG were also 
analyzed in order to quantify the amount of glucuronide found in the samples. Acquired HPLC data 
were processed with PC1000 software (Spectrasystem). Pearson correlation analysis revealed a 
significant association between the expression of vimentin and glucuronidation (r = -0.63; p<0.05). 
(E) The MTT assay was used to study the impact of DMSO2 and 2-HIBA on mitochondrial metabolism. 
Cells were exposed for 48 h to both solutes as described above. Afterwards, cells were incubated for 
4 h with MTT-solution at 37 °C. Subsequently, produced formazan crystals were dissolved in DMSO 
and extinction was measured at 570 nm. Results are presented as mean ± SEM of three independent 
experiments performed minimally in triplicate.
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myo-inositol and trimethylamine N-oxide were elevated in stage 3-4 CKD patients. 
Previously, Choi et al., used 1H-NMR spectroscopy to study the metabolic status of dialysis 
patients [122]. They reported that a multitude of uremic toxins were retained including 
myo-inositol and 3-methylhistidine, similar to our findings in non-dialysis CKD patients. In 
addition, Rhee et al. studied the metabolomic profile of 44 hemodialysis patients using 
three different LC-MS methods [90]. In total, 40 metabolites were elevated at baseline in 
patients, compared to healthy controls. In concordance with our results, they demonstrated 
retention of hippuric acid, trimethylamine N-oxide and dimethylglycine. Both studies did 
not report the retention of 1-methylhistidine, pseudouridine and betaine. However, 
accumulation of 1-methylhistidine in patients treated with hemodialysis has been 
demonstrated by HPLC previously [123]. And Niwa et al., reported that pseudouridine 
levels were increased in both CRF and dialysis patients compared with controls [124]. Taken 
together, there is a clear overlap in the solutes retained in both the early stages of CKD and 
patients with end-stage renal disease. 
Previously, using HPLC and LC-MS/MS, our group demonstrated that indole-3-acetic acid, 
indoxyl sulfate and kynurenic acid accumulated in CRF patients with mean concentrations 
of 4.4 µM, 67 µM and 0.6 µM, respectively [89]. These compounds were not identified 
during the present study due to the limited sensitivity of proton NMR spectroscopy. Other 
widely deployed techniques, such as HPLC and LC-MS/MS, have a higher sensitivity with 
detection limits in the nano- or even picomolar range although the sensitivity highly 
varies depending on the compound of interest. The present study was an initial proof-of-
concept study to determine whether 1H-NMR spectroscopy could be used as a tool to 
expand our knowledge about uremic retention solutes and if this technique can be 
utilized in the search for CKD biomarkers. As such, a small number of CKD patients was 
included, which limited our power to identify uremic retention solutes for which levels 
greatly differ among individual patients. Still, the current study is the first to provide an 
overview of the metabolome of non-dialysis CKD patients by means of NMR spectroscopy. 
One has to take into account that, due to the reasons stated above, not all of the potential 
toxic solutes retained in stage 3-4 CKD patients are identified. Further studies with 
additional subjects and analytical techniques should provide a more complete overview 
of metabolites retained in CKD patients. 
In conclusion, a hallmark of renal failure is the retention of a plethora of metabolites, 
belonging to multiple physico-chemical classes, with potential deleterious effects on total 
body homeostasis. In this study, we have demonstrated that both ultrafiltration and 
acetonitrile extraction are required as deproteinization methods to elucidate the 
metabolomic profile of stage 3-4 CKD patients by means of 1H-NMR spectroscopy. Moreover, 
using this technique, we have successfully identified a total of 14 metabolites, including 2 
novel uremic solutes, that possibly contribute to the co-morbidity and mortality in CKD 
patients. These results might aid in revealing new biomarkers for CKD and possibly contribute 
to a better understanding of the progressive character of renal disease.               
lecular-weight metabolites and a improved signal-to-noise ratio [94]. These studies 
corroborate our notion that multiple deproteinization strategies are needed when 
investigating the metabolome.
Here, we report for the first time that DMSO2 and 2-HIBA are retained in CKD patients. 
Moreover, both solutes were demonstrated to negatively influence renal cell physiology 
using ciPTEC. Already in 1966, Williams et al. reported the presence of DMSO2 in urine [104]. 
Yet, it took several decades to establish that DMSO2 is a common metabolite present in 
blood and cerebrospinal fluid [105,106]. DMSO2 can originate from dietary sources such as, 
milk and port wine [106-108]. Moreover, it can be formed during bacterial metabolism of 
methanethiol in the gut or endogenous human methanethiol metabolism [106,109]. 
Recently, it has been described that DMSO2 attenuated both constitutive as well as 
IL-1β-induced IL-6 and IL-8 production in human chondrocyte cell line, possibly by 
inhibiting the ERK1/2 signaling pathway [110]. Older studies indicated that DMSO2 inhibited 
oxidant production in activated neutrophils and diminished the proliferation of vascular 
smooth muscle cells and endothelial cells [111,112]. Regarding 2-HIBA, two recent studies 
reported that this compound is constitutively present in human urine and serum [113,114]. 
Moreover, 2-HIBA is the major urinary metabolite in humans following exposure to the 
gasoline additives methyl-tert.butyl ether and ethyl-tert.butyl ether [115,116]. Elevated 
plasma concentrations of 2-HIBA were observed in patients with type 2 diabetes mellitus, 
possibly due to disturbances in fatty acid metabolism [117]. Moreover, a recent 
genome-wide association study revealed a significant negative association with urinary 
2-HIBA levels and SNP rs830124, an intronic SNP of the WDR66 gene on chromosome 12, 
which is closely associated with mean platelet volume [118,119]. At present, little is known 
regarding the biological activity of DMSO2 and 2-HIBA. Our results provide the first proof 
that these metabolites induce a loss of defined renal epithelial features and are possibly 
involved in the progression of CKD. However, more research is necessary to definitely label 
these solutes as uremic toxins.   
It is known that uremic toxin levels rise in concordance with CKD severity [2]. Therefore, it 
is suggested that eGFR, as a marker of kidney function, should reflect retention state and 
the levels of uremic solutes in CKD patients. In this study, we did not observe any 
correlation between eGFR and plasma concentration of DMSO2 or 2-HIBA, which suggests 
that eGFR is a poor marker for the accumulation of these solutes. These findings are in 
agreement with previous studies demonstrating that eGFR is an unsuitable tool to predict 
levels of uremic toxins from different classes (e.g. middle weight and protein-bound) in 
CKD patients [120,121]. Furthermore, these results suggest that the renal clearance of both 
metabolites is mainly dependent on active tubular transport, possibly due to binding of 
the compounds to plasma proteins. Yet, more research is needed to fully elucidate the 
chemical properties, including protein-binding, of DMSO2 and 2-HIBA.
Next to DMSO2 and 2-HIBA, the present study showed that 1-methylhistidine, 3-methyl-
histidine, hippuric acid, p-cresyl sulphate, N,N-dimethylglycine, pseudouridine, betaine, 
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INTRODUCTION
Approximately 5% of the adult population in the developed countries suffers from chronic 
kidney disease (CKD) stage III-V, which is defined by a decreased estimated glomerular 
filtration rate (eGFR) [5]. A main feature at this stage of CKD is the accumulation of solutes 
that are normally excreted in urine. These uremic retention solutes, also known as uremic 
toxins, are a heterogeneous group of organic compounds. Currently, 110 compounds are 
considered to be uremic toxins and they are classified into three groups depending on 
their chemical properties that largely influence the possibility to remove these toxins 
using current dialysis strategies, namely size and solubility. The currently defined groups, 
as described by Vanholder et al. 2008, are: (1) the small water-soluble compounds, with a 
molecular weight (MW) arbitrarily set at ≤ 500 Da, for example, urea and creatinine; these 
compounds are easily removed via dialysis and their toxic potential is limited. (2) The 
middle molecules, with a MW > 500 Da, such as β2-microglobulin; due to their size, these 
retention solutes can only be cleared using dialyzer membranes with large pores, which 
focus on filtration via convection instead of diffusion. (3) The protein-bound solutes; the 
compounds in this group mostly have a small MW and prototypes include indoxyl sulfate 
and p-cresyl sulfate. Solutes belonging to this group are very difficult to clear using current 
dialysis strategies and they exhibit toxic effects [23]. Uremic toxins are thought to 
contribute to the plethora of pathologies observed in patients with CKD, including 
anemia, bone disorders, renal fibrosis and cardio-vascular disease. Administration of the 
oral sorbent AST-120 is currently the only therapy to prevent accumulation of protein-bound 
uremic toxins in patients with CKD. Unfortunately, AST-120 prevents no more than the 
uptake of indoxyl sulfate and p-cresol in the intestinal tract [125]. Understanding the 
endogenous clearance of protein-bound solutes could lead to the development of novel 
therapeutic strategies for the removal of uremic toxins.
In the healthy population, uremic toxins are cleared by the kidney and this process is 
largely dependent on glomerular filtration and tubular secretion via a multitude of 
transport proteins expressed in renal proximal tubules. Moreover, it has been demonstrated 
that both organic anion transporter (OAT) 1 and OAT3 play important roles in the renal 
tubular uptake of uremic toxins and organic anions [64,72,126]. Both transporters show 
overlapping substrate specificities, but differential contributions to uremic toxin clearance 
have been reported as well. For example, indoxyl sulfate is equally transported by OAT1 
and OAT3, but indole-3-acetic acid and hippuric acid are preferable substrates for OAT1, 
and uptake of 3-carboxy-4-methyl-5-propyl-2-furanpropionate is mediated by OAT3 
solely [72]. In addition, using a rat model of renal failure, the basolaterally expressed 
kidney- specific organic anion transporting polypeptide 4C1 (SLCO4C1) was recently 
shown to facilitate the removal of several uremic toxins, including guanidino succinate, in 
the proximal tubule [60]. Thus, basolateral uptake of uremic toxins in renal proximal 
tubules cells is fairly well characterized, however, little is known about the transport of 
ABSTRACT
During chronic kidney disease (CKD), there is a progressive accumulation of toxic solutes 
due to inadequate renal clearance. Here, the interaction between uremic toxins and two 
important efflux pumps, viz. multidrug resistance protein 4 (MRP4) and breast cancer 
resistance protein (BCRP) was investigated. Membrane vesicles isolated from MRP4- or 
BCRP-overexpressing human embryonic kidney cells were used to study the impact of 
uremic toxins on substrate specific uptake. Furthermore, the concentrations of various 
uremic toxins were determined in plasma of CKD patients using high performance liquid 
chromatography and liquid chromatography/tandem mass spectrometry. Our results 
show that hippuric acid, indoxyl sulfate and kynurenic acid inhibit MRP4-mediated 
[3H]-methotrexate ([3H]-MTX) uptake (calculated Ki values: 2.5 mM, 1 mM, 25 µM, 
respectively) and BCRP-mediated [3H]-estrone sulfate ([3H]-E1S) uptake (Ki values: 4 mM, 
500 µM and 50 µM, respectively), whereas indole-3-acetic acid and phenylacetic acid 
reduce [3H]-MTX uptake by MRP4 only (Ki value: 2 mM and IC50 value: 7 mM, respectively). 
In contrast, p-cresol, p-toluenesulfonic acid, putrescine, oxalate and quinolinic acid did 
not alter transport mediated by MRP4 or BCRP. In addition, our results show that hippuric 
acid, indole-3-acetic acid, indoxyl sulfate, kynurenic acid and phenylacetic acid accumulate 
in plasma of end-stage CKD patients with mean concentrations of 160 µM, 4 µM, 129 µM, 
1 µM and 18 µM, respectively. Moreover, calculated Ki values are below the maximal 
plasma concentrations of the tested toxins. In conclusion, this study shows that several 
uremic toxins inhibit active transport by MRP4 and BCRP at clinically relevant concentrations. 
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or enhanced yellow fluorescent protein (EYFP), generated via the Bac-to-Bac system 
(Invitrogen) as previously described [132]. To transduce HEK293 cells, they were cultured in 
500 cm2 flasks until 70% confluence. Subsequently, medium was removed and 10 ml of 
virus and 25 ml of medium were added and incubated for 30 min at 37 ºC. Next, 50 ml of 
medium was added and after 2 h of transduction 5 mM sodium butyrate was added.         
Membrane vesicle preparation
Three days after transduction, cells were harvested and pelleted by centrifugation (30 min 
at 4,000 x g). Afterwards, the cells were resuspended in ice-cold hypotonic TS buffer (0.5 
mM sodium phosphate, 0.1 mM EDTA, pH 7.0) containing protease inhibitors (100 µM 
phenylmethylsulfonyl fluoride, 5 µg/ml aprotinin, 5 µg/ml leupeptin, 1 µg/ml pepstatin 
and 1 µg/ml E-64) and shaken for 30 min at 4 ºC. Cells were then centrifuged at 100,000 x 
g for 30 min at 4 ºC. Subsequently, pellet was resuspended in ice-cold isotonic buffer (10 
mM Tris-HEPES and 250 mM sucrose, pH 7.4, adjusted with HEPES) supplemented with 
protease inhibitors and homogenized using a tight fitting Dounce homogenizer followed 
by centrifugation (1,000 x g, 20 min, 4 ºC). Afterwards, supernatant was centrifuged at 
100,000 x g for 1 h at 4 ºC. The resulting pellet was resuspended in isotonic buffer and 
passed through a 27-gauge needle 25 times to obtain crude membrane vesicles. The 
protein content of samples was determined using the Bio-Rad protein assay (Veenendaal, 
the Netherlands), according to manufacturers recommendations. Vesicles were frozen in 
liquid nitrogen and stored at -80 ºC until use. The orientation of the membrane vesicles 
was not determined, since ATP-dependent uptake occurs only in inside-out vesicles.       
Western blotting
Overexpression of MRP4 or BCRP in membrane vesicles was studied using the Odyssey 
western blotting technique. Total protein (15 µg) was separated via SDS/PAGE using a 10% 
(w/v) gel, and blotted onto nitrocellulose membranes using the iBlot dry blotting system 
(Invitrogen). Afterwards, the membrane was blocked using Odyssey Blocking Buffer, (1:1 
diluted with PBS; Westburg BV, Leusden, the Netherlands) for 1 hour at RT. The membrane 
was then incubated overnight at 4 ºC with rabbit-α-MRP4 (1:5,000; van Aubel et al. [127]) or 
mouse-α-BCRP (1:200; Clone BXP-21; Kamiya Biomedical, Seattle, USA) in Odyssey Blocking 
Buffer containing 0.1% (v/v) Tween-20. Afterwards, the membrane was thoroughly washed 
three times during 10 min with PBS containing 0.1% (v/v) Tween-20. The secondary 
antibodies, goat-α-rabbit IRDye 800 (1:10,000; Sigma) and goat-α-mouse Alexa Fluor 680 
(1:10,000; Rockland, Heerhugowaard, the Netherlands), were incubated for 1 hour at RT in 
Odyssey Blocking Buffer containing 0.1% (v/v) Tween-20 and 0.01% (w/v) SDS. The 
membrane was thoroughly washed, as described above, and then scanned using the 
Odyssey Infrared Imaging System (LI-COR Biotechnology). Expression of MRP4 was 
assessed using channel 800 and BCRP expression was determined using channel 700. 
uremic toxins over the apical membrane into urine. Two important renal efflux pumps at 
the apical membrane are multidrug resistance protein 4 (MRP4) and breast cancer 
resistance protein (BCRP) [127,128]. Both MRP4 and BCRP are known to transport urate, 
[87,88] a uremic toxin involved in the pathogenesis of gout and cardiovascular disease 
[129]. Furthermore, functional and nonfunctional mutations in the BCRP gene cause 
 hyperuricemia-based gout, supporting the importance of the efflux pump in urate 
secretion [88,130]. Therefore, it seems likely that both MRP4 and BCRP are involved in the 
transport of uremic toxins into the proximal tubule lumen. 
The present study was designed to investigate the interaction between several uremic 
toxins, mainly belonging to the group of protein-bound solutes, and MRP4- and 
BCRP-mediated transport. Our results show that hippuric acid, indoxyl sulfate and 
kynurenic acid inhibit substrate specific uptake by both MRP4 and BCRP, whereas in-
dole-3-acetic acid and phenylacetic acid only reduce transport by MRP4. Moreover, 
inhibition of transport by multiple uremic toxins mainly occurs at clinically relevant 
concentrations, suggesting that uremic toxins may contribute to the many complications 
of CKD.
MATERIALS AND METHODS
Ethics Statement
The ethical committee of the Radboud University Nijmegen Medical Centre on research 
involving human subjects approved this study, and oral informed consent was obtained 
from each patient and each healthy volunteer.
Chemicals
All chemicals were obtained from Sigma (Zwijndrecht, the Netherlands) unless stated 
otherwise. Stock solutions of uremic toxins were prepared as previously described [131], 
and stored at -20 ºC. [3’,5’,7’-3H(n)]-methotrexate disodium salt ([3H]-MTX) with a specific 
activity ranging between 13.4 and 25.3 Ci/mmol was purchased from Moravek (Brea, USA) 
and [6’,7’-3H(n)]-estrone-sulfate ammonium salt ([3H]-E1S) with a specific activity of 54.26 
Ci/mmol was obtained from Perkin Elmer (Groningen, the Netherlands).   
Cell culture and transfection
Human embryonic kidney (HEK293; purchased at American Type Culture Collection, 
Manassas, VA) cells were cultured in Dulbecco’s modified Eagle’s medium (Invitrogen life 
sciences, Breda, the Netherlands) containing 10% (v/v) fetal calf serum (MP Biomedicals, 
Uden, the Netherlands) at 37 ºC in a 5% (v/v) CO2 atmosphere. To functionally overexpress 
MRP4 and BCRP, HEK293 cells were transduced with baculoviruses of human MRP4, BCRP 
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min, 100% eluent A. The flow rate was 1 ml/min and phenylacetic acid was measured at a 
wavelength of 215 nm. Standards of the compounds were also run in order to quantify the 
amount of toxins found in the samples. Acquired data were processed with PC1000 
software (Spectrasystem).
Liquid chromatography-tandem mass spectrometry (LC-MS/MS)
To determine the levels of kynurenic acid, blood was collected from CRF patients and 
processed as described above. Subsequently, 10 µl of the clear supernatant was injected 
into the LC-MS/MS system that consisted of an Accela HPLC system (Thermo scientific, 
Breda, the Netherlands) equipped with a C18 HPLC column (VisionHT C18 B 100x2 mm, 1.5 
µm; Grace). Separation was performed at a flow rate of 150 µl/min with eluent A (5mM 
ammonium formate + 0.01% (v/v) trifluoroacetic acid) and eluent B (50% acetonitrile) 
under the following gradient conditions: 0-10 min, 98-50% eluent A; 10-15 min, 50% eluent 
A; 15-16 min, 50-98% eluent A; 16-21 min, 98% eluent A. The fractions eluted were directly 
passed through a TSQ Vantage tandem mass spectrometer (Thermo scientific) equipped 
with an electro-spray ionization source operating in the positive ion mode. The ion spray 
voltage was 4 kV, source temperature was 350 ºC and collision gas pressure was 1.5 bar. 
Kynurinic acid and the internal standard 1-methyl-tryptophan were quantified by selected 
reaction monitoring (SRM). The following SRM transitions were used: m/z 190 (parent ion) 
to m/z 89 and 144 (both product ions) for kynurenic acid and m/z 219.1 (parent ion) to m/z 
160 and 202.1 (product ions) for methyl-tryptophan. A calibration curve of kynurenic acid 
was made to quantify the amount of toxin found in the samples and the results were 
corrected using the internal standard. Acquired data were processed with Thermo Xcaliber 
software (Thermo scientific).    
Membrane vesicle transport inhibition assay
A rapid filtration technique was used to study the uptake of [3H]-MTX and [3H]-E1S into 
MRP4 or BCRP membrane vesicles, as previously described [133]. In short, 25 µl of TS buffer 
containing 4 mM ATP, 10 mM MgCl2 and radiolabeled substrate was added to 5 µl of the 
membrane vesicles (1.5 mg/ml). The transport assay was performed in the absence or 
presence of various concentrations of uremic toxins to evaluate the inhibitory effects of 
these compounds on MRP4-mediated [3H]-MTX uptake and BCRP-mediated [3H]-E1S 
uptake. Transport was started by incubating the mixture at 37 ºC for 1 min (BCRP) or 10 
min (MRP4), time points at which substrate uptake was previously shown to be linear 
[132,134]. Uptake was stopped by placing the samples on ice and the addition of 150 µl ice 
cold TS buffer. Subsequently, the samples were transferred to a 96 well filter plate (Millipore, 
Etten-leur, the Netherlands) pre-incubated with TS buffer and filtered using a Multiscreen 
HTS-Vacuum Manifold filtration device (Millipore). Afterwards, 2 ml of scintillation liquid 
was added to each filter and radioactivity was determined using liquid scintillation 
counting. As negative controls ATP was substituted for AMP and EYFP-membrane vesicles 
were used. Each experiment was performed in triplicates.  
High-performance liquid chromatography (HPLC)
Blood samples were obtained from 4 patients with chronic renal failure (CRF) during 
regular check-up, 6 patients with end-stage renal disease (ESRD) before hemodialysis and 
4 healthy controls. Clinical characteristics of study subjects are listed in Table 1. None of 
the subjects had been fasting at the time of blood sampling. Blood was collected in an 
EDTA Vacutainer and was immediately centrifuged at 3,000 x g for 10 min. Subsequently, 
plasma was collected and stored at -20 °C. Before chromatography an aliquot of plasma 
was diluted in H2O (1:1) and deproteinized with perchloric acid (final concentration 3.3% 
(v/v)). Next, samples were centrifuged at 12,000 x g for 3 min and 50µl of the supernatant 
was injected into the HPLC-system (Spectra-Physics Analytical, Spectrasystem SCM400). 
To measure indole-3-acetic acid, indoxyl sulfate and hippuric acid, the HPLC was equipped 
with a C18 HPLC column (GraceSmart RP 18 5u 150 x 4.6 mm; Grace, Breda, the Netherlands). 
Separation was performed at a flow rate of 1 ml/min with eluent A (95% (v/v) H2O, 5% (v/v) 
acetonitril and 0.1% (v/v) heptafluorobutyric acid) and eluent B (50% (v/v) H2O, 50% (v/v) 
acetonitrile and 0.1% (v/v) heptafluorobutyric acid) under the following gradient 
conditions: 0-1 min, 100% eluent A; 1-15 min, 100-25% eluent A; 15-17 min, 25% eluent A; 
17-18 min, 0-100% eluent A; 18-23 min, 100% eluent A. The compounds were detected at 
a wavelength of 230 nm. For the detection of phenylacetic acid, chromatography was 
performed on a C18 HPLC column (Polaris 3 C18-A 150 x 4.6 mm; Varian, Middelburg, the 
Netherlands) with eluent A (97% (v/v) 50 mM sodium phosphate buffer [pH 6.5] and 3% 
(v/v) methanol) and eluent B (50% (v/v) H2O, 49% (v/v) acetonitrile and 1% (v/v) tetrahydro-
furan) using the following gradient: 0-1 min, 100% eluent A; 1-15 min, 100-90% eluent A; 
15-18 min, 10-100% eluent B; 18-22 min, 100% eluent B; 22-25 min, 0-100% eluent A; 25-30 
Table 1   Characteristics of study subjects
CRF ESRD Control
Number 4 6 4
Age (years) 54 ± 20 58 ± 13 34 ± 10
Women (%) 25 33 25
Ureum (mmol/l) 32 ± 6 21 ± 6 ND
Creatinine (µmol/l) 510 ± 210 720 ± 90 ND
Dialysis strategy NA 4 HD, 2 CAPD NA
Values are shown as mean ± SD. CRF, chronic renal failure; ESRD, end-stage renal disease; ND, not determined; 
NA, not applicable; HD, hemodialysis; CAPD, continuous ambulatory peritoneal dialysis.
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Uremic toxins inhibit transport
Using membrane vesicles overexpressing either transport protein, the interaction 
between ten uremic toxins and substrate specific transport by MRP4 and BCRP was 
studied. Hippuric acid dose-dependently inhibited MRP4-mediated [3H]-MTX uptake 
(Figure 3) and BCRP-mediated [3H]-E1S uptake (Figure 4) in a concentration range of 0.1 
mM to 3.5 mM. The compound did not completely inhibit transport by MRP4, as depicted 
by the plateau at 50% of the inhibition curve, whereas uptake of [3H]-E1S by BCRP was 
completely blocked by hippuric acid. Indoxyl sulfate inhibited transport by both MRP4 
and BCRP at concentrations ranging from 0.1 mM to 4 mM and 50 µM to 3 mM, respectively. 
Kynurenic acid inhibited substrate specific uptake by both MRP4 and BCRP in a 
concentration range of 0.1 µM to 1 mM. In addition, our results illustrate that indole-3- 
acetic acid and phenylacetic acid only reduced [3H]-MTX uptake by MRP4 both at 
concentrations ranging from 0.1 mM to 5 mM. Differences in initial substrate uptake arose 
from batch-to-batch variations of the membrane vesicles, however, all vesicles used 
Kinetic analysis and statistics
Statistics were performed using GraphPad Prism 5.02 via an unpaired t test or a Kruskal- 
Wallis test followed by a Dunn’s Multiple Comparison test. Differences between groups 
were considered to be statistically significant when p < 0.05. The software was also used 
to perform (non-)linear regression analysis, curve fitting details are summarized in Table S1. 
The mean IC50 and IC20 values were calculated from the inhibition curves used for the 
Dixon analysis and to determine the inhibition constant (Ki) from the Dixon plots. Transport 
inhibition studies were performed in triplicate and repeated at least three times. 
RESULTS
Selection of uremic toxins
The number of solutes that are considered to be uremic toxins is constantly increasing 
[135]. As stated before, protein-bound toxins are difficult to eliminate via dialysis and, 
therefore, these toxins accumulate and become players in the multitude of pathologies 
observed in uremic patients. In our study, ten toxins were selected containing one 
water-soluble solute (oxalate) and nine protein-bound solutes. The latter group contained 
four indoles (indoxyl sulfate, indole-3-acetic acid, kynurenic acid and quinolinic acid), 
three phenols (phenylacetic acid, p-cresol and p-toluenesulfonic acid as a model 
compound for p-cresyl sulfate), one hippurate (hippuric acid) and one polyamine 
(putrescine). Chemical characteristics of the solutes studied are depicted in Figure 1.        
Expression of MRP4 and BCRP, and uptake of [3H]-MTX and [3H]-E1S  
by membrane vesicles
Human embryonic kidney (HEK293) cells were transduced using a baculovirus system to 
overexpress human MRP4, BCRP or enhanced yellow fluorescent protein (EYFP; negative 
control). Using the Odyssey Western blot technique, MRP4 and BCRP were detected in 
membrane vesicles isolated from MRP4- and BCRP-overexpressing HEK293 cells at 150 kD 
and 75 kD, respectively. Protein expression of the transporters was absent in EYFP- 
transduced cells, indicating that endogenous expression was undetectable. For functionality 
of MRP4, the uptake of methotrexate (MTX) was investigated by using a radiotracer of the 
drug [133]. Figure 2A shows that the ATP-dependent uptake of [3H]-MTX in MRP4-over-
expressing vesicles is 11-fold higher as compared to EYFP vesicles with an average rate of 
1.3 pmol/mg*min. To determine the transport activity of BCRP, radioactively labeled 
estrone sulfate (E1S) was used as typical substrate [134]. BCRP-overexpressing vesicles 
showed 24-fold higher ATP-dependent uptake of [3H]-E1S, compared to EYFP controls 
with an average rate of 15.5 pmol/mg*min (Figure 2B). Furthermore, Figure 2 demonstrates that 
for both transporters non-specific, AMP-dependent, uptake is very low. Therefore, AMP- 
corrected uptake is shown in subsequent figures. These results support the functional 
expression of the transporters.      
Figure 1  Selected uremic toxins. 
p-toluenesulfonic acid was used as a model compound for p-cresyl sulfate. 
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with a Ki of 4 mM and 0.5 mM, respectively. Furthermore, our results indicated non-com-
petitive inhibition of MRP4-mediated transport by indole-3-acetic acid (Ki: 2mM) and 
kynurenic acid (Ki: 25 µM), while the latter compound acted as a mixed inhibitor for 
[3H]-E1S transport by BCRP. Mixed inhibition is considered to be composed of competitive 
and non-competitive inhibition. The mode of inhibition induced by phenylacetic acid, 
could not be elucidated due to incomplete inhibition of MRP4-mediated transport by this 
toxin. The kinetic analysis is summarized in Table 2.
demonstrated high substrate-specific uptake. The other toxins tested, viz. oxalate, p-cresol, 
p-toluenesulfonic acid, putrescine and quinolinic acid, did not decrease transport 
mediated by MRP4 or BCRP with more than 10% at a concentration of 1 mM, compared to 
control (Figure S1). 
To investigate the mode of interaction, the uptake of three different concentrations of 
substrate in the absence and presence of uremic toxin was studied. The resulting inhibition 
curves were transformed to a Dixon plot and analyzed by linear regression. As depicted in 
the Dixon plots, most curves intersect with the x-axis, indicating non-competitive 
inhibition. Figures 5 and 6 show that hippuric acid and indoxyl sulfate inhibited 
MRP4-mediated transport in a non-competitive manner, with a Ki of 25 µM and 1 mM, 
respectively. Both toxins also inhibited transport by BCRP in a non-competitive fashion 
Figure 2  Transport expression and activity in isolated membrane vesicles. 
HEK293 cells were transfected with a baculovirus of either human MRP4 or BCRP. Cells transfected 
with EYFP were used as a negative control. Subsequently, membranes were isolated and vesicles 
were prepared. Proteins were separated via SDS/PAGE and blotted onto nitrocellulose membranes. 
Blots were incubated with an antibody against MRP4 or BCRP and the appropriated fluorescently 
labeled secondary antibodies. MRP4 was detected at 150 kD (upper panel A) and BCRP was 
detected at 75 kD (upper panel B). A rapid filtration technique was used to study the ATP-dependent 
uptake of [3H]-MTX into MRP4- overexpressing membrane vesicles (lower panel A) and [3H]-E1S into 
BCRP membrane vesicles (lower panel B). As negative control ATP was substituted for AMP. Results 
are presented as mean ± SEM of one representative experiment performed in triplicate. M = marker, 
* indicates p < 0.0001 compared to EYFP. Experiments were performed at least three times. 
Figure 3  Uremic toxins inhibit MRP4-mediated transport. 
A rapid filtration technique was used to study uptake of [3H]-MTX into MRP4 membrane vesicles in 
the presence of various concentrations of uremic toxins. Radioactivity was determined using liquid 
scintillation counting. Nonlinear regression analysis was performed using Graphpad Prism 5.02. 
Results are presented as mean ± SEM of one representative experiment performed in triplicate. 
Experiments were performed at least three times. 
52 53
Uremic toxin-induced transport inhibition
3
Inhibition of MRP4- and BCRP-mediated transport occurs at clinical 
relevant concentrations
The calculated Ki and IC20 values were compared with the mean plasma concentrations 
measured in ESRD patients during this study (Cm), the highest mean/median (Cu) and the 
highest maximal plasma concentrations (Cmax ) measured in the literature in patients with 
CKD are also shown. The IC20 value was used since we believe that a 20% decrease in 
transport can already have a clinical impact. The Cu and Cmax values were obtained from 
the online database of the European Uremic Toxin (EUTox) Work Group (www.
Accumulation of uremic toxins in plasma
To investigate whether the observed transport inhibition induced by several uremic toxins 
occurs at clinically relevant concentrations, the plasma levels of these toxins were 
measured in CRF and ESRD patients using HPLC and LC-MS/MS. Figure 7 illustrates that 
mean hippuric acid levels increased from 2.2 µM to 25 µM in CRF patients and to 160 µM 
in patients with ESRD. Furthermore, it was observed that indoxyl sulfate concentrations 
markedly increased from 13 µM (control) to 65 µM (CRF) and 129 µM (ESRD). The levels of 
indole-3-acetic acid significantly increased in patients with renal failure compared to 
control (2 µM), however, no differences were observed between patients with CRF (4 µM) 
or ESRD (4 µM). Furthermore, mean kynurenic acid levels significantly increased from 0.05 
µM to 0.6 µM in CRF patients and to 1 µM in patients with ESRD. The mean plasma 
concentrations of phenylacetic acid slightly increased during CKD (CRF: 4 µM, ESRD: 18 µM), 
compared to control levels (5 µM), although not significantly. Hence, the interindividual 
variability increased with disease severity, with maximum concentrations reaching 9 µM 
in CRF patients and 83 µM in patients with ESRD.   
Figure 4  Uremic toxins inhibit BCRP-mediated transport. 
A rapid filtration technique was used to study uptake of [3H]-E1S into BCRP membrane vesicles in the 
presence of various concentrations of uremic toxins. Radioactivity was determined using liquid 
scintillation counting. Nonlinear regression analysis was performed using Graphpad Prism 5.02. 
Results are presented as mean ± SEM of one representative experiment performed in triplicate. 
Experiments were performed at least three times. 
Figure 5   Uremic toxins inhibit MRP4-mediated transport mainly in a non-competitive 
fashion. 
A rapid filtration technique was used to study substrate specific uptake by MRP4 membrane vesicles 
in the presence of various concentrations of uremic toxins. Radioactivity was determined using 
liquid scintillation counting. Three independent dose-response experiments were performed, each 
in triplicate, using different concentrations of [3H]-MTX. A Dixon plot of the reciprocal of velocity was 
plotted against the concentration of different uremic toxins. 
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uptake by BCRP at a concentration below the maximal uremic concentration (500 µM vs. 
940 µM). Furthermore, hippuric acid inhibited 20% of the [3H]-E1S uptake by BCRP at a 
concentration almost two-fold lower than the highest median uremic concentration (690 
µM vs. 1.4 mM), whereas the Ki (4 mM) was higher than the Cmax (2.6 mM). 
uremic-toxins.org; [21]), unless stated otherwise. The results are summarized in Table 2. 
Kynurenic acid potently inhibited transport by MRP4, the Ki (25 µM) being notably lower 
than Cmax (50 µM) and the IC20 (1.5 µM) similar to the mean concentration of this compound. 
Furthermore, our results indicated that 50% of MRP4-mediated uptake was inhibited by 
2.5 mM hippuric acid, which is lower than the Cmax of this solute (2.6 mM) and the IC20 (0.35 
mM) is four times lower than the Cu. Phenylacetic acid inhibited 50% of the transport by 
MRP4 at a concentration lower than the Cmax (7 mM vs. 7.7 mM), whereas, 20% of the 
transport was inhibited at a concentration lower than the highest median plasma 
concentration (1.6 mM vs. 3.5 mM). Moreover, the Ki of indoxyl sulfate is almost similar to 
the Cmax of this solute (1 mM vs. 940 µM), whereas, the IC20 (530 µM) is approximately 
two-times below the maximal concentration. Indole-3-acetic acid is the least potent 
inhibitor of MRP4-mediated transport, with both the Ki (2 mM) and the IC20 (570 µM) 
noticeably higher than the Cmax (52 µM). BCRP-mediated transport is significantly inhibited 
by kynurenic acid, with the Ki (50 µM) comparable to the peak uremic toxin concentration 
(50 µM) and the IC20 (10 µM) lower than the Cmax. Indoxyl sulfate acid inhibited 50% of the 
Figure 6   Uremic toxins inhibit BCRP-mediated transport mainly in a non-competitive 
fashion. 
A rapid filtration technique was used to study substrate specific uptake by BCRP membrane vesicles 
in the presence of various concentrations of uremic toxins. Radioactivity was determined using 
liquid scintillation counting. Three independent dose-response experiments were performed, each 
in triplicate, using different concentrations of [3H]-E1S. A Dixon plot of the reciprocal of velocity was 
plotted against the concentration of different uremic toxins. 
Figure 7   Accumulation of uremic toxins during CKD. 
HPLC was used to measure the total plasma concentrations of hippuric acid, indole-3-acetic acid, 
indoxyl sulfate and phenylacetic acid. LC-MS/MS was used to measure kynurenic acid. Plasma 
samples were obtained from healthy volunteers (n=4) and patients with CRF (n=4) or ESRD (n=6). 
Standards of the compounds were also analyzed in order to quantify the amount of toxins found in 
the samples. Acquired HPLC data were processed with PC1000 software (Spectrasystem) and LC-MS/
MS data were processed with Xcaliber software (Thermo scientific). Results are presented as mean ± 
SEM. * indicates p < 0.05 compared to control. 
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DISCUSSION
This study reports, for the first time, that several uremic toxins directly inhibit transport by 
two important efflux pumps, viz. MRP4 and BCRP, at clinically relevant concentrations. 
Since MRP4 and BCRP are located at the apical membrane of proximal tubule cells, 
transport activity depends on the intracellular levels of substrates rather than substrate 
concentrations in the blood. Previously, Masereeuw et al. demonstrated that methyl 
hippuric acids accumulate during secretory transport in the isolated perfused rat kidney 
[137,138]. Furthermore, they showed that 2-methyl hippuric acid levels were 175-times 
higher in kidney tissue compared to the perfusate and 4-methyl hippuric acid 
concentrations were even 600-times higher. Thus, it is likely that intracellular uremic toxin 
concentrations are much higher than total plasma concentrations. This indicates that our 
results probably underestimate the potential inhibitory effect of uremic toxins on MRP4- 
and BCRP-mediated transport in vivo.
Both MRP4 and BCRP belong to the superfamily of ATP-binding cassette (ABC) transporters, 
a family of transmembrane proteins involved in the efflux of endo- and xenobiotics [58]. 
They are expressed in several tissues including liver, intestine, brain and the kidney [58,139]. 
In addition to their contribution to the renal secretion of endogenous compounds, MRP4 
and BCRP are involved in the extrusion of a broad range of drugs [58]. Despite their 
importance, little is known about the expression and activity of both MRP4 and BCRP 
during renal disease. Lu et al. showed, in a rat model of CKD, that BCRP gene expression 
decreased in correlation with disease severity in male rats. In contrast, both gene and 
protein expression of MRP4 remained unaltered [140]. Furthermore, it was demonstrated 
that following acute kidney injury in mice the gene expression of MRP4 increased whereas 
the expression of BCRP decreased. Conversely, protein expression of both transporters 
showed an opposite effect [141]. The impact of kidney disease on transporter expression 
and the inhibition of transport activity by uremic toxins, as described in this study, 
indicates that during CKD  drug disposition may be altered leading to an increased risk of 
adverse drug reactions.
Other transporters of the ABC family are P-glycoprotein (P-gp) and MRP2. These 
transporters are also expressed in the apical membrane of proximal tubule cells, amongst 
other tissues, and, similar to MRP4 and BCRP, they are involved in the urinary excretion of 
drugs [58]. It was described that the activity of P-gp in rat kidneys decreased following 
glycerol-induced acute kidney injury, whereas, P-gp expression increased [142]. In addition, 
it was demonstrated in rats that CRF induced the expression of MRP2 in the kidney while 
P-gp expression remained unaltered [86]. Although P-gp and MRP2 have not been 
associated with uremic toxin clearance, these reports further support the hypothesis that 
pharmacokinetics can be altered during kidney disease due to alterations in expression 
and activity of transporters.
Competition for renal excretion by different compounds with similar structural character-
istics has been demonstrated decades ago in canine models [143]. These classic 
experiments used in vivo models to investigate the effect of certain compounds on the 
renal clearance of an entity with a similar chemical structure. However, these models do 
not allow to distinguish between competitive or non-competitive inhibition, but merely 
showed an overall effect on renal clearance which includes various kinetic steps. 
Nowadays, by applying molecular tools such as the membrane vesicle transport assay, the 
interaction between substrates/inhibitors and a transporter of interest can be studied in 
detail without the interference of other transporters and metabolizing enzymes present 
in available in vivo and in vitro models. However, the membrane vesicle transport assay is 
based on the premise that in vitro uptake is similar to in vivo efflux. Nevertheless, the use of 
isolated membrane vesicles to study transport by efflux transporters has been proven to 
be suitable in both fundamental science and drug discovery [58].The uremic toxins inhibit 
transport predominantly in a non-competitive fashion, suggesting that the toxins tested 
may use a different binding site than [3H]-MTX or [3H]-E1S for either MRP4 or BCRP, or that 
Table 2   Transport inhibition occurs at clinically relevant concentrations
MRP4
Uremic toxin IC50 (µM) IC20 (µM) Ki (µM) Cm (µM) Cu (µM) Cmax (µM)
kynurenic acid 8 ± 1 1.5 ± 0.3 25 ± 2 1 - 50
hippuric acid 990 ± 180 350 ± 20 2500 ± 50 160 1380 2631
phenylacetic acid 7100 ± 1600 1600 ± 170 - 18 3490a 7664b
indoxyl sulfate 1750 ± 110 530 ± 70 1000 ± 90 129 211 940
indole-3-acetic acid 1795 ± 8 570 ± 30 2000 ± 70 4 5 52
BCRP
Uremic toxin IC50 (µM) IC20 (µM) Ki (µM) Cm (µM) Cu (µM) Cmax (µM)
kynurenic acid 40 ± 1 10 ± 1 50c 1 - 50
hippuric acid 3670 ± 170 690 ± 70 4000 ± 100 160 1380 2631
indoxyl sulfate 770 ± 120 390 ± 30 500 129 211 940
Values are shown as mean (Cm; concentration determined in this study), highest mean/median (Cu) and 
maximal uremic concentration (Cmax). Both Cu and Cmax were obtained from www.uremic-toxins.org, unless 
stated otherwise. IC50 and IC20 values are shown as mean ± SEM of three separate experiments performed in 
triplicate.
a Cu obtained from literature [136].
b Hypothetical Cmax, calculated as Cmax = Cu + 2 SD, as previously described [21]. 
c Ki for competitive inhibition
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the toxins are not a substrate for the efflux pumps. It is known that MRP4 has multiple 
binding sites and simultaneously transports urate and cAMP or cGMP [87]. Moreover, 
there is also evidence suggesting that BCRP contains multiple binding regions [144,145]. 
These findings suggest that the toxins tested may show different inhibition profiles when 
studied with other substrates for the transporters. Therefore, it is still possible that the 
tested uremic toxins are also substrates for MRP4 and BCRP. Evidently, more research is 
needed to fully elucidate the molecular interaction of uremic toxins with MRP4 and BCRP. 
Our study further demonstrates that uremic toxins accumulate in patients with renal 
failure. We hypothesize that increasing MRP4- and BCRP-mediated transport activity is an 
important therapeutic target to prevent or reduce the accumulation of uremic toxins in 
dialysis patients. This hypothesis is supported by the study of Toyohara et al. who showed 
that overexpression of SLCO4C1 in the kidney reduces plasma levels of several uremic 
toxins in nephrectomized rats. Furthermore, they demonstrated that the transcription of 
SLCO4C1 is regulated by a xenobiotic responsive core element and that several statins 
induced the transcription of SLCO4C1 [60]. It would be interesting to examine whether 
statins, or drugs with a similar safety and tolerability profile, affect the expression and 
activity of MRP4 and BCRP. 
In the present study the concentrations of five uremic toxins were measured in patients 
with CRF and ESRD. The CRF patients have severe renal insufficiency but were not yet on 
dialysis. The ESRD patients were treated with either peritoneal dialysis or hemodialysis. 
Plasma levels of urea and creatinine, substances not actively secreted to a considerable 
extent, were quite comparable between the groups. Still, our results indicate that the 
levels of several uremic toxins were higher in the ESRD patients as compared to the CRF 
patients. These results are in line with previous studies demonstrating that  blood levels of 
indoxyl sulfate, p-cresol and uric acid are lower in patients with residual renal function 
[146,147]. Thus, residual renal function importantly contributes to the clearance of uremic 
toxins, supporting the hypothesis that active transport is a necessity for the removal of 
uremic toxins. 
Importantly, the mean concentrations of hippuric acid, indoxyl sulfate and phenylacetic 
acid reported in this study are lower than the mean/median concentrations in patients 
reported in literature [21,136]. In contrast, the fold-increase of these toxins in ESRD patients 
compared to healthy controls, are higher in our study than in a preceding study [90]. 
Previously, Vanholder et al. noted that many discrepancies exist in the reported blood 
levels of uremic toxins in patients with renal failure [21]. These authors proposed several 
causes for these differences, including technical reasons (e.g. incomplete elution of 
compounds during chromatography or insufficient extraction of compounds from blood) 
and deviations in study population. Furthermore, it is important to notice that the largest 
variations were found in the concentrations of solutes derived from dietary intake. For 
example, hippuric acid is a metabolite of phenolic compounds found in tea, wine and fruit 
juices and phenylacetic acid is present in many fruits. Thus, it is likely that differences in 
diet between the study populations contribute largely to the observed variations in 
uremic toxin levels.   
CKD is characterized by progressive and irreversible loss of renal function and the patho-
physiological mechanisms underlying the progression of renal failure remain elusive. 
Concluding, several uremic toxins inhibit substrate-specific transport by MRP4 and BCRP 
at clinically relevant concentrations. Our results depict a novel pathway via which uremic 
toxins impede kidney excretory function and can contribute to accumulation of these 
potentially toxic uremic retention solutes.  
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INTRODUCTION
A hallmark of chronic kidney disease (CKD) is the retention and accumulation of a wide 
variety of potential toxic metabolites [21,22], associated with the plethora of pathologies 
observed in uremic patients, including renal fibrosis and cardio-vascular disease [23,135]. 
In the healthy population, these so-called uremic toxins are cleared via the kidney by 
means of glomerular filtration and transporter-mediated tubular excretion. In the early 
days of uremic toxin research, p-cresol, a phenol derived from tyrosine metabolism, was 
widely studied and a broad array of pathophysiological effects observed in CKD patients 
were contributed to this compound, including endothelial and immunological dysfunction 
[30]. However, several years ago it was demonstrated, by several groups, that not p-cresol 
but the metabolites, p-cresyl sulfate (pCS) and p-cresyl glucuronide (pCG), are retained 
during CKD [51,148,149]. P-cresol is formed in the gut during protein fermentation and is 
subsequently conjugated to either sulfate or glucuronic acid in the intestinal wall resulting 
in the formation of pCS or pCG, respectively [125]. In a study by Aronov et al., it was 
elegantly demonstrated that the colon indeed plays a key role in the production of pCS 
[92]. In addition, our group recently showed renal p-cresol metabolism and subsequent 
formation of pCG in human proximal tubular cells [100]. Thus, the origin of pCS and pCG is 
reasonably well understood; however the molecular transport mechanisms involved in 
physiological urinary excretion of both solutes are not fully elucidated. Two pumps that 
likely contribute to the renal excretion of the p-cresol metabolites are multidrug resistance 
protein 4 (MRP4) and breast cancer resistance protein (BCRP). Both pumps are trans -
membrane proteins belonging to the superfamily of ATP-binding cassette (ABC) 
transporters. They are expressed in several tissues with a barrier function, including liver, 
intestine, brain and kidney, and both transporters are known to transport a wide variety of 
drugs and endogenous compounds against steep concentration gradients [58,150]. 
Previously, we reported that several uremic toxins, such as kynurenic acid, hippuric acid 
and indoxyl sulfate, inhibited substrate-specific transport by MRP4 and BCRP at clinically 
relevant concentrations [89]. Since pCS and pCG share structural characteristics with the 
previously studied uremic solutes, we hypothesized that both pumps are also involved in 
the transport of pCS and pCG into the proximal tubule lumen. 
Ever since it has been reported that pCS accumulates in CKD patients, this compound has 
been widely used as a model solute to elucidate the capacity of different dialysis modalities 
to remove protein-bound uremic toxins from the circulation of CKD patients [149]. In 
addition, several studies have shown that pCS can contribute to the pathophysiology of 
CKD. For instance, pCS can increase the shedding of endothelial micro particles by 
endothelial cells in vitro, indicating that pCS is involved in endothelial dysfunction [151]. 
Moreover, pCS can contribute to inflammation [43], suppresses the expression of the 
renoprotective antiaging gene Klotho both in vitro and in vivo [152], and causes insulin 
resistance and metabolic disturbances associated with CKD in mice by activating the 
ABSTRACT
Chronic kidney disease (CKD) is characterized by the progressive accumulation of potential 
toxic metabolites due to impaired renal clearance. Here, we studied the retention of 
p -cresyl sulfate (pCS) and p -cresyl glucuronide (pCG) in different stages of CKD, and we 
aimed to identify the transporters involved in the tubular excretion of pCS and pCG. 
Moreover, the nephrotoxic activity of both solutes was investigated using human 
conditionally immortalized renal proximal tubule epithelial cells (ciPTEC). Our results show 
that pCS and pCG accumulate in plasma of end-stage CKD patients with mean 
concentrations of 161 µM and µM 46, respectively. Moreover, pCS inhibited multidrug 
resistance protein 4 (MRP4)-mediated [3H]-methotrexate ([3H]-MTX) uptake with 40% and 
breast cancer resistance protein (BCRP)-mediated [3H]-estrone sulfate uptake with 25%, 
whereas pCG only reduced [3H]-MTX uptake by MRP4 with 75%. Exposure of ciPTEC to 
pCG caused a 1.4-fold increased protein expression of the mesenchymal marker, vimentin, 
and a 1.5-fold induction of Bcl-2 gene expression, suggesting epithelial-to-mesenchymal 
transition (EMT). This process was associated with changes in the expression of key tubular 
transporters as demonstrated by decreased mRNA levels of organic anion transporting 
polypeptide 4C1 (33-fold) and elevated BCRP expression, with a fold change of 2.2. 
Moreover, both solutes did not induce tubular damage as observed by the gene expression 
of the biomarkers kidney injury molecule-1 and vanin-1. In conclusion, this study shows 
that pCS and pCG plasma levels are elevated during uremia. Moreover, we demonstrated 
that MRP4 and BCRP are likely involved in the renal excretion of both solutes. In addition, 
pCS was shown to lack biological activity in ciPTEC, whereas pCG induced cell stress and 
EMT.   
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4HPLC column (GraceSmart RP 18 5u 150 x 4.6 mm) with eluent A (95% (v/v) 50 mM KH2PO4 
(pH 3.0) and 5% (v/v) acetonitrile) and eluent B (50 mM KH2PO4 (pH 3.0), methanol and 
acetonitrile in a 1:1:1 ratio) using the following gradient: 0-15 min, 100-20% eluent A; 15-16 
min, 20-100% eluent A; 16-21 min, 100% eluent A. The flow rate was 1 ml/min and the 
p-cresol conjugates were detected at a wavelength of 220 nm. Standards of the 
compounds were also run in order to quantify the amount of metabolites found in the 
samples. Acquired data were processed with PC1000 software (Spectrasystem).
Transduction of Human Embryonic Kidney cells and membrane 
vesicle preparation
Human embryonic kidney (HEK293; purchased at American Type Culture Collection, 
Manassas, VA) cells were cultured in Dulbecco’s modified Eagle’s medium (Invitrogen life 
sciences, Breda, the Netherlands) containing 10% (v/v) fetal calf serum (MP Biomedicals, 
Uden, the Netherlands) at 37ºC in a 5% (v/v) CO2 atmosphere. To functionally overexpress 
MRP4 and BCRP, HEK293 cells were transduced with baculoviruses of human MRP4, BCRP 
or enhanced yellow fluorescent protein (eYFP; as a negative control), generated via the 
Bac-to-Bac system (Invitrogen) as previously described [132]. Subsequently, cell membranes 
were isolated and resuspended in isotonic buffer (10 mM Tris-HEPES and 250 mM sucrose, 
pH 7.4, adjusted with HEPES). Membrane vesicles were prepared via ultrafiltration as 
described previously [132]. Afterwards, vesicles were frozen in liquid nitrogen and stored 
at -80 ºC until use. The orientation of the membrane vesicles was not determined, since 
ATP-dependent uptake occurs only in inside-out vesicles.       
ERK1/2 pathway [8]. Furthermore, pCS is often studied in conjunction with indoxyl sulfate, 
a protein-bound uremic toxin derived from tryptophan, and it was recently reported by 
Kim et al. that this solute induces epithelial-to-mesenchymal transition (EMT) in proximal 
tubular cells [153]. Conversely, little is known about the biological activity of pCG and the 
nephrotoxic potential of both p -cresol conjugates is not clear.         
Therefore, this study aimed to elucidate the interaction between pCS and pCG and the 
renal efflux transporters MRP4 and BCRP. Moreover, the human renal proximal tubule cell 
line (ciPTEC) was used to investigate the potential contribution of both p-cresol metabolites 
to CKD progression.  
MATERIALS AND METHODS
Ethics statement
The ethical committee of the Radboud University Nijmegen Medical Centre on research 
involving human subjects approved this study, and written informed consent was 
obtained from each patient and each healthy volunteer.
Chemicals
All chemicals were obtained from Sigma (Zwijndrecht, the Netherlands) unless stated 
otherwise. Both pCS and pCG were kindly provided by Dr. Vanholder (University Hospital 
Ghent, Belgium). pCS was synthesized as a potassium salt as described previously [97]. 
pCG was produced from glucuronyl-trichloroacetimidate and p-cresol using the method 
previously described by Van der Eycken et al. [154]. Since pCS and pCG were obtained as a 
potassium and an ammonium salt, respectively, KCl and NH4Cl solutions were used as 
controls. [3’,5’,7’-3H(n)]-methotrexate disodium salt ([3H]-MTX) was purchased from 
Moravek (Brea, USA) and [6’,7’-3H(n)]-estrone-sulfate ammonium salt ([3H]-E1S) was 
obtained from Perkin Elmer (Groningen, the Netherlands).   
High-performance liquid chromatography (HPLC)
Blood samples were obtained from 4 patients with chronic renal failure (CRF) during 
regular check-up, 4 patients with end-stage renal disease (ESRD) before hemodialysis and 
4 healthy controls. Clinical characteristics of study subjects are listed in Table 1. None of 
the subjects had been fasting at the time of blood sampling. Blood was collected in an 
EDTA Vacutainer and was immediately centrifuged at 3,000 x g for 10 min. Subsequently, 
plasma was collected and stored at -20°C. Before chromatography an aliquot of plasma 
was diluted in H2O (1:1) and deproteinized with perchloric acid (PCA, final concentration 
3.3% (v/v)). Next, samples were centrifuged at 12,000 x g for 3 min and 50 µl of the 
supernatant was injected into the HPLC-system (Spectra-Physics Analytical, Spectrasystem 
SCM400). For the detection of pCS and pCG, chromatography was performed on a C18 
Table 1   Characteristics of study subjects
CRF ESRD Control
Number 4 4 4
Age (years) 51 ± 6 57 ± 10 40 ± 12
Women (%) 0 25 50
Ureum (mmol/l) 22 ± 13 20 ± 6 ND
Creatinine (µmol/l) 211 ± 38 709 ± 105 ND
eGFR (ml/min/1.73 m2) a 30 ± 5 7 ± 1 ND
Dialysis strategy NA 3 HD, 1 CAPD NA
 
Values are shown as mean ± SD. CRF, chronic renal failure; ESRD, end-stage renal disease; ND, not determined; 
NA, not applicable; HD, hemodialysis; CAPD, continuous ambulatory peritoneal dialysis.
aeGFR was calculated using the Modification of Diet in Renal Disease (MDRD) equation.
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Quantitative PCR array
To study gene expression, total RNA was isolated from human kidney homogenate, HK-2 
cells or ciPTEC (exposed to pCS or pCG) using an RNeasy Mini kit (Qiagen, Venlo, the 
Netherlands) according to the manufacturers recommendations. Subsequently, cDNA 
was generated using the Omniscript RT-kit (Qiagen) according to the manufacturers rec-
ommendations. Following cDNA-synthesis, quantitative PCR was performed using a 
CFX96 Real-Time PCR detection system (Bio-rad, Veenendaal, the Netherlands). GAPDH 
was used as housekeeping gene, and relative expression levels were calculated as 
percentage as compared with GAPDH (100%) or as fold change, calculated using the 2-ΔΔCT 
method. The primer-probe sets were obtained from Applied Biosystems (GAPDH, 
hs99999905_m1; OAT1, hs00537914_m1; OAT3, hs00188599_m1; OATP4C1, hs00698884_
m1; Bcl-2, hs00608023_m1; Snail, hs00195591_m1; BCRP, hs00184979_m1; MRP4, 
hs00195260_m1; KIM-1, hs03054855_g1; Vanin-1, hs01546812_m1) 
 
Kinetic analysis and statistics
Statistics were performed using GraphPad Prism 5.02 via one-way analysis of variance 
(ANOVA) followed by Bonferroni’s or Dunnett’s Multiple Comparison Test. Differences 
between groups were considered to be statistically significant when p < 0.05. 
RESULTS AND DISCUSSION
Accumulation of pCS and pCG and changes in p-cresol metabolism 
in CKD patients
Figure 1A-B illustrates that mean pCS levels markedly increased from 20 µM in healthy 
controls to 107 µM in non-dialysis CRF patients and to 161 µM in dialysis patients. Moreover, 
the concentration of pCG increased from 0.3 µM (control) to 3 µM (CRF) and 46 µM (ESRD). 
Interestingly, the paradigm of p-cresol being one of the most important uremic toxins was 
an artifact resulting from strong acidification of plasma samples for deproteinization 
resulting in hydrolysis of both pCS and pCG [5]. In the current study, PCA extraction was 
used as a method for protein removal, still the pCS levels determined here are similar to 
the concentrations reported by several groups using different deproteinization methods 
including methanol extraction, enzymatic degradation or heating [6; 8; 22; 23]. Reports on 
pCG concentrations in CKD patients are scarce and considerably diverse, the results 
presented here corroborate the findings by Meert et al., suggesting that pCG levels are 
much higher than previously reported [23]. Taken together, our results indicate that 
acidification can be successfully used as a deproteinization method when measuring 
plasma levels of pCS and pCG; yet one has to take into account that the p -cresol conjugates 
are prone to hydrolysis.
Membrane vesicle transport inhibition assay
A rapid filtration technique, well-established in our laboratory [89,132,150,155], was used to 
study the uptake of [3H]-MTX and [3H]-E1S into MRP4 or BCRP membrane vesicles. In short, 
25 µl of TS buffer containing 4 mM ATP, 10 mM MgCl2 and radiolabeled substrate was 
added to 5 µl of the membrane vesicles (1.5 mg/ml). The transport assay was performed 
in the absence or presence of various concentrations of pCS or pCG to evaluate the 
inhibitory effects of these compounds on MRP4-mediated [3H]-MTX uptake and 
BCRP-mediated [3H]-E1S uptake. Transport was started by incubating the mixture at 37 ºC 
for 1 min (BCRP) or 10 min (MRP4), time points at which substrate uptake was previously 
shown to be linear [132,134]. Uptake was stopped by placing the samples on ice and the 
addition of 150 µl ice cold TS buffer. Subsequently, the samples were transferred to a 96 
well filter plate (Millipore, Etten-leur, the Netherlands) pre-incubated with TS buffer and 
filtered using a Multiscreen HTS-Vacuum Manifold filtration device (Millipore). Afterwards, 
2 ml of scintillation liquid was added to each filter and radioactivity was determined using 
liquid scintillation counting. As negative controls ATP was substituted for AMP and 
eYFP-membrane vesicles were used. Each experiment was performed in triplicates.  
Proximal tubule cell culture
The ciPTEC line was generated as previously described by Wilmer et al. [98]. The cells were 
cultured in ciPTEC medium containing phenol red free DMEM/F12 medium (Gibco/
Invitrogen, Breda, the Netherlands) supplemented with 10% (v/v) fetal calf serum (FCS; MP 
Biomedicals, Uden, the Netherlands), insulin (5 µg/ml), transferrin (5 µg/ml), selenium (5 
ng/ml), hydrocortisone (36 ng/ml), epithelial growth factor (10 ng/ml), and tri-iodothy-
ronine (40 pg/ml) at 33ºC in a 5% (v/v) CO2 atmosphere. Propagation of cells was 
maintained by subculturing the cells at a dilution of 1:3 to 1:6 at 33°C. For experiments, 
cells were cultured at 33ºC to 40% confluency, followed by maturation for 7 days at 37ºC. 
Experiments were performed using cells between passages 30 and 40.
Flow cytometry
In this study, flow cytometry was used to study the expression of vimentin, a mesenchymal 
cell marker. ciPTEC were seeded at 40% confluence in 12-well plates and allowed to adhere 
over night at 33ºC followed by maturation for 7 days at 37ºC, before being treated for 48 
hours with either pCS or pCG (0-2 mM). After incubation, cells were harvested using 
trypsin-EDTA and centrifuged at 600 x g during 5 min. Subsequently, supernatant was 
removed and the cell pellet was resuspended in 100 µL PBS containing 1 µL mouse-α-human 
Vimentin-PE (Abcam, Cambridge, UK) followed by 30 min incubation at RT. Samples were 
acquired with a BD FACSCalibur (Becton Dickinson, Breda, the Netherlands) using channel 
FL-2. Analysis was performed using Flow Jo software (TreeStar, Ashland, USA), gating on 
live cells. 
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be sustained for a limited time in culture [34]. In the study from Miyamoto et al., protein 
expression of OATs was solely demonstrated by an unconvincing Western blot. Previously, 
it has been reported that OATs can become non-functional upon culturing due to inter-
nalization [32]. These findings indicate that, although protein expression seems to be 
present, multiple assays are required to demonstrate functionality of transporters.
How can the uptake of pCS as observed by Miyamoto et al. be explained? Another kidney- 
specific basolateral transporter demonstrated to be involved in the removal of uremic 
toxins is the organic anion transporting polypeptide 4C1 (OATP4C1) [35; 36]. Note that the 
lack of inhibition by digoxin, as demonstrated by Miyamoto et al., is not conclusive for the 
involvement of this transporter [36]. Using quantitative PCR, we indeed demonstrated the 
expression of OATP4C1 in human kidney homogenates and HK-2 cells with a 6-fold and 
It is widely known that drug disposition is altered in CKD patients [24; 25], including the 
kinetics of drugs solely cleared via phase II metabolism [26-28]. Enzymes belonging to 
this class catalyze conjugation reactions such as glucuronidation, acetylation and 
sulfation [50]. Recently, using ciPTEC, our group demonstrated that uremic toxins can 
diminish renal UDP-glucuronosyltransferase functionality, probably through interference 
with mitochondrial succinate dehydrogenase activity and by reducing the reserve 
capacity of the energy-generating oxidative phosphorylation system [13]. Moreover, 
Simard et al., reported that exposure of rat hepatocytes to uremic serum resulted in a 
decreased expression of N-acetyltransferase (NAT)1 and NAT2 [29]. Expression of both 
enzymes was also lower in the liver of CRF rats, which was accompanied by a reduction in 
NAT2-mediated acetylation of p-aminobenzoic acid [29]. However, little is known about 
sulfotransferase (SULT) expression and functionality in patients with renal failure. In the 
current study, HPLC revealed that the p-cresol metabolite fraction shifted from sulfation to 
glucuronidation with a pCG percentage of 2% in CRF patients and 22% in ESRD patients 
(Figure 1C). These findings provide the first evidence that SULT-mediated p-cresol 
metabolism is saturated or reduced in dialysis patients. Of interest, Sugimura et al. reported 
that SULT1C2 gene expression was decreased in an acquired polycystic kidney disease 
model in rats [30]. Still, the link between CKD and SULTs requires further investigation and 
may contribute to our understanding of the pathophysiology of CKD.   
Basolateral transport of p-cresyl sulfate
Our results demonstrated that pCS and pCG are retained during CKD and it is known that 
active tubular transport is a necessity for the clearance of protein-bound uremic toxins 
[17]. Therefore, we aimed to identify the proximal tubular pumps involved in the renal 
handling of pCS and pCG. Recently, Miyamoto et al., described a role for organic anion 
transporters (OATs) in the uptake of pCS using rat renal cortical slices and a human proximal 
tubule cell model, viz. HK-2 cells [31]. In their study, uptake of pCS in both model systems 
could be inhibited by several OAT inhibitors including probenecid and p-aminohippuric 
acid. As described by the authors, specificity of pCS transport was investigated using 
well-known substrates for OATs at a concentration of 1 or 10 mM in renal slices or HK-2 
cells, respectively. As these concentrations are much higher compared to their inhibitory 
potencies reported [32], it could be argued that the affinity of pCS for OATs is very low in 
both models. Moreover, such concentrations are hardly soluble in an aqueous solution at 
physiological pH and highly influence cell viability [33]. 
In our opinion, it is more likely that HK-2 cells have only little or no expression at all of OATs. 
Functional transport by OATs is generally studied using heterologous expression in 
cultured cells or Xenopus leavis oocytes [32]. These systems are used because there are no 
stable cell lines known to date that highly express functional endogenous OATs and, to 
our knowledge, no publications are available for functional OAT transport in HK-2 cells. 
Moreover, functional expression of OATs in primary human proximal tubule cells can only 
Figure 1   Accumulation of p-cresol metabolites during CKD. 
HPLC was used to measure the total plasma concentrations of (A) pCS and (B) pCG. Plasma samples 
were obtained from healthy volunteers (n=4) and patients with CRF (n=4) or ESRD (n=4). Standards 
of the compounds were also analyzed in order to quantify the amount of toxins found in the 
samples. Acquired HPLC data were processed with PC1000 software (Spectrasystem). (C) Percentage 
of pCS and pCS. Statistical analysis was performed via one-way ANOVA followed by the Dunnett’s 
Multiple Comparison Test for each toxin. Results are presented as mean ± SEM. * indicates p < 0.05 
compared to control. 
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was demonstrated that, at the highest concentration (1 mM), pCS inhibited MRP4-mediated 
[3H]-MTX uptake with 40% and BCRP-mediated [3H]-E1S uptake with 25% (Figure 3A-B). 
In contrast, Figure 3A showed that pCG solely reduces [3H]-MTX uptake by MRP4, 
concentration- dependently, with a 18% reduction in transport at 1 µM and a reduction of 
75% at 1 mM. These results suggest that MRP4 and BCRP might contribute to the renal 
handling of p-cresol metabolites.    
Induction of phenotypical changes by pCS and pCG 
As described above, the toxicity of pCS is widely investigated and the metabolite is linked 
to the development of cardiovascular disease in CKD patients. In contrast, little is known 
about the biological activity of pCG. One of the first reports on the toxic effects of pCG 
demonstrated that the solute itself did not influence oxidative burst activity in multiple 
leukocyte subtypes [8]. Nonetheless, pCG did potentiate the pro-inflammatory effect of 
pCS [8]. Furthermore, pCS is often studied in conjunction with indoxyl sulfate, a 
protein-bound uremic toxin derived from tryptophan, and it was recently reported by Kim 
et al. that this solute induces epithelial-to-mesenchymal transition (EMT) in proximal 
tubular cells [39]. Therefore, the nephrotoxicity of both p-cresol conjugates was 
investigated, with an emphasis on EMT. Figure 4A shows that pCG concentration-de-
pendently increased the expression of the mesenchymal marker vimentin and a 1.4-fold 
induction was observed at the highest concentration. Moreover, it is known that 
transitioning epithelial cells are resistant to apoptosis [40], indeed pCG induced expression 
163-fold increased relative expression, respectively (Figure 2; GAPDH 100%), whereas gene 
expression levels of OAT1 and OAT3 were undetectable in the cell line (Figure 2B). These 
findings were recently confirmed in a study by Jenkinson et al, demonstrating that HK-2 
cells indeed express OATP4C1 and lack OAT1 and OAT3 expression, as compared with 
human renal cortex samples [37]. In addition, they stated that HK-2 cells are a limited 
model of transporter expression and activity in the proximal tubule [37].     
Taken together, the low affinity of pCS as demonstrated together with the absence of 
OATs in the HK-2 model suggest that the mechanism of pCS excretion in the kidney is 
more complicated than postulated by Miyamoto et al., and the possible contribution of 
OATP4C1 warrants further investigation.
Apical transporters involved in pCS and pCG clearance 
Two pumps that likely contribute to the urinary excretion of the p-cresol metabolites are 
multidrug resistance protein 4 (MRP4) and breast cancer resistance protein (BCRP). Both 
pumps are transmembrane proteins belonging to the superfamily of ATP-binding cassette 
(ABC) transporters. They are expressed in several tissues with a barrier function, including 
liver, intestine, brain and kidney, and both transporters are known to transport a wide 
variety of drugs and endogenous compounds against steep concentration gradients [18; 
38]. Previously, we reported that several uremic toxins, such as kynurenic acid, hippuric 
acid and indoxyl sulfate, inhibited substrate-specific transport by MRP4 and BCRP at 
clinically relevant concentrations [17]. Since pCS and pCG share structural characteristics 
with the previously studied uremic solutes, we hypothesized that both pumps are also 
involved in the transport of pCS and pCG into the proximal tubule lumen. Using membrane 
vesicles isolated from MRP4- or BCRP-overexpressing human embryonic kidney cells it 
Figure 2   Expression of basolateral transporters. 
Total mRNA was isolated from (A) human kidney homogenate or (B) HK-2 cells. Afterwards, cDNA 
was synthesized and transporter gene expression was studied using qPCR. Relative expression was 
calculated using the household gene GAPDH (100%). Bars represent mean ± SEM of one experiment. 
ND, not detected. 
Figure 3   Uremic toxins inhibit MRP4- and BCRP-mediated transport. 
A rapid filtration technique was used to study (A) MRP4-mediated [3H]-MTX uptake or (B) 
BCRP-mediated [3H]-E1S uptake into membrane vesicles in the presence of various concentrations of 
p-cresol metabolites. Radioactivity was determined using liquid scintillation counting. Statistical 
analysis was performed via one-way ANOVA followed by the Dunnett’s Multiple Comparison Test for 
each toxin. Results are presented as mean ± SEM of one representative experiment performed in 
triplicate. * indicates p < 0.05 compared to control. 
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Since pCG exposure resulted in a loss of proximal tubular characteristics, gene expression 
of key transporters was studied in more detail. Following treatment with pCG, OATP4C1 
expression was significantly reduced, whereas expression of BCRP increased more than 
2-fold (Figure 5A-B). In addition, no changes in MRP4 mRNA levels were observed, as 
demonstrated in Figure 5C. Together with the observed induction of EMT, these results 
suggest that pCG exposure causes cell stress. 
Next, it was investigated whether pCS and pCG induced cell injury by determining the 
mRNA levels of two early markers of tubular damage, namely kidney injury molecule-1 
(KIM-1) and vanin-1 [42; 43]. Figure 6A shows that exposure of ciPTEc to pCG caused a 
significant, concentration-dependent, reduction in KIM-1 expression; while pCS did not 
change expression levels. Moreover, vanin-1 mRNA levels remained unchanged following 
treatment with either pCS or pCG (Figure 6B). This suggests, that both solutes did not 
induce tubular damage. 
of the anti-apoptotic gene Bcl-2, as demonstrated in Figure 4B. The process of EMT is 
regulated by several transcription factors, including Slug, Twist and Snail. As depicted in 
Figure 4C, Snail gene expression was significantly down-regulated following pCG 
exposure. In contrast to our findings, up-regulation of vimentin is normally secondary 
to increased mRNA levels of Snail. However, Berzal et al., demonstrated in HK-2 cells, that 
during cyclosporine A-induced EMT, Snail gene expression decreased while protein 
expression increased due to a reduced rate of protein degradation [41]. Thus, our results 
indicate that pCG can induce EMT in ciPTEC, thereby possibly augmenting CKD development. 
Figure 4   Induction of EMT by pCS and pCG in ciPTEC. 
Cells were exposed for 48 h to salt control solution (grey bar), 1 mM (white bars) or 2 mM  (black bars) 
of pCS or pCG. (A) Following treatment, cells were harvested and stained with mouse-α-human 
Vimentin-PE. Quantification of staining was done with a BD FACSCalibur flow cytometer using 
channel FL-2, and analyzed with FlowJo software, gating on live cells. Statistical analysis was 
performed via one-way ANOVA followed by the Dunnett’s Multiple Comparison Test for each toxin. 
Results are presented as mean ± SEM of four independent experiments performed in duplicate. * 
indicates p < 0.05 compared with control. (B-C) Following treatment, ciPTEC were harvested and 
total mRNA was isolated. Afterwards, cDNA was synthesized and (B) Bcl-2 and (C) Snail expression 
was studied using qPCR. GAPDH was used as housekeeping gene and relative expression levels 
were calculated using the 2-ΔΔCT method. Statistical analysis was performed via one-way ANOVA 
followed by the Bonferonni’s Multiple Comparison Test for each toxin. Values are shown as mean ± SEM 
of three independent experiments performed in triplicate. * indicates p < 0.05 compared to control. 
Figure 5   Impact of pCS and pCG on expression of apical transporters. 
Cells were exposed for 48 h to salt control solution (grey bar), 1 mM (white bars) or 2 mM  (black bars) 
of pCS or pCG. Following treatment, ciPTEC were harvested and total mRNA was isolated. Afterwards, 
cDNA was synthesized and (A) OATP4C1, (B) BCRP and (C) MRP4 expression was studied using qPCR. 
GAPDH was used as housekeeping gene and relative expression levels were calculated using the 
2-ΔΔCT method. Statistical analysis was performed via one-way ANOVA followed by the Bonferonni’s 
Multiple Comparison Test for each toxin. Values are shown as mean ± SEM of minimally two 
independent experiments performed in triplicate. * indicates p < 0.05 compared to control. 
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In contrast to the marked impact of pCG on ciPTEC phenotype, e.g. increased vimentin 
expression and altered expression of in- and efflux transporters, no changes were 
observed following exposure to pCS (Figure 4 and 5). Which is in stark disparity with 
previous results obtained in leukocytes [8]. This suggests, that the toxicity of both p-cresol 
metabolites is cell type-specific. Moreover, a drawback of the present study is that the pCS 
and pCG concentrations used do not reflect the clinical situation. Still, we are the first to 
demonstrate, to the best of our knowledge, that pCG might promote CKD progression by 
inducing phenotypical changes in human proximal tubule cells.      
In conclusion, in this study we report the retention of pCS and pCG in CKD patients and 
we provide the first evidence for the involvement of MRP4 and BCRP in the physiological 
renal clearance of both solutes. Moreover, our results demonstrated that pCS does not 
exert nephrotoxic effects, whereas pCG induced cell stress and EMT in ciTPEC. These 
findings offer novel insights on the divers contribution of both p -cresol conjugates in CKD 
pathophysiology.      
ACKNOWLEDGEMENTS
This work was supported by the Dutch Kidney Foundation (grant number IK08.03; www.
nierstichting.nl). M.J.G. Wilmer was supported by a grant from the Dutch government 
to the Netherlands Institute for Regenerative Medicine (NIRM, grant No. FES0908; 
www.nirm.nl) and J.G. Hoenderop was supported by an EURYI award from the European 
Science Foundation. 
Figure 6   pCS and pCG do not induce proximal tubular damage. 
Cells were exposed for 48 h to salt control solution (grey bar), 1 mM (white bars) or 2 mM  (black bars) 
of pCS or pCG. Following treatment, ciPTEC were harvested and total mRNA was isolated. Afterwards, 
cDNA was synthesized and (A) KIM-1 and (B) vanin-1 expression was studied using qPCR. GAPDH 
was used as housekeeping gene and relative expression levels were calculated using the 2-ΔΔCT 
method. Statistical analysis was performed via one-way ANOVA followed by the Bonferonni’s 
Multiple Comparison Test for each toxin. Values are shown as mean ± SEM of minimally two 
independent experiments performed in triplicate. * indicates p < 0.05 compared to control. 
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INTRODUCTION
Uric acid is a weak organic acid and the end-product of purine nucleotides degradation in 
humans. One of the enzymes involved in this process is xanthine oxidoreductase, which 
enables the oxidation of hypoxanthine to xanthine and can further catalyze the oxidation 
of xanthine to uric acid. During this reaction, reactive oxygen species are generated as 
by-product [156,157]. Therefore, uric acid is recognized as a marker for oxidative stress. 
However, the molecule itself has antioxidant properties and can act as a free radical 
scavenger and chelator of transitional metal ions which are converted into poorly reactive 
forms [158]. Hyperuricemia, i.e. elevated plasma uric acid levels (≥ 360 µM) [159], is related 
to a variety of pathologies, including gout, cardiovascular disease and chronic kidney 
disease (CKD). Gout is the most common form of inflammatory arthritis caused by sodium 
uric acid crystal precipitation, which is followed by phagocytosis of the crystals by 
neutrophils and macrophages and activation of acute inflammation and tissue injury 
[160]. Epidemiological studies show that prevalence and incidence are still increasing 
[161,162]. Formation of uric acid crystals is also the cause of nephrolithiasis, i.e. kidney 
stones, which is significantly more common among patients diagnosed with metabolic 
syndrome, obesity and type 2 diabetes [163]. Hyperuricemia also correlates with the 
development and progression of cardiovascular diseases [164-166], potentially via 
interfering with nitric oxide function. In animal models, it has been shown that mild 
hyperuricemia contributes to the development of hypertension as a result of endothelial 
dysfunction and reduction of nitric oxide levels [165,167,168]. Recently, hyperuricemia has 
received attention as a possible risk factor for CKD [159,169], which affects approximately 
10% of the adult population in developed countries [5]. Hyperuricemia has been associated 
with a hazard ratio of 2.1 and 1.3 for men and women for developing CKD [159], respectively. 
Several mechanisms were proposed via which uric acid could contribute to the 
development of CKD, including uric acid-induced glomerular hypertrophy and endothelial 
dysfunction [159,170]. However, the pathophysiological mechanism has as of yet not been 
fully elucidated.
In healthy individuals, two-thirds of uric acid is excreted by the kidney and one-third by 
the intestine due to breakdown of urate by gut bacteria. Purine ingestion, endogenous 
synthesis of purines from nonpurine precursors and reutilization of preformed purine 
compounds are the sources of uric acid production, a process that, under steady-state 
conditions, is in balance with the uric acid disposal [171,172]. Hyperuricemia can develop 
due to overproduction or a diminished excretion of uric acid. Maintaining uric acid 
homeostasis is highly dependent on kidney function and regulated by a number of 
transporters, including the urate transporter 1 (URAT1; SLC22A12) - responsible for up to 
99% of uric acid reabsorption after glomerular filtration - the facilitated glucose transporter 
(solute carrier family 2 member 9 (SLC2A9) [173], several organic anion transporters 
including OAT1 (SLC22A6) and OAT3 (SLC22A8) [160], and the ATP-dependent urate efflux 
ABSTRACT
Hyperuricemia is related to a variety of pathologies, including chronic kidney disease 
(CKD). However, the pathophysiological mechanisms underlying disease development 
are not yet fully elucidated. Here, we studied the effect of hyperuricemia on tryptophan 
metabolism and the potential role herein of two important uric acid efflux transporters, 
multidrug resistance protein 4 (MRP4) and breast cancer resistance protein (BCRP). 
Hyperuricemia was induced in mice by treatment with the uricase inhibitor oxonic acid, 
confirmed by the presence of urate crystals in the urine of treated animals. A transport 
assay, using membrane vesicles of cells overexpressing the transporters, revealed that uric 
acid inhibited substrate-specific transport by BCRP at clinically relevant concentrations 
(calculated IC50 value: 365 ± 13 µM), as was previously reported for MRP4. Moreover, we 
identified kynurenic acid as a novel substrate for MRP4 and BCRP. This finding was 
corroborated by increased plasma levels of kynurenic acid observed in Mrp4-/- (107 ± 19 
nM; p = 0.145) and Bcrp-/- mice (133 ± 10 nM; p = 0.0007) compared to wild type animals 
(71 ± 11 nM). Hyperuricemia was associated with >1.5 fold increase in plasma kynurenine 
levels in all strains. Moreover, hyperuricemia led to elevated plasma kynurenic acid levels 
(128 ± 13 nM, p = 0.005) in wild type mice but did not further increase kynurenic acid levels 
in knockout mice. Based on our results, we postulate that elevated uric acid levels hamper 
MRP4 and BCRP functioning, thereby promoting the retention of other potentially toxic 
substrates, including kynurenic acid, which could contribute to the development of CKD.
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of TS buffer supplemented with 4 mM ATP/AMP, 10 mM MgCl2 and 250 nM [
3H]-metho-
trexate (MTX; for MRP4) or [3H]-estrone sulphate (E1S; for BCRP) at pH 7.4 was added to 7.5 
µg of membrane vesicles (based on total protein content). After incubation at 37 ºC to 
enable ATP-dependent uptake, the reaction was stopped by placing the samples on ice 
and by addition of ice-cold TS buffer. Reaction mix was removed and the vesicles were 
washed by means of a rapid filtration technique using filter plates (Millipore, Etten-Leur, 
The Netherlands). Scintillation fluid was added to the filters and the amount of radioactivity 
was determined using a scintillation counter (Tri-Carb® 2900TR; Perkin Elmer, Waltham, MA, 
USA). Reference samples were measured to calculate the amount of transported MTX and 
E1S. ATP-dependent transport was calculated by subtracting values measured in the 
presence of AMP from those measured in the presence of ATP. Net transporter-mediated 
substrate uptake was calculated by subtracting ATP-dependent uptake in HEK293-mock 
vesicles from that of HEK293-transporter vesicles. 
Uptake of kynurenic acid into MRP4-overexpressing membrane vesicles was established 
using the same assay. Vesicles were incubated with 0.1 mM kynurenic acid in the presence 
of AMP or ATP. After the described washing step, kynurenic acid was determined by 
LC-MS/MS. 
Oxonic acid-mediated induction of hyperuricemia in mice
All experiments were approved by the local Animal Welfare Committee of the Radboud 
University Nijmegen Medical Centre (RU-DEC 2012-018), in accordance with the directive 
for animal experiments (2010/63/EU) of the European Parliament. The effects of 
hyperuricemia in vivo were examined in wild type (WT) Friend leukemia virus B (FVB) mice 
as well as Mrp4-/- and Bcrp-/- mice (both FVB background). The WT FVB and Bcrp-/- mice 
were kindly provided by Dr. A. Schinkel (Netherlands Cancer Institute, Amsterdam, The 
Netherlands) and the Mrp4-/- mice by Dr. J. Schuetz (St. Jude Children’s Research Hospital, 
Memphis, TN, USA) and Dr. P. Borst (Netherlands Cancer Institute, Amsterdam, The 
Netherlands), all animals were bred and housed at the Central Animal Laboratory of the 
RUNMC. The animals (N=9) received the uricase inhibitor oxonic acid (2% w/v; pH 7) via 
their drinking water, ad libitum, to induce hyperuricemia [178]. The animals were individually 
caged and housed under controlled conditions. Parallel control groups were also 
individually caged and received normal tap water at equal pH. After 14 days, mice were 
placed individually in metabolic cages (Techniplast, Germany GmbH) to collect 24 h urine 
samples, with access to water (with or without oxonic acid 2% w/v) and pulverized 
standard chow ad libitum. Next, blood was collected from the orbital sinus in lithium-hep-
arin tubes via a terminal procedure performed under isoflurane anesthesia and centrifuged 
for 15 min at 3,000 x g to obtain plasma. Animals were sacrificed by cervical dislocation. 
Isolated kidneys, plasma and urine were immediately snap frozen in liquid nitrogen and 
stored at -80 °C until further analysis. Biochemical parameters were determined by routine 
clinical chemistry.
transporters multidrug resistance protein 4 (MRP4; ABCC4) [87] and breast cancer resistance 
protein (BCRP; ABCG2) [88,130,174]. 
As uric acid is one of the important factors in a variety of pathologies, tight regulation of 
this metabolite is of key importance. The vital role of transporters in uric acid homeostasis 
can clearly be observed in patients suffering from hyperuricemia due to single nucleotide 
polymorphisms (SNPs) that render the transporters inactive, such as the common SNP 
C421A encoding the Q141K mutation of BCRP [88,130,175] and several genetic variants for 
SLC2A9 [173]. Next to genetic factors, high plasma levels of uric acid might also result in a 
reduced transporter activity [87]. Since these transporters are also involved in the excretion 
of a wide variety of other compounds, changes in transport efficacy could result in 
metabolic disturbances. This hypothesis is corroborated by two recent studies showing 
that high uric acid levels in patients with acute gout were associated with altered 
tryptophan concentrations in plasma and urine [176,177]. Therefore, the aim of our study 
was to investigate the effect of hyperuricemia on tryptophan metabolism and the 
potential role herein of two important uric acid efflux transporters, MRP4 and BCRP. Both 
transporters are expressed in the apical membrane of renal proximal tubule cells, amongst 
other tissues, and are involved in the urinary excretion of a multitude of endogenous 
compounds and drugs [84]. Using Mrp4-/- and Bcrp-/- mice, we show that hyperuricemia is 
associated with the accumulation of tryptophan and associated metabolites, most likely 
due to transporter dysfunction. 
MATERIAL AND METHODS
Transduction of Human Embryonic Kidney cells and preparation 
of membrane vesicles
Overexpression of MRP4 and BCRP in human embryonic kidney cells (HEK293; American 
Type Culture Collection, Manassas, VA) was established using baculoviruses, which were 
produced using the Bac-to-Bac and the Gateway system (Invitrogen, The Netherlands), as 
described previously [132,150]. As a control, the enhanced yellow fluorescent protein 
(eYFP) was introduced as mock protein into the baculovirus expression system. Crude 
membranes of HEK293-MRP4, -BCRP and -mock cells were isolated, resuspended in TS 
buffer (10 mM Tris-HEPES and 250 mM sucrose, pH 7.4) and membrane vesicles were 
prepared according to a previously described method [132] by means of ultracentrifuga-
tion. Crude membrane vesicles were dispensed in aliquots, snap frozen in liquid nitrogen, 
and stored at -80 °C until further use.
Membrane vesicle inhibition and uptake assays
The effects of uric acid and oxonic acid on MRP4 and/or BCRP activity were assessed by a 
well-established assay in our laboratory [89,132,150,155]. In brief, a reaction mix consisting 
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between all groups as well as an unpaired Student’s t-test to study the impact of oxonic 
acid treatment within each strain. Differences between groups were considered to be 
statistically significant when p < 0.05. GraphPad Prism was also used to perform non-linear 
regression analysis. 
RESULTS
Oxonic acid induces hyperuricemia 
To study the impact of hyperuricemia on murine physiology, wild type (WT), Mrp4-/- and 
Bcrp-/- mice were treated with the uricase inhibitor oxonic acid as described before [178]. 
Two weeks of oxonic acid treatment did neither affect overall weight of the mice, nor 
plasma levels of urea, sodium and calcium (Table 1). Interestingly, water intake was strongly 
increased after oxonic acid treatment in all strains investigated, with an increase up to four 
times that of controls in Bcrp-deficient mice. This was accompanied by a two-fold increase 
in urine flow in treated WT animals; whereas no significant changes were observed in 
knockout animals. Yet baseline urine flow of Bcrp-/- mice tended to be increased as 
compared to WT animals. 
Following oxonic acid treatment, the urine collected from all animals was turbid due to 
presence of crystals (Figure 1A-D). Energy-dispersive X-ray microanalysis (EDX) revealed 
that the major constituents of the urinary crystals were sodium, potassium, phosphorus 
and calcium; the copper signals arose from the sample grid used in the analysis (Figure 1E). 
Two types of crystals could be distinguished: first, crystals that showed an archetypical 
peak pattern corresponding to uric acid crystals, which consisted primarily of sodium, 
calcium and phosphorus (Figure 1F). Second, crystals that mainly contained calcium and 
potassium (Figure 1G), which was likely due to the treatment with oxonic acid potassium 
salt. These data are in accordance with the development of hyperuricemia in oxonic 
acid-treated mice. 
Uric acid inhibits BCRP activity
Plasma urate levels are controlled by an interplay of transporters expressed in the kidney 
proximal tubules. MRP4 and BCRP have been associated with active urinary urate efflux, 
and MRP4 was also sensitive to inhibition by urate [87]. We determined the inhibitory 
properties of uric acid on BCRP activity using membrane vesicles prepared from 
BCRP-overexpressing HEK293 cells. Uric acid dose-dependently inhibited BCRP-mediated 
uptake of the substrate E1S (Figure 2A) with a calculated half maximal inhibitory 
concentration (IC50) value of 365 ± 13 µM. Complete inhibition of BCRP activity was found 
at the highest uric acid concentration used (i.e. 1 mM). These findings indicate that uric 
acid can reduce transport activity of two important efflux pumps at concentrations 
demonstrated in patients with hyperuricemia (≥ 360 µM).
Energy-dispersive X-ray (EDX) microanalysis 
Transmission electron microscopy and EDX were performed for identification of the 
ultrastructure and composition of the insoluble crystals found in the urine samples of 
oxonic acid-treated mice. Urine samples were spotted onto copper grids (100 mesh) 
coated with a support film, air dried, negative stained with uranyl acetate and examined 
using a Jeol 1200 EX II. For EDX measurements, the grids were examined using a Jeol 1200/
STEM in combination with a Thermo Noran microanalysis six system. Accelerated voltage 
of 60 KeV was used for X-ray microanalysis. X-ray spectra for element distribution were 
acquired. In each sample, 3-5 measuring points were selected.
RNA isolation and quantitative PCR
Effects of hyperuricemia on kidney injury were evaluated by determining mRNA expression 
levels of early renal injury markers kidney injury molecule-1 (Kim-1) and neutrophil gelatinase- 
associated lipocalin (Ngal) in kidneys of treated and control mice. Frozen kidneys were 
homogenized using a Mikro-dismembrator U (Sartorius B. Braun Biotech Int., Melsungen, 
Germany). Subsequently, total RNA was isolated using a NucleoSpin® RNA II kit (Macherey-
Nagel, Düren, Germany) according to manufacturer’s instructions. Immediately, a reverse 
transcriptase reaction was performed with 250 ng RNA using random primers (Invitrogen, 
Breda, The Netherlands) and an Omniscript® RT kit (Qiagen, Hilden, Germany), following 
manufacturer’s recommendations. Synthesized cDNA was used for quantitative PCR, 
performed in a StepOnePlus™ Real-Time PCR system by means of the TaqMan® protocol 
(Applied Biosystems, Warrington, UK). Kim-1 and Ngal mRNA concentrations were normalized 
to the mRNA concentration of the housekeeping gene glyceraldehyde-3-phosphate 
dehydrogenase (Gapdh). The primer-probe sets were obtained from Applied Biosystems 
(Gapdh; Mm999999915_g1, Kim-1; havcr1 Mm00506686_m1, Ngal; lcn2 Mm01324470_m1).
Tryptophan, kynurenine and kynurenic acid measurements by LC-MS/MS
After the vesicle uptake experiments, kynurenic acid was extracted from the filters in 3.3% 
perchloric acid. Plasma samples were diluted in H2O (1:1) prior to LC-MS/MS measurements 
and deproteinized with perchloric acid (final concentration 3.3%). Samples were 
centrifuged at 12,000 x g for 3 min. Clear supernatant was injected into the LC-MS/MS 
system that consisted of an Accela HPLC system (Thermo scientific, Breda, the Netherlands) 
equipped with a C18 HPLC column (VisionHT C18 B 10062 mm, 1.5 mm; Grace). Tryptophan, 
kynurenine and kynurenic acid were measured in the same run. Deuterated kynurenic 
acid was added as an internal standard for quantification. Measurements were performed 
as published earlier [89]. 
Kinetic analysis and statistics
Statistics were performed using GraphPad Prism 5.02 via one-way analysis of variance 
(ANOVA) followed by the Dunnett’s Multiple Comparison Test to study differences 
84 85
Hyperuricemia alters tryptophan metabolism
5
Retention of tryptophan and its metabolites during hyperuricemia
As uric acid can inhibit MRP4 and BCRP-mediated transport and kynurenic acid is a 
substrate for both pumps, we determined the effects of hyperuricemia on tryptophan 
metabolism and the role of the efflux pumps herein. Plasma tryptophan levels were similar 
in all untreated groups, but oxonic acid treatment led to increased tryptophan levels in 
Mrp4-/- mice (125 µM) as compared to untreated animals (93 µM; Figure 3). Baseline plasma 
levels of the intermediate tryptophan metabolite, kynurenine, were similar in knockout 
animals as compared to WT animals. And oxonic acid treatment led to a >1.5 fold increase 
in kynurenine plasma levels in all three strains, without differences between strains. In 
contrast, baseline plasma kynurenic acid levels of knockout mice were elevated compared 
to WT mice, which was significant for Bcrp-/- mice. Hyperuricemia did not further increase 
plasma kynurenic acid levels in knockout mice, but led to significantly elevated levels in 
WT animals to the levels of untreated knockout mice. Furthermore, IDO activity, 
represented by the ratio between tryptophan and kynurenine, was similar in untreated 
MRP4-mediated transport of kynurenic acid
There is some evidence linking hyperuricemia to changes in tryptophan levels [176]. In 
addition, we recently reported that kynurenic acid, a tryptophan derivative, can interact 
with MRP4 and BCRP [89], and we identified kynurenic acid as a BCRP substrate (Dankers 
et al., submitted for publication). Here, we investigated whether kynurenic acid is also a 
substrate for MRP4. Figure 2B shows that the ATP-dependent uptake of kynurenic acid in 
MRP4-overexpressing vesicles is 7-fold higher as compared to controls with an average 
rate of 21.6 pmol/mg*min-1. Furthermore, Figure 2B demonstrates that non-specific, 
AMP-dependent, uptake is very low. These results indicate that kynurenic acid is indeed 
transported by MRP4.
Figure 1   Analysis of urine samples of WT, Mrp4-/- and Bcrp-/- mice after 14 days of 
treatment with oxonic acid via their drinking water. 
A representative sample of clear urine of an untreated animal (A, left and B) and turbid, crystal-filled 
urine of an oxonic acid-treated animal (A, right and C) is shown by a photograph and micrographs 
(magnification 10x). The contents of the insoluble crystals were determined by energy dispersive 
X-ray microanalysis (EDX). In each sample, 3-5 measuring points were selected (D). The components 
of all urinary crystals of three oxonic acid-treated WT mice were depicted as mean + SEM of twelve 
measurements (E). Mainly two types of crystals were found. A typical EDX spectrum of urate crystals, 
containing sodium, calcium and phosphorus, is depicted in panel (F), while panel (G) represents an 
EDX spectrum of oxonic acid crystals consisting of calcium and potassium. 
Table 1   General characteristics and serum and urine biochemistry of experimental 
groups
WT WT + 
oxonic acid
Mrp4-/- Mrp4-/- + 
oxonic acid
Bcrp-/- Brcp-/- + 
oxonic acid
General 
characteristics
Weight d.0 (g) 22.4 ± 0.8 25.3 ± 1.1 23.4 ± 1.4 25.0 ± 1.5 23.8 ± 1.1 25.7 ± 1.0
Weight d.14 (g) 24.6 ± 1.0 24.9 ± 1.2 23.5 ± 0.9 24.6 ± 0.9 24.5 ± 0.7 24.6 ± 0.6
Water intake 
(ml/24h)
1.6 ± 0.4 5.5 ± 0.8*** 2.9 ± 0.6 5.5 ± 1.0* 2.1 ± 0.7 8.5 ± 0.5***
Urine flow (ml/24h) 0.3 ± 0.1 0.6 ± 0.1* 0.3 ± 0.1 0.7 ± 0.3 0.7 ± 0.2 0.7 ± 0.1
Plasma
Urea (mM) 12.5 ± 0.8 11.8 ± 0.7 11.4 ± 0.4 10.5 ± 0.5 12.5 ± 0.5 11.7 ± 0.6
Sodium (mM) 149.7 ± 1.1 151.1 ± 1.4 147.6 ± 1.8 151.7 ± 0.8 149.4 ± 0.9 148.0 ± 1.0
Calcium (mM) 2.3 ± 0.02 2.4 ± 0.03 2.2 ± 0.02 2.3 ± 0.02 2.3 ± 0.01 2.3 ± 0.02
Urine
Creatinine 
(µmol/24h)
1.4 ± 0.6 1.6 ± 0.2 1.1 ± 0.2 1.5 ± 0.3 2.4 ± 0.8 1.3 ± 0.3
Sodium (µmol/24h) 139.7 ± 63.1 126.3 ± 14.1 93.4 ± 17.4 150.8 ± 42.7 196.0 ± 49.2 138.8 ± 21.4
Individually caged mice were treated with oxonic acid via their drinking water for 14 days. Mice were weighed 
before and after treatment period. Water intake, urine flow and urine content were determined after a 
24h-period in metabolic cages at day 14. Plasma was collected at day 14. Data represent means ± SEM of 9 
mice per group. *indicates p < 0.05 and *** indicates p < 0.001 compared to untreated mice from the same 
strain using a Student’s t-test. Differences between the strains were not significant (one-way ANOVA).
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strains, but significantly increased after oxonic acid treatment in Bcrp-/- mice (0.5 vs 0.7). 
Thus, hyperuricemia clearly affects tryptophan metabolism. 
Oxonic acid does not influence MRP4 and BCRP activity
To exclude the possibility that oxonic acid itself inhibited the efflux pumps resulting in 
metabolite retention, we investigated the effect of oxonic acid on MRP4 and BCRP 
transport activity. Membrane vesicle uptake studies revealed that oxonic acid itself did 
not affect MRP4-mediated MTX uptake and BCRP-mediated E1S uptake with more than 
15% in a concentration range of 1 µM to 1000 µM (Figure 4).
Hyperuricemia induces expression of the early kidney injury marker Ngal
Finally, we studied whether hyperuricemia and changes in tryptophan metabolism 
coincided with an amelioration of kidney function. Renal damage was evaluated by 
assessing mRNA expression of the early renal injury markers Kim-1 and Ngal in kidneys of 
treated and control mice. As shown in Figure 5A, Kim-1 was not differentially expressed in 
oxonic acid-treated mice compared to untreated mice. In contrast, renal Ngal expression 
Figure 3   Plasma tryptophan metabolism in WT, Mrp4-/- en Bcrp-/- mice. 
Plasma tryptophan, kynurenine and kynurenic acid levels and IDO activity of untreated (grey) and oxonic 
acid-treated (black) WT, Mrp4-/- en Bcrp-/- mice after 14 days of treatment via drinking water, determined by 
LC-MS/MS analysis. IDO activity is expressed as the ratio between kynurenine and tryptophan * 100. Bars 
represent means + SEM of 9 mice per group. Statistical analysis was performed using both one-way 
ANOVA followed by the Dunnett’s Multiple Comparison Test and an unpaired Student’s t-test. * indicates p 
< 0.05 and ** indicates p < 0.01 by Student’s t-test and # indicates p < 0.001 by one-way ANOVA. 
Figure 2   Concentration-dependent inhibition of net BCRP-mediated [3H]-estrone 
sulphate (E1S) uptake by uric acid and MRP4-mediated kynurenic acid uptake 
into membrane vesicles. 
(A) Membrane vesicles were incubated with 250 nM E1S and increasing concentrations of uric acid 
in the presence of AMP or ATP, for 60 sec at 37 ºC. Net BCRP-mediated E1S uptake was calculated by 
subtraction of corresponding mock values. Curve fitting was performed by non-linear regression 
analysis using GraphPad Prism software (version 5.02, GraphPad Software Inc., San Diego, CA, USA). 
Graph represents means ± SEM of three independent experiments. (B) Kynurenic acid uptake was 
assessed by LC-MS/MS analysis after incubating membrane vesicles with 0.1 mM kynurenic acid in 
the presence of AMP or ATP, for five min at 37 ºC. Bars represent means + SEM of three independent 
experiments. *** indicates p < 0.001 compared to other bars by one-way ANOVA followed by 
Dunnett’s post hoc test. 
Figure 4   Oxonic acid does not interfere with MRP4-mediated MTX uptake and BCRP- 
mediated E1S uptake. 
Membrane vesicles were incubated with 250 nM [3H]-MTX or [3H]-E1S and indicated concentrations of oxonic 
acid for 5 min at 37 °C in the presence of AMP or ATP. AMP values were subtracted from ATP values. Net 
transporter-mediated uptake was expressed as means + SEM of triplicate measurements in a representative 
experiment. Results were analyzed by one-way ANOVA followed by Dunnett’s post hoc test.
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DISCUSSION
This study reports for the first time that hyperuricemia is associated with disturbances in 
tryptophan metabolism, most likely due to uric acid-induced dysfunction of the renal 
efflux pumps MRP4 and BCRP. High levels of uric acid are associated with an increased risk 
for the development of various diseases and the common mode of action is the formation 
of crystals (e.g. gout and nephrolithiasis) or by negatively influencing the endothelium (e.g. 
hypertension). Here, we hypothesized that hyperuricemia could also contribute to disease 
development in an indirect manner by promoting the retention of other potentially toxic 
metabolites. Our results revealed that oxonic acid-induced hyperuricemia resulted in 
elevated plasma levels of tryptophan, kynurenine and kynurenic acid in vivo. The findings 
are in agreement with two recent studies by Liu et al. [176,177], who reported that plasma 
levels of tryptophan were increased in patients with acute gout while their urinary 
concentrations were decreased. Hence, there appears to be a link between hyperuricemia 
and disturbances in tryptophan metabolism. 
The efflux transporters MRP4 and BCRP are important in regulating uric acid levels, but 
also essential for the clearance of many exogenous and endogenous waste products. 
Recently, we demonstrated that kynurenic acid could interact with MRP4 and BCRP 
activity in the membrane vesicle transport assay, suggesting that the metabolite is a 
possible substrate for both transporters [89]. Using the same assay, we have shown that 
kynurenic acid is indeed transported by BCRP (Dankers et al., submitted for publication) 
and here we report that kynurenic acid is also a substrate for MRP4. These findings are in 
agreement with the observed increase in plasma kynurenic acid levels in Mrp4-/- and 
Bcrp-/- mice. Therefore, MRP4 and BCRP could be potential novel therapeutic targets for 
the regulation of kynurenic acid levels in a variety of diseases. 
Kynurenic acid is a widely studied antagonist of the N-methyl-D-aspartate-receptor and 
the α7-nicotinic acetylcholine receptors, and elevated levels of kynurenic acid are related 
to several neurological disorders [179]. Another target of kynurenic acid is the orphan 
G-protein-coupled receptor GPR35, of which kynurenic acid is one of the most potent 
endogenous agonists currently known. The receptor is highly expressed in the intestine 
and in several immune cells, including monocytes and T cells. Kynurenic acid also alters 
the release of multiple growth factors such as nerve growth factor and fibroblast growth 
factor-1 [55]. Thus, perturbations in kynurenic acid levels can result in marked effects on 
receptor activation and changes in growth factors. With regard to pathophysiological 
effects, classic experiments have demonstrated that kynurenic acid inhibited pro-insulin 
synthesis in isolated rat pancreatic islets and increased the release of insulin in rats, 
suggesting a role in diabetes [180,181]. Furthermore, in CKD patients, kynurenic acid 
accumulates [89] and increased levels correlate positively to multiple markers of endothelial 
dysfunction, namely von Willebrand factor, thrombomodulin and soluble adhesion 
molecules (sICAM-1, sVCAM-1) [182,183]. In addition, kynurenic acid is suggested to be an 
(Figure 5B) was increased after oxonic acid-induced hyperuricemia. These increases were 
significant for both knockout strains, and in Mrp4-/- mice expression levels rose up to 2.3 
times that of untreated mice. With regard to kidney function, no significant effect was 
observed on creatinine and sodium excretion (Table 1), suggesting the absence of overt 
kidney damage which was confirmed by histology. Light microscopic evaluation of 
HE-stained kidney slices (Figure 5C) revealed intact brush borders and absence of casts or 
destroyed tubules in exposed animals. Taken together, these results indicate that two 
weeks of oxonic acid-induced hyperuricemia reveals, at most, early signs of kidney damage.
Figure 5   Expression of kidney injury markers and histology after oxonic acid treatment. 
Relative mRNA expression levels of kidney injury markers (A) Kim-1 and (B) Ngal in kidney tissue of 
untreated (grey) and oxonic acid-treated (black) mice obtained by qPCR. Animals were exposed to 
oxonic acid via their drinking water for 14 days. Cycle threshold (Ct) values were normalized for the 
endogenous reference gene Gapdh and expressed as mean fold difference from untreated animals 
+ SEM (N=9). * indicates p < 0.05 by Student’s t-test. Both genes were not differentially expressed in 
untreated animals of the different strains. (C) representative micrograph of a oxonic acid-treated WT 
mice and shows that no kidney damage was observed in oxonic acid-treated mice (HE staining), 
which was comparable in treated knockout mice.
90 91
Hyperuricemia alters tryptophan metabolism
5
more prone to the development of renal failure. Since, kynurenic acid levels were already 
elevated in Mrp4-/- and Bcrp-/- animals before the induction of hyperuricemia, one could 
argue that other tryptophan metabolites are responsible for induction of Ngal observed 
in knockout mice. To better understand the effect of hyperuricemia on the development 
of CKD, future studies should include longer treatment periods (> 2 wk) and also determine 
the levels of other intermediates and end-products of tryptophan metabolism. 
In conclusion, our results showed that uric acid dose-dependently inhibited BCRP activity 
and inhibition occurred at physiologically relevant levels as was reported previously for 
MRP4 [87]. Moreover, we demonstrated that Mrp4- and Bcrp-deficiency as well as 
hyperuricemia are associated with alterations in tryptophan metabolism and the retention 
of kynurenine and kynurenic acid, two metabolites with a broad array of biological 
activities. Therefore, we postulate that elevated uric acid levels hamper MRP4 and BCRP 
functioning, thereby promoting the retention of other potentially toxic substrates, 
including KynA, which could contribute to the development of CKD. These finding 
underline the complex relation between hyperuricemia and linked pathologies, which 
should be taken into account when interpreting results obtained using in vivo 
hyperuricemia models.
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important early mediator of leukocyte recruitment [184]. Moreover, kynurenic acid reduces 
glucuronidation activity of UDP-glucuronosyltransferases, as shown in proximal tubule 
cells, thereby affecting the metabolic capacity of the kidney [100]. Hence, elevated levels 
of kynurenic acid induced by hyperuricemia, as observed in our study, might play a pivotal 
role in the pathophysiological effects currently attributed to uric acid.
Our results further demonstrated that kynurenine levels were similar in untreated WT and 
knockout animals, suggesting that the levels of this metabolite are not influenced by 
MRP4 and BCRP activity. Following induction of hyperuricemia, kynurenine levels were 
markedly increased in all groups. The observed increase might be due to a reduced 
activity of a uric acid transporter other than MRP4 and BCRP, elevated tryptophan levels, as 
seen in Mrp4-/- mice, and/or increased activity of indoleamine 2,3-dioxygenase (IDO), as 
observed in Bcrp-/- mice. Interestingly, IDO is involved in immune regulation and enzyme 
activity is higher during chronic inflammation and in CKD patients [185]. The exact 
interaction between hyperuricemia and IDO requires further investigation. For a long 
time, kynurenine was regarded as an intermediate of tryptophan metabolism with little 
biological activity. Yet Opitz et al. [186] recently demonstrated that this metabolite is a 
ligand for the aryl hydrocarbon receptor (AHR) and can promote tumor cell survival and 
suppress antitumor immune responses. The AHR signaling pathway is involved in a myriad 
of cellular processes, including embryogenesis, inflammation and phase I and phase II 
metabolism. Fascinatingly, another tryptophan metabolite, indoxyl sulfate, is also reported 
to activate the AHR in primary human hepatocytes and human umbilical vein endothelial 
cells [187,188]. Thus, by disturbing tryptophan metabolism, hyperuricemia could indirectly 
be involved in AHR activation and subsequent pathologies. 
Several polymorphisms in transporter genes are associated with elevated serum uric acid 
levels. For instance, Woodward et al. [88], described that the common single nucleotide 
polymorphism (SNP) rs2231142 encoding the Q141K mutation of BCRP caused hyperurice-
mia-based gout. Also in a Japanese population, Q141K was shown to be a common 
dysfunctional form of BCRP causing gout [130]. Another transporter recently implicated in 
uric acid metabolism is SLC2A9. Using Xenopus oocytes, Vitart et al. [173] demonstrated 
that SLC2A9-mediated uptake of uric acid was sevenfold higher in SLC2A9-expressing 
oocytes compared to URAT1-expressing oocytes. These findings have been confirmed by 
others [165,189]. Moreover, multiple genome-wide association studies reported a 
relationship between uric acid levels and SNPs in several transporters including SLC17A3, 
SLC22A11 and SLC22A12 [174,190,191]. Taken together, when studying the link between 
uric acid and disease progression it is important to take into consideration the presence of 
possible polymorphisms in transporter genes as well as changes in metabolite levels of 
transporter-specific substrates.
Two weeks of hyperuricemia induced early signs of kidney damage, as observed by an 
increased mRNA expression of Ngal in knockout animals. In contrast, no signs of renal 
damage were seen in WT animals. These findings suggest that knockout animals were 
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INTRODUCTION
Renal function is an important aspect in drug clearance and it is widely known that drug 
disposition is altered in patients with chronic kidney disease (CKD) [49,192,193]. These 
changes in pharmacokinetics are partially due to a decreased glomerular filtration and 
tubular secretion. Another hallmark of CKD is the accumulation of potentially toxic solutes 
that are normally excreted via the urine. These uremic toxins can cause a multitude of 
pathologies, including renal fibrosis, anemia, bone disorders and cardio-vascular disease 
[135,194]. Currently, more than 110 uremic toxins are known, divided into three distinct 
classes based on their physico-chemical properties: the small water-soluble compounds, 
the middle molecules and the protein-bound solutes [23,135]. The latter group of retention 
solutes are actively secreted by the healthy kidney and are difficult to eliminate using 
current dialysis strategies [195]. Since protein-bound uremic toxins accumulate during 
renal failure it could be argued that these compounds affect drug metabolism in CKD 
patients by interacting with renal enzymes.  Many drugs commonly used in the clinic are 
metabolized by phase II enzymes, which catalyze conjugation reactions, including 
sulfation, acetylation and glucuronidation [196]. Several studies demonstrated that the 
pharmacokinetics of drugs solely cleared via phase II metabolism is changed in CKD 
patients. For instance, a decreased glucuronidation of metoclopramide, chloramphenicol, 
p-aminobenzoic acid, zidovudine and morphine have been reported in patients with 
chronic renal failure (CRF) [48,197-201]. Moreover, the acetylation of isoniazid is reduced in 
CKD patients [202]. However, little information is available about the mechanism 
underlying the observed decrease in phase II metabolism during renal failure. 
UDP-glucuronosyltransferases (UGT) are an important class of phase II enzymes that 
catalyze the conjugation of glucuronic acid to many xenobiotics, environmental pollutants 
and endogenous compounds [203,204]. Next to drugs, uremic retention solutes are also 
prone to glucuronidation, and at least two glucuronides have been identified in uremic 
biological fluids, p-cresyl glucuronide and indoxyl glucuronide [43,52,53]. UGTs are 
expressed in several organs including the liver, gastro-intestinal tract and kidney, and to 
date 19 human UGT proteins have been identified [205,206]. Due to the relative abundance 
of the essential cofactor UDP-glucuronic acid (UDPGA), glucuronidation is the most 
prevalent conjugation reaction and under normal metabolic conditions, the supply of 
UDPGA is not rate-limiting for this process [50]. Yet, during excessive glycogenesis or 
under altered redox conditions, UGT activity is impaired [50,207]. After the liver, UGT 
activity is highest in the kidney, emphasizing the pivotal role of this organ in facilitating 
xenobiotic clearance via glucuronidation [196,208]. Previously, Yu et al. demonstrated that 
UGT expression and activity were down-regulated in the liver and kidney of 5/6 
nephrectomized rats. However, this effect was also observed in control pair-fed rats and 
was possibly due to a decreased food intake [209]. Thus, the repercussions of CKD on UGTs 
remain to be elucidated. 
ABSTRACT
During chronic kidney disease (CKD), drug metabolism is affected leading to changes in 
drug disposition. Furthermore, there is a progressive accumulation of uremic retention 
solutes due to impaired renal clearance. Here, we investigated whether uremic toxins can 
influence the metabolic functionality of human conditionally immortalized renal proximal 
tubule epithelial cells (ciPTEC) with the focus on UDP-glucuronosyltransferases (UGTs) and 
mitochondrial activity. Our results showed that ciPTEC express a wide variety of metabolic 
enzymes, including UGTs. These enzymes were functionally active as demonstrated by 
the glucuronidation of 7-hydroxycoumarin (7-OHC; Km of 12 ± 2 µM and a Vmax of 76 ± 3 
pmol/min/mg) and p-cresol (Km of 33 ± 13 µM and a Vmax of 266 ± 25 pmol/min/mg). 
Furthermore, a wide variety of uremic toxins, including indole-3-acetic acid, indoxyl 
sulfate, phenylacetic acid and kynurenic acid, reduced 7-OHC glucuronidation with more 
than 30% as compared with controls (p < 0.05), whereas UGT1A and UGT2B protein 
expressions remained unaltered. In addition, our results showed that several uremic toxins 
inhibited mitochondrial succinate dehydrogenase (i.e. complex II) activity with more than 
20% as compared with controls (p < 0.05). Moreover, indole-3-acetic acid decreased the 
reserve capacity of the electron transport system with 18% (p < 0.03). In conclusion, this 
study shows that multiple uremic toxins inhibit UGT activity and mitochondrial activity in 
ciPTEC, thereby affecting the metabolic capacity of the kidney during CKD. This may have 
a significant impact on drug and uremic retention solute disposition in CKD patients.       
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tions. Subsequently, cDNA was generated using the Omniscript RT-kit (Qiagen) according 
to the manufacturers recommendations. Following cDNA-synthesis, RT2 Profiler PCR arrays 
(drug metabolism: phase I and phase II enzymes; Qiagen) were performed according to 
the manufacturers recommendations, using a CFX96 Real-Time PCR detection system 
(Bio-rad, Veenendaal, the Netherlands). Quantification of gene expression was performed 
using the CFX96 system software (Bio-rad) and the web-based PCR array data analysis 
software (Qiagen). GAPDH was used as housekeeping gene, and relative expression levels 
were calculated as percentage as compared with GAPDH (100%). 
Western blotting
To study the protein expression of UGT1A and UGT2B, ciPTEC were cultured and exposed 
to 0–2 mM of different uremic toxins for 48 h. After treatment, cells were harvested using 
RIPA buffer containing 1% (v/v) Igepal CA630, 0.5% (v/v) Nadeoxycholate, 0.1% (w/v) SDS, 
0.01% (w/v) phenylmethane sulphonylfluoride, 3% (v/v) aprotinin and 1 mM Na-orthova-
nadate. Total protein (50 µg) was separated via SDS/PAGE using 10% (w/v) gels and blotted 
onto nitrocellulose membranes using the iBlot dry blotting system (Invitrogen). Afterwards, 
the membrane was blocked using Odyssey Blocking Buffer, (1:1 diluted with PBS; LI-COR 
Biosciences, Lincoln, NE, USA) during 1 h at RT. The membrane was then incubated 
overnight at 4ºC with rabbit polyclonal UGT1A or UGT2B antibody (1:200; both Santa Cruz 
Biotechnology, Inc., Santa Cruz, CA, USA). Mouse monoclonal β-actin antibody (1:10,000; 
Sigma) was simultaneously incubated to serve as a protein loading control. Antibodies 
were diluted in Odyssey Blocking Buffer containing 0.1% (v/v) Tween-20. Afterwards, the 
membrane was thoroughly washed three times during 10 min with PBS containing 0.1% 
(v/v) Tween-20. The secondary antibodies, goat-α-mouse Alexa Fluor 680 (1:20,000; 
Invitrogen) and goat-α-rabbit IRDye 800 (1:20,000; Rockland, Gilbertsville, PA, USA), were 
incubated for 1 h at RT in Odyssey Blocking Buffer containing 0.1% (v/v) Tween-20 and 
0.01% (w/v) SDS. The membrane was thoroughly washed, as described above, and then 
scanned using the Odyssey Infrared Imaging System (LI-COR Biotechnology). Intensity of 
the protein bands was quantified using the Odyssey Application software version 2.1.   
Confocal microscopy 
Cellular localization of UGT1A and UGT2B proteins was investigated using confocal 
microscopy. ciPTEC were seeded on 12-well Corning Costar Transwell Permeable Supports 
(type 3460, Corning Costar, NY, USA). Before seeding, the supports were coated with 50 
µg/ml collagen type IV for 2 h at 37ºC. Subsequently, supports were washed with HBSS 
buffer (Gibco) and cells were seeded at a density of 1.33 x 105 cells/cm2. Following 
maturation, as described above, cells were washed with wash solution (4% (v/v) FCS in 
HBSS) and fixed for 5 min with 2% (w/v) paraformaldehyde in HBSS. Next, cells were 
permeabilized for 10 min in HBSS with 0.3% (v/v) Triton and aspecific epitopes were 
blocked for 30 min with blocking buffer (2% (v/v) FCS, 0.5% (w/v) bovine serum albumin 
In the present study, conditionally immortalized human renal proximal tubule epithelial 
cells (ciPTEC) were used to investigate the impact of multiple uremic toxins on renal UGT 
activity. Our results show that ciPTEC express a broad array of drug metabolism enzymes, 
similar to human kidney. Furthermore, UGT proteins were functionally active in ciPTEC, as 
demonstrated by 7-hydroxycoumarin (7-OHC) and p-cresol glucuronidation. Uremic 
toxins inhibited the glucuronidation of 7-OHC without affecting UGT1A and UGT2B 
protein expression, indicating a reduction in enzyme activity. Moreover, exposure of 
ciPTEC to uremic toxins caused a reduction in mitochondrial succinate dehydrogenase 
activity and in the maximum capacity of the oxidative phosphorylation (OXPHOS) system, 
which could explain the observed inhibitory effect of uremic toxins on glucuronide 
formation. These results present a novel pathway via which uremic retention solutes affect 
the metabolic capacity of the kidney and are likely involved in altering drug metabolism 
by glucuronidation in CKD patients. 
MATERIALS AND METHODS
Chemicals
All chemicals were obtained from Sigma (Zwijndrecht, the Netherlands) unless stated 
otherwise. Stock solutions of uremic toxins were prepared as described by Cohen et al., 
[131] and were stored at -20ºC. Both p-cresyl sulfate and phenyl sulfate were synthesized 
as a potassium salt as described previously [97]. P-cresyl glucuronide was produced from 
glucuronyl-trichloroacetimidate and p-cresol using the method previously described by 
Van der Eycken et al. [154].  
Cell culture 
The ciPTEC line was generated as previously described by Wilmer et al. [98]. The cells were 
cultured in ciPTEC medium containing phenol red free DMEM/F12 medium (Gibco/
Invitrogen, Breda, the Netherlands) supplemented with 10% (v/v) fetal calf serum (FCS; MP 
Biomedicals, Uden, the Netherlands), insulin (5 µg/ml), transferrin (5 µg/ml), selenium (5 
ng/ml), hydrocortisone (36 ng/ml), epithelial growth factor (10 ng/ml), and tri-iodothy-
ronine (40 pg/ml) at 33ºC in a 5% (v/v) CO2 atmosphere. Propagation of cells was 
maintained by subculturing the cells at a dilution of 1:3 to 1:6 at 33°C. For experiments, 
cells were cultured at 33ºC to 40% confluency, followed by maturation for 7 days at 37ºC. 
Experiments were performed on the cells between passages 30 and 40. 
Quantitative PCR array
To study the gene expression of drug metabolism enzymes, ciPTEC were cultured and 
differentiated cells (7 days at 37ºC) were harvested. Total RNA was isolated using an RNeasy 
Mini kit (Qiagen, Venlo, the Netherlands) according to the manufacturers recommenda-
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3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) assay
Mitochondrial succinate dehydrogenase activity was assessed using the MTT assay. ciPTEC 
were cultured in a 96 well culture plate and exposed to 1 mM or 2 mM of uremic toxins for 
48 h. Next, medium was removed and 20 μl preheated (37ºC) MTT-solution (5 mg 3-[4,5-di-
methylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide/ml ciPTEC medium) was added and 
incubated for 4 h at 37ºC. Afterwards, MTT-solution was removed, followed by the addition 
of 200 μl DMSO to dissolve produced formazan crystals. The extinction of the solution was 
measured at 570 nm using a Benchmark Plus Microplate Spectrophotometer (Bio-rad). 
Flow cytometry
In this study, flow cytometry was used to study ciPTEC morphology and viability. Cells were 
cultured in 12-well culture plates and treated for 48 h with 2 mM of uremic toxins. After 
incubation, cells were harvested using trypsin-EDTA and centrifuged at 600xg during 5 min. 
Subsequently, supernatant was removed and the cell pellet was resuspended in 100 µl PBS 
containing 4% (w/v) paraformaldehyde and 0.1% (v/v) saponin followed by 10 min incubation 
on ice. Subsequently, samples were centrifuged (600xg for 5 min) and resuspended in 100 µl 
PBS. Samples were acquired on a BD FACSCalibur (Becton Dickinson, Breda, the Netherlands). 
Analysis was performed using Flow Jo software (TreeStar, Ashland, USA), gating on live cells. 
High-resolution respirometry
Cells were cultured in T25 culture flasks and treated for 48 h with 2 mM indole-3-acetic 
acid. Subsequently, cells were harvested using trypsin-EDTA and centrifuged at 1500xg 
during 5 min. Afterwards, the supernatant was removed and the cell pellet was 
resuspended in ciPTEC medium to obtain a suspension of approximately 1 x 106 cells/ml. 
Two milliliters of the cell suspension was used to measure cellular oxygen consumption. 
Oxygen consumption was measured at 37ºC using polarographic oxygen sensors in a 
two-chamber Oxygraph (Oroboros Instruments, Innsbruck, Austria) using an established 
protocol [210]. The cells were allowed to respire at basal level for at least 10 min until the 
flux was stable, representing routine respiration (R). Next, leak respiration (L) was 
determined by addition of the specific mitochondrial ATP synthase inhibitor oligomycin A 
(omy; 2.5 µM). Then, maximal ETS capacity (E) was quantified using increasing 
concentrations of the mitochondrial uncoupler p-trifluoromethoxy carbonyl cyanide 
phenyl hydrazone (FCCP; 2.5 µM maximal concentration). Finally, non-mitochondrial 
respiration (ROX) was assessed by adding a maximal (0.5 µM) concentration of the specific 
mitochondrial complex I inhibitor rotenone (ROT) followed by the Complex III inhibitor 
antimycin A (AA; 2.5 µM).
Kinetic analysis and statistics
Statistics were performed using GraphPad Prism 5.02 via one-way analysis of variance 
(ANOVA) followed by Dunnett’s Multiple Comparison Test or an unpaired t test. Differences 
and 0.1% (v/v) Tween-20 in HBSS). Subsequently, the cells were incubated overnight at 4ºC 
with rabbit polyclonal UGT1A or UGT2B antibody (1:50 in blocking buffer, Santa Cruz 
Biotechnology) using dynamic conditions. Afterwards, cells were incubated for 30 min 
with the secondary antibody goat-α-rabbit Alexa568 (1:200, Molecular Probes, Invitrogen). 
Subsequently, ciPTEC were incubated for 1 h with a mouse monoclonal antibody against 
the tight junction protein ZO-1 (1:50 in blocking buffer, Invitrogen, CA, USA). Next, the cells 
were simultaneously incubated for 30 min with goat-α-mouse Alexa488 (1:200, Molecular 
Probes, Invitrogen) and DAPI nucleic acid stain (300 nM, Molecular Probes, Invitrogen). The 
slides were then mounted using Fluorescent Mounting Medium (DakoCytomation, Dako 
Netherlands b.v., Heverlee, Belgium). Between all incubation steps the cells were washed 
with wash solution. Fluorescence was examined using the Olympus FV1000 Confocal 
Laser Scanning Microscope (Olympus, UK) and images were captured using the Olympus 
software FV10-ASW version 1.7.
High-performance liquid chromatography (HPLC)
HPLC was used to measure UGT activity via the glucuronidation of 7-hydroxycoumarin 
(7-OCH), as described previously, [99] and p-cresol. To determine enzyme kinetics, ciPTEC 
were exposed to 7-OCH or p-cresol dissolved in HBSS at 37°C and 4°C (as negative control) 
using different concentrations (0–500 µM) and different incubation times (0–5 h). When 
used, β-glucuronidase from Helix Pomatia was added 1 h prior to incubation with 7-OHC 
(50 µM for 3 h). In addition, UGT activity was also determined following exposure to uremic 
toxins for 48 h. Following treatment, ciPTEC were incubated with 10 µM 7-OCH for 3 h at 
37°C. Before chromatography an aliquot of culture medium was collected and centrifuged 
at 12,000xg for 3 min and 50 µl of the supernatant was injected into the HPLC-system 
(Spectra-Physics Analytical, Spectrasystem SCM400). To measure 7-OCH and 7-OCH 
glucuronide (7-OCHG) the HPLC was equipped with a C18 HPLC column (GraceSmart RP 
18 5u 150 x 4.6 mm; Grace, Breda, the Netherlands). Separation was performed at a flow 
rate of 1 ml/min with eluent A (95% (v/v) H2O, 5% (v/v) methanol and 0.2% (v/v) acetic acid) 
and eluent B (50% (v/v) H2O, 49% (v/v) acetonitrile and 1% (v/v) tetrahydrofuran) under the 
following gradient conditions: 0-3 min, 80-50% eluent A; 3-8 min, 50% eluent A; 8-9 min, 
50-80% eluent A; 9-14 min, 80% eluent A. The compounds were detected at a wavelength 
of 316/382 nm. For the detection of p-cresyl sulfate and p-cresyl glucuronide, 
chromatography was performed on a C18 HPLC column (GraceSmart RP 18 5u 150 x 4.6 
mm) with eluent A (95% (v/v) 50 mM KH2PO4 (pH 3.0) and 5% (v/v) acetonitrile) and eluent 
B (50 mM KH2PO4 (pH 3.0), methanol and acetonitrile in a 1:1:1 ratio) using the following 
gradient: 0-15 min, 100-20% eluent A; 15-16 min, 20-100% eluent A; 16-21 min, 100% eluent 
A. The flow rate was 1 ml/min and the p-cresol metabolites were detected at a wavelength 
of 220 nm. Standards of the compounds were also run in order to quantify the amount of 
metabolites found in the samples. Acquired data were processed with PC1000 software 
(Spectrasystem).
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between groups were considered to be statistically significant when p < 0.05. The software 
was also used to perform linear and nonlinear regression analysis (Michaelis-Menten) and 
correlation analysis (Spearman). 
RESULTS
Selection of uremic toxins
In our study, 13 uremic solutes were selected containing one water-soluble solute (oxalate, Ox) 
and 12 protein-bound solutes. The latter group contained 4 tryptophan metabolites 
(indoxyl sulfate, IS; indole-3-acetic acid, I3A; kynurenic acid, KA; and quinolinic acid, QA), 
six phenols (phenylacetic acid, PHA; phenyl glucuronide, PHG; phenyl sulfate, PHS; p-cresol, 
pC; p-cresyl sulfate, pCS; and p-cresyl glucuronide, pCG), one hippurate (hippuric acid, HA) 
and one polyamine (putrescine, Pu). Moreover, a mix of several uremic toxins (Mix) was 
used, consisting of putrescine, oxalate, indoxyl sulfate and p-toluenesulfonic acid, a 
previously described phenolic model compound (1:1:1:1) [89]. This specific mix was chosen 
because it contained different classes of solutes, of which the stock solutions were all 
prepared in the same solvent (e.g. milli-Q).  
Expression and activity of UGT in ciPTEC
Extrahepatic glucuronidation occurs mainly in the kidney and UGT expression and activity 
were demonstrated in both human and rat primary proximal tubule cells [196,211,212]. 
We used a recently established human renal proximal tubule cell line, [98,101] in which 
phase I and phase II drug metabolism enzyme expression levels were studied, with an 
emphasis on the class of UGT enzymes. A complete overview of the drug metabolism 
enzyme gene expression in ciPTEC is provided in Figure S1. This figure clearly demonstrates 
that ciPTEC express a broad range of drug metabolism enzymes, including cytochrome 
p450 (CYP), sulfotransferase (SULT) and glutathione S-transferase (GST) enzymes, next to 
members of the UGT family. Figure 1A shows that the gene expression of 18 UGTs was 
detected in ciPTEC of which UGT1A1, 1A9, 2B7, 2B10 and 2B28 were most abundantly 
expressed compared with GAPDH, with a relative expression of 11%, 2143%, 16%, 145% 
and 9%, respectively. Furthermore, using Western blotting UGT1A and 2B family members 
were detected in ciPTEC, with the predicted molecular weight of the enzymes 
(approximately 68 kD; Figure 1B-C). Protein expression of the enzymes was also 
demonstrated in human kidney lysates, whereas their expression was absent in human 
embryonic kidney (HEK293) cells. Glucuronide formation occurs in the cytosol, and 
confocal microscopy demonstrated that both UGT1A and 2B enzymes exhibit cytosolic 
localization in ciTPEC (Figure 1D-E). Moreover, expression of tight junction protein 1 (ZO-1) 
revealed that ciPTEC form tight monolayers and that the cells maintain their epithelial 
characteristics during culturing.  
Figure 1   Expression of UGTs in ciPTEC. 
(A) Differentiated ciPTEC were harvested and total mRNA was isolated. Afterwards, cDNA was 
synthesized and UGT gene expression was studied using a qPCR array. Relative expression was 
calculated using the household gene GAPDH (100%). Bars represent mean ± SEM of two experiments. 
(B-C) UGT1A and UGT2B protein expression was studied by Western blotting. Proteins were 
separated via SDS/PAGE and blotted onto nitrocellulose membranes. Lysates of HEK293 cells were 
used as a negative control and homogenates from human kidney (HuKid) were used as positive 
control. Both UGT1A and UGT2B were detected at 68 kD. 
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transferases, the enzymes that catalyze sulfation reactions (Figure S1). Furthermore, 
HPLC revealed that p-cresol inhibited 7-OHCG formation by 72% (Figure 5B). Yet, both 
p-cresol metabolites also inhibited UGT activity with approximately 20%.
To determine whether the UGTs were enzymatically active, a glucuronidation assay was 
performed using 7-OHC as a substrate. A concentration-dependent formation of 7-OHC 
glucuronide was observed (Figure 2A), and curve fitting revealed an apparent Km of 12 
± 2 µM and a Vmax of 76 ± 3 pmol/min/mg. Glucuronidation was demonstrated to be 
linear up to 5 h (Figure 2B). Furthermore, as depicted in Figure 2A and 2B, 7-OHC 
metabolism was completely absent at 4ºC, indicating enzyme-dependent conjugation. 
Glucuronidation of 50 µM 7-OHC was concentration-dependently inhibited by β-glucu-
ronidase with an approximate IC50
 value of 50 U/ml, as demonstrated in Figure 2C. 
Uremic toxins decrease UGT activity 
Next, it was investigated whether exposure of ciPTEC to uremic toxins could influence 
7-OHC glucuronidation. Figure 3 shows that a myriad of uremic toxins belonging to three 
different physico-chemical classes, viz. tryptophan metabolites, phenols and water-soluble 
compounds, concentration-dependently inhibited the glucuronidation of 7-OHC. Kynurenic 
acid, indole-3-acetic acid, phenylacetic acid and a mixture of uremic toxins most potently 
inhibited UGT activity (Figure 3A-C). At the highest concentration, these toxins decreased 
glucuronide formation by 52%, 44%, 36% and 50%, respectively. In addition, at the same 
concentration, indoxyl sulfate, phenyl sulfate, oxalate, putrescine and hippuric acid inhibited 
the formation of 7-OHCG by 32%, 30%, 16%, 18% and 32%, respectively. In contrast, 
quinolinic acid and phenyl glucuronide did not affect 7-OHC metabolism. 
A decline in enzyme activity is often secondary to a decrease in protein expression, 
therefore, the impact of uremic toxins on UGT expression was examined. Exposure of 
ciPTEC to none of the different toxins reduced UGT1A and UGT2B protein expression with 
more than 15%, with both tested concentrations, compared to control. A representative 
sample of toxins is shown in Figure 4, and the other toxins in Figure S2. 
P-cresol metabolism and impact on glucuronidation
To further investigate the mode of inhibition, ciPTEC were exposed to p-cresol, which can 
be metabolized to both p-cresyl sulfate and p-cresyl glucuronide [30]. Figure 5A shows 
that p-cresol is indeed conjugated to glucuronic acid in ciPTEC and a concentration- 
dependent formation of p-cresyl glucuronide is demonstrated with a calculated Km of 33 
± 13 µM and a Vmax of 266 ± 25 pmol/min/mg. In contrast, ciPTEC did not metabolize 
p-cresol to p-cresyl sulfate (data not shown), despite the expression of multiple sulfo-
Figure 2   UGTs are functionally active. 
HPLC was used to study UGT activity via 7-OHC glucuronidation. Cells were incubated with 7-OHC 
(0–500 µM) for 0–5 h at 37ºC (•) or 4ºC (negative control; ). To further demonstrate specificity of the 
HPLC method, cells were incubated with 50 µM 7-OHC for 3 h in the presence of β-glucuronidase 
(0–1000 U/ml).  (A) Concentration-dependent formation of 7-OHCG. (B) Time curve of 7-OHC glucu-
ronidation. (C) β-glucuronidase inhibits glucuronide formation. Standards of 7-OHCG were also 
analyzed in order to quantify the amount of glucuronide found in the samples. Acquired HPLC data 
were processed with PC1000 software (Spectrasystem). Nonlinear and linear regression analyses 
were performed using Graphpad Prism 5.02. Results are presented as mean ± SEM of three 
independent experiments performed in triplicate. 
Figure 1   Continued. 
(D-E) Confocal microscopy was used to study intracellular localization of UGTs in ciPTEC. Following 
maturation, cells were fixed and permeabilized and subsequently stained using an antibody against 
UGT1A or UGT2B and ZO-1. Detection was performed using Alexa568 for UGTs (red) and Alexa488 
for ZO-1 (green) labeled secondary antibodies. Nucleus was stained with DAPI (blue). (B-E) 
Representative images of two independent experiments. 
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Uremic toxins inhibit mitochondrial metabolism 
Reduction of MTT is mainly dependent on mitochondrial succinate dehydrogenase 
activity [213]. Our results indicate that the majority of the toxins tested (e.g. putrescine, 
oxalate, indoxyl sulfate) did not significantly decrease MTT reduction with more than 15% 
compared to control (Figure S3). Yet, p-cresol, p-cresyl sulfate and p-cresyl glucuronide 
significantly reduced mitochondrial succinate dehydrogenase activity with 28%, 21% and 
14%, respectively (Figure 6A). In addition, the toxins that most potently inhibited UGT 
activity (i.e. indole-3-acetic acid, phenylacetic acid and a mixture of uremic toxins) also 
significantly decreased MTT reduction at the highest concentration by 28%, 26% and 33%, 
respectively. Moreover, we observed a significant correlation between the two parameters 
studied, with a calculated Spearman r of 0.69 (p < 0.005; Figure 6B). Since the MTT assay is 
often used to study cell viability, we aimed to confirm that the observed correlation was 
not due to the induction of cell death by uremic toxins. Flow cytometry revealed that 
exposure of ciPTEC to the solutes that had the most pronounced impact on cellular and 
mitochondrial metabolism did not affect cell morphology nor the percentage of living 
cells as compared with untreated cells (Figure S4). 
Figure 3   Uremic toxins inhibit 7-OHC glucuronidation. 
Impact of uremic toxin exposure on 7-OHC glucuronidation was studied using HPLC. Cells were 
exposed for 48 h to ciPTEC medium (gray bar), 1 mM (white bars) or 2 mM (black bars) of several 
uremic toxins belonging to three different physico-chemical classes: (A) tryptophan metabolites, (B) 
phenols and (C) water-soluble compounds. Following treatment, ciPTEC were incubated for 3 h 
with 10 µM 7-OHC. Afterwards, an aliquot of culture medium was collected and injected into the 
HPLC-system. Standards of 7-OHCG were also analyzed in order to quantify the amount of 
glucuronide found in the samples. Acquired HPLC data were processed with PC1000 software 
(Spectrasystem). Statistical analysis was performed via one-way ANOVA followed by Dunnett’s 
Multiple Comparison Test for each toxin. Results are presented as mean ± SEM of three experiments 
performed in duplicate or triplicate. * indicates p < 0.05 compared with control. HA, hippuric acid; 
I3A, indole-3-acetic acid; IS, indoxyl sulfate; KA, kynurenic acid; M, medium; Mix, uremic toxin mix; Ox, 
oxalate; PHG, phenyl glucuronide; PHS, phenyl sulfate; PHA, phenylacetic acid; Pu, putrescine; QA, 
quinolinic acid. 
Figure 4   UGT1A and UGT2B protein expression is not affected by uremic toxins. 
UGT1A and UGT2B protein expression was studied via Western blot. Cells were exposed for 48 h to 
ciPTEC medium (gray bar), 1 mM (white bars) or 2 mM (black bars) of several uremic toxins. (A/C) 
Afterwards cells were lysed and proteins were separated via SDS/PAGE and blotted onto 
nitrocellulose membranes. Both UGT1A and UGT2B were detected at 68 kD. (B/D) Fluorescence of 
the specific protein bands was determined using the Odyssey Infrared Imaging System. Bars 
represent mean ± SEM of the UGT band intensities corrected for β-actin from 3 independent 
experiments. IS, indoxyl sulfate; M, medium; Mix, uremic toxin mix; Ox, oxalate; Pu, putrescine. 
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that was not coupled to ATP production (L; LEAK) and non-mitochondrial respiration 
(ROX; residual oxygen consumption) was not compromised by indole-3-acetic acid 
(Figure 7A-B), further supporting the impression that uremic toxins did not induce cell 
Inhibition of mitochondrial respiration by indole-3-acetic acid
Mitochondrial succinate dehydrogenase plays an essential role in the electron transfer 
chain and the tricarboxylic acid cycle (i.e. citric acid cycle) [214]. Therefore, we investigated 
the impact of indole-3-acetic acid on the OXPHOS system, since this solute had the most 
profound effect on both 7-OHC glucuronidation and MTT reduction. High-resolution 
respirometry revealed that basal mitochondrial respiration (R; ROUTINE), electron transport 
Figure 5   P-cresol glucuronidation and impact on UGT activity by cresols. 
(A) HPLC was used to study p-cresol glucuronidation. Cells were incubated with p-cresol (0–500 µM) 
for 1 h at 37ºC (•) or 4ºC (negative control; ). (B) Cells were exposed for 48 h to ciPTEC medium (gray 
bar), 1 mM (white bars) or 2 mM (black bars) of p-cresol or the metabolites. Following treatment, 
ciPTEC were incubated for 3 h with 10 µM 7-OHC. After incubation with p-cresol or 7-OHC, an aliquot 
of culture medium was collected and injected into the HPLC-system. Standards of the compounds 
were also analyzed in order to quantify the amount of metabolites found in the samples. Acquired 
HPLC data were processed with PC1000 software (Spectrasystem). Nonlinear analysis was performed 
using Graphpad Prism 5.02 and statistical analysis was performed via one-way ANOVA followed by 
Dunnett’s Multiple Comparison Test for each toxin. Results are presented as mean ± SEM of three 
independent experiments performed in duplicate or triplicate. * indicates p < 0.05 compared with 
control. M, medium; pC, p-cresol; pCG, p-cresyl glucuronide; pCS, p-cresyl sulfate.
Figure 6   Inhibitory effect of uremic toxins on MTT reduction. 
(A) The MTT assay was used to study the impact of uremic toxins on mitochondrial metabolism. 
Cells were exposed for 48 h to ciPTEC medium (gray bar), 1 mM (white bars) or 2 mM (black bars) of 
several uremic toxins. Afterwards, cells were incubated for 4 h with MTT-medium at 37ºC. 
Subsequently, produced formazan crystals were dissolved in DMSO and extinction was measured at 
570 nm. Statistical analysis was performed via one-way ANOVA followed by Dunnett’s Multiple 
Comparison Test for each toxin. Results are presented as mean ± SEM of three independent 
experiments performed in triplicate. * indicates p < 0.05 compared with control. I3A, indole-3-acetic 
acid; M, medium; Mix, uremic toxin mix; pC, p-cresol; pCG, p-cresyl glucuronide; pCS, p-cresyl sulfate; 
PHA, phenylacetic acid. (B) Correlation between UGT activity and MTT reduction. Cells were 
exposed for 48 h to 1 mM ( ) or 2 mM ( ) of several uremic toxins and 7-OHC glucuronidation and 
MTT reduction were investigated. Nonparametric Spearman correlation analysis revealed a 
significant association between the reduction in glucuronidation and mitochondrial dehydrogenase 
activity when ciPTEC were treated with 2 mM of uremic toxins (r = 0.69; p < 0.005). Following 
exposure to 1 mM of uremic toxins, no significant correlation was observed (r = 0.48; p = 0.07).
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death in ciPTEC. In contrast, the maximum capacity of the electron transport system (E; 
ETS) was reduced from 221 ± 21 pmol/s∙106 cells in untreated cells to 182 ± 17 pmol/s∙106 
cells in ciPTEC exposed to indole-3-acetic acid, indicating that treatment caused a 
reduction in the reserve capacity for energy production. Figure 7C shows that exposure of 
the cells to indole-3-acetic acid resulted in a significantly increased netRoutine/ETS ratio, 
with a 1.3 fold change. This signifies that a higher proportion of the maximum capacity of 
the OXPHOS system is activated to drive ATP synthesis, and implies that ciPTEC exposed 
to uremic toxins have a limited ability to supply energy for other cellular processes, such as 
enzymatic activity.
DISCUSSION
This study reports for the first time that multiple uremic toxins directly inhibit the function 
of an important class of phase II drug metabolism enzymes, namely UGTs, in human renal 
proximal tubule cells. Our results showed that uremic toxin-induced UGT inhibition was 
independent of an effect on protein expression, and inhibition seemed to occur in both a 
competitive (e.g. p-cresol) and non-competitive fashion (e.g. p-cresyl sulfate). It is likely 
that most uremic solutes act as non-competitive inhibitors of UGT activity, since the 
majority of these compounds are end-products of endogenous metabolism. 
To further unravel the mode of inhibition, mitochondrial respiration was studied and the 
results indicated that indole-3-acetic acid reduced the reserve capacity of the electron 
transport system. This finding provides more insight into the mechanism by which uremic 
toxins possibly inhibit UGT activity. As stated before, glucuronide formation is dependent 
on the availability of UDPGA, the donor of the glucuronide moiety [50]. UDPGA is formed 
from UDP-glucose by UDP-glucose dehydrogenase using nicotinamide adenine 
dinucleotide (NAD+), a coenzyme that plays an important role in energy metabolism [215]. 
In the mitochondria, enzymes of the citric acid cycle reduce NAD+ to NADH. Subsequently, 
NADH is oxidized by complex I of the electron transport chain during OXPHOS-mediated 
ATP production, resulting in the conversion of NADH to NAD+ [215]. Therefore, we postulate 
that a reduction in the activity of the mitochondrial electron transport chain induced by 
uremic toxins, as demonstrated in this study, caused a drop in NAD+ levels and, 
consequently, led to depletion of UDPGA, thereby decreasing UGT-mediated metabolism. 
De novo synthesis of NAD+ in mammals is dependent on tryptophan metabolism via the 
kynurenine pathway [215]. Dietary tryptophan is converted to kynurenine by tryptophan 
2,3-dioxygenase and indoleamine 2,3-dioxygenase, which are both considered the 
rate-limiting steps in this pathway [55,215]. Kynurenine can, subsequently, be metabolized 
to kynurenic acid by kynurenine aminotransferase or, via several other enzymatic steps, to 
quinolinic acid [55]. The latter metabolite is used by quinolinic acid phosphoribosyl 
transferase to form NAD+. Interestingly, it is known that plasma tryptophan levels are 
Figure 7   Reduction in mitochondrial respiration by indole-3-acetic acid. 
High-resolution respirometry was used to measure mitochondrial oxygen consumption. Cells were 
treated for 48 h with ciPTEC medium (white bar) or 2 mM indole-3-acetic acid (black bar) and oxygen 
consumption was measured at 37ºC using polarographic oxygen sensors in an Oxygraph. (A) Online 
high-resolution respirometry traces of mitochondrial respiration in a representative experiment 
with control (solid line) and indole-3-acetic acid (dashed line) treated cells. Titrations: ROUTINE (R) 
respiration (intact cells), omy (LEAK respiration; L), FCCP (ETS capacity; E), Rot and AA (ROX). (B) 
Quantification of cellular respiration. (C) Quantification of cellular respiration corrected for electron 
transport system capacity. Statistical analysis was performed via an unpaired t test. Results are 
presented as mean ± SEM of three experiments performed in duplicate. * indicates p < 0.05 
compared with control.
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significantly diminished in CKD patients [90]. Furthermore, Fukuwatari et al. reported that 
NAD (NAD+ + NADH) concentrations were decreased in the liver, kidney and blood of rats 
with adenine-induced renal failure [216]. Thus, it is likely that UDPGA levels are reduced in 
patients with CKD due to altered tryptophan metabolism, resulting in a reduced UGT 
activity. To our knowledge, this is the first report to demonstrate the influence of uremic 
toxins on mitochondrial metabolism and respiration in human proximal tubule cells. 
Previously, Owada et al. demonstrated that indoxyl sulfate stimulated renal mitochondrial 
superoxide production in rats [217]. Dzurik et al. described that hippuric acid reduced 
ammonia production by P-dependent mitochondrial glutaminase in kidney homogenates 
of acidified rats [218]. Furthermore, using isolated rat liver mitochondria, Kitagawa revealed 
that p-cresol inhibited state 3 respiration without affecting oxidative phosphorylation 
[219]. Yet, p-cresol is no longer regarded as a uremic toxin, [30] and it remains to be 
elucidated whether its major metabolite, p-cresyl sulfate, has a similar impact on 
mitochondrial respiration. Additionally, Riegel et al. reported that treatment of hepatocytes 
with ultrafiltrates of patients treated with high-flux membrane dialyzer significantly 
diminished MTT reduction [220]. However, the effect correlated with an increased LDH 
release, a marker of cell injury, and the decrease in metabolic activity might have been due 
to hepatotoxicity. These findings, together with our current results, suggest that uremic 
toxins might directly influence mitochondrial activity in different organs. 
The uremic toxin concentrations used in this study do not always reflect the plasma levels 
determined in CKD patients, for instance the highest concentration reported for kynurenic 
acid is 50 µM, whereas the maximal uremic concentration for hippuric acid and 
phenylacetic acid are 2.6 and 7.7 mM, respectively [21,136]. An overview of the maximal 
uremic concentrations of the solutes used in the present study are provided in Table S1, 
and for a detailed description of uremic toxin concentrations the interested reader is 
referred to reviews by the European Uremic Toxin Work Group [21,22]. 
Since UGTs are located in the cytosol, enzyme activity depends on the intracellular levels 
of substrates rather than substrate concentrations in the blood. Uptake of uremic toxins in 
renal proximal tubules is fairly well characterized and shown to be dependent on a wide 
variety of transport proteins. Both organic anion transporter (OAT) 1 and OAT3, as well as 
organic anion transporting polypeptide 4C1, play an important role in the tubular uptake 
of uremic toxins [60,64,72,221]. In addition, it has been demonstrated that the multi-ligand 
receptor megalin is involved in the endocytotic uptake of a specific group of uremic 
toxins, i.e. advanced glycation end products [222]. Previously, Masereeuw et al. 
demonstrated that methyl hippuric acids accumulate in the isolated perfused rat kidney 
during secretory transport [137,138]. They reported that 2-methyl hippuric acid levels were 
175-times higher in renal tissue compared to the perfusate and 4-methyl hippuric acid 
concentrations were even 600-times higher. Thus, it is likely that intracellular uremic toxin 
concentrations are much higher than total plasma concentrations. Therefore, it is 
complicated to extrapolate our findings to the clinical situation. 
The present study demonstrates that UGT1A1, 1A9, 2B7 and 2B28 are highly expressed in 
ciPTEC, which corroborates previous reports on proximal tubule cells [205,211]. Lash et al. 
described that primary human proximal tubule cells (PTEC) express UGT1A1, 1A6 and 2B7 
on protein level [211]. Furthermore, they postulated that UGT2B7 is the major UGT isoform 
present in PTEC cells. In the study from Ohno and coworkers, gene expression was 
demonstrated for UGT1A5, 1A6, 1A7, 1A9, 2B4, 2B7 and 2B17 in human kidney tissue, and 
they reported that UGT1A9 and 2B7 were most abundantly expressed [205]. Next to 
members of the UGT family, ciPTEC were currently demonstrated to have RNA expression 
of phase I enzymes, such as CYP3A4, CYP4A11, CYP2D6, that have previously been detected 
in primary PTEC by Lash et al. [211]. Additionally, the phase II enzymes GSTA4, GSTP, GSTT 
and SULT1A3 were demonstrated in our current study, as well as in primary PTEC. Taken 
together, ciPTEC have a similar phase I and phase II enzyme expression profile compared 
with primary PTEC, indicating that this cell line is a suitable model to study extrahepatic 
drug metabolism. Together with the endogenous expression of renal influx and efflux 
drug transporters, previously described by our group, [98] these data demonstrate that 
human ciPTEC is a unique tool to study renal pharmacokinetics.
The majority of studies investigating the effect of renal failure on drug metabolism focused on 
CYP enzymes. For instance, Leblond et al. demonstrated that during CKD, both hepatic protein 
and gene expression of CYP2C11, CYP3A1 and CYP3A2 decreased in rats, which correlated with 
a decreased metabolism of aminopyrine and erythromycin [223,224]. The same group also 
showed that 48 h exposure of HK-2 cells to serum from uremic rats decreased the protein 
expression of CYP3A1, suggesting a role for uremic toxins in this process [225]. Moreover, using 
rat liver microsomes, Sun et al. described that indoxyl sulfate and 3-carboxy-4-methyl-5- propyl-
2-furanpropanoic acid (CMPF) directly inhibited CYP3A-mediated metabolism of erythromycin 
[226]. With regard to phase II drug metabolism, Simard et al. demonstrated that N-acetyl -
transferase (NAT)1 and NAT2 expression decreased in the liver of CRF rats accompanied by a 
decrease in NAT2-mediated N-acetylation of p-aminobenzoic acid [197]. Furthermore, 
expression of both NAT1 and NAT2 decreased in rat hepatocytes following exposure to uremic 
serum, possibly via the action of parathyroid hormone, a known uremic toxin [197]. Taken 
together, there is a clear impact of uremic solutes on both phase I and phase II drug metabolism. 
Hepatic and renal transporters play an important role in xenobiotic handling. Previously, 
our group described that several uremic toxins, including hippuric acid and indoxyl 
sulfate, inhibited transport by two important renal efflux transporters, namely breast 
cancer resistance protein and multidrug resistance protein 4 [89]. Huang et al. showed that 
uremic plasma, obtained from rats with CRF, inhibited p-glycoprotein-mediated transport 
[142]. Moreover, it is demonstrated that CMPF and hippuric acid inhibited the uptake by 
the renal uptake transporter OAT3 [64]. The impact of uremic toxins on the functionality of 
multiple transporters in those reports, and the inhibition of enzyme activity described in 
this study, indicate that the altered drug disposition observed in CKD patients can be 
attributed, at least in part, to uremic retention solutes.
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In the present study, renal glucuronidation was solely studied in vitro using the ciPTEC 
model, which could differ from in vivo metabolism. Generally, UGT activity is studied using 
microsomes isolated from the organ of interest; however, by using a complete cell model 
instead of microsomes, we were able to unravel the possible mechanism via which uremic 
toxins indirectly influence UGT functionality. Moreover, it is known that there are species 
differences in renal glucuronidation [227], which did not hamper our study since ciPTEC 
are of human origin. Another possible drawback of the present study is that we studied 
renal metabolism, while during CKD, xenobiotics are metabolized mainly in the liver and 
intestine. However, it is known that both renal and non-renal clearance are affected in CKD 
patients [48], therefore we postulate that our results uncovered a general mechanism via 
which uremic toxins can diminish both renal and non-renal UGT activity, irrespective of 
the tissue-specific UGT expression profiles [205].                
A main feature of CKD is the dysfunction of multiple organs and alterations in xenobiotic 
elimination pathways, however, the pathophysiological mechanism underlying these 
changes are not fully elucidated. In this study we demonstrated that a wide variety of 
uremic toxins, belonging to several physico-chemical classes, inhibited renal glucuronida-
tion, most likely by reducing the reserve capacity of the energy-generating OXPHOS 
system. Our results provide additional insight into the widespread toxic effect of uremic 
solutes and depict a novel pathway via which uremic toxins impede renal metabolic 
function and may have a clinically significant impact on drug disposition in patients with 
CKD. 
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The kidney is essential for the clearance of diverse xenobiotics and endogenous metabolic 
waste products from the systemic circulation [18]. To facilitate this process, the kidney is 
equipped with filter units, the glomeruli, and a broad array of transport proteins located in 
the tubular system, that work in concert to remove waste and potential harmful elements 
from the body [18]. Mitigation of physiological functioning of the kidney, as is the case in 
patients with chronic kidney disease (CKD), will result in the retention of solutes that are 
normally excreted into the urine by the healthy kidney [21]. These uremic retention solutes 
elicit a myriad of toxic effects and may contribute to renal disease progression and the 
development of comorbidities associated with CKD, including cardio-vascular disease 
[135,194]. In this thesis, we strived to gain more insight into the broad expanse of solutes 
retained in CKD patients during different stages of the disease, as well as the nephrotoxic 
effect of a multitude of both known and hitherto unknown uremic retention solutes.     
Methods to determine uremic solute levels
Over the years many uremic toxins have been studied using targeted analytical approaches 
including enzyme-linked immunosorbent assay (ELISA) and high-performance liquid 
chromatography (HPLC) [21]. Recently, there has been a surge in the number of compounds 
identified as uremic solutes due to the widespread use of untargeted techniques such as 
metabolomics and proteomic profiling [22,90,95,96,122]. Targeted techniques solely 
measure defined compounds, whereas untargeted approaches provide a comprehensive 
overview of all the metabolites in a biological sample without prior identification. In this 
thesis, both targeted techniques, i.e. HPLC and liquid chromatography-tandem mass 
spectrometry (LC-MS/MS; Chapters 3-5) and 1H-nuclear magnetic resonance (NMR) 
spectroscopy (Chapter 2), an untargeted approach, were applied to study the 
accumulation of uremic solutes in different stages of CKD. Using these analytical 
techniques we have successfully investigated to which extent uremic solutes accumulated 
in non-dialysis CKD patients in addition to patients treated with either hemodialysis or 
continuous ambulatory peritoneal dialysis. However, precise determination of uremic 
solute concentrations is cumbersome and fraught with technical difficulties due to the 
physico-chemical characteristics of these compounds, including binding to plasma 
proteins. Therefore, it is essential to have a clear understanding of the pros and cons of 
each analytical approach before setting out to study the uremic metabolome. 1H-NMR 
spectroscopy makes use of the magnetic properties of hydrogen atoms present in 
molecules to obtain information regarding the chemical properties, including structure, 
of organic compounds. For a detailed description of NMR spectroscopy the interested 
reader is referred to the NMR handbook by Engelke et al. [228] (freely available from www.
bodyfluidnmr.nl). As stated above, NMR is an untargeted approach, indicating that 
advance knowledge of the metabolic status is not required, and the technique is used to 
obtain an overview of the metabolome of individuals. This makes NMR an extremely 
valuable tool in finding novel uremic solutes and potential CKD biomarkers. Moreover, 
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provides information about potential therapeutic targets other than dialysis. The uremic 
solutes scrutinized in Chapters 2-4 mostly fit in the origin-based categories described 
above. Yet, using NMR-spectroscopy the previously unknown uremic solute 2-hydroxy-
isobutyric acid (2-HIBA; Chapter 2) was identified, which defies classification in the 
currently defined groups. 2-HIBA is constitutively present in human urine and serum 
[113,114], and it is the major urinary metabolite in humans following exposure to the 
gasoline additives methyl tert-butyl ether and ethyl tert-butyl ether [115,116]. Inhalation is 
the major route of exposure to both oxygenates and is highest in industrialized countries. 
Although it is widely accepted that there is a link between occupational exposure to toxic 
molecules, including heavy metals and industrial solvents [229], and the development of 
kidney disease, little information is available regarding exposure to common air pollutants, 
such as exhaust fumes, and CKD. Recently, Qin et al. reported that inhalation exposure to 
a mixture of gasoline, dimethylbenzene and formaldehyde induced severe proximal 
tubular damage in rats [230]. Furthermore, it was demonstrated in rats that diesel exhaust 
particles enhanced cisplatin-induced acute renal failure [231]. Thus, inhaled substances 
may have a deleterious effect on the kidney and it is interesting to speculate that the air 
that we breathe is also a potential source of uremic toxins. Therefore, we would like to 
postulate that, next to the three previously described origin-based categories of uremic 
solutes, there is a fourth class namely compounds originating from air pollutants and, to the 
best of our knowledge, 2-HIBA is the first described uremic solute belonging to this group. 
On the origin of uremic solutes (Eat Me, Drink Me)
Many of the well-studied uremic toxins originate from the diet and are generated in the 
colon due to putrefaction, i.e. protein fermentation, by intestinal bacteria including 
Escherichia Coli and anaerobes from the genera Lactobacillus, Enterobacter and Clostridium 
every metabolite has a specific fingerprint, i.e. NMR spectrum, allowing for precise 
identification of solutes. The identity of metabolites can be gleaned from previously 
recorded spectra or authentic compounds used as reference standard. However, NMR has 
a limited sensitivity with detection limits in the micromolar range. In addition, quantification 
of metabolite concentrations is based upon an internal standard that is added to the 
sample before spectroscopy, in our case trimethylsilyl-2,2,3,3-tetradeuteropropionic acid 
(TSP), therefore, NMR is semi-quantitative. For this thesis, both HPLC and LC-MS/MS were 
used as targeted approaches, even though LC-MS/MS may also be used for untargeted 
metabolomic studies. For targeted analysis of metabolites, prior knowledge regarding the 
compound of interest is a prerequisite and before each measurement the instruments 
need to be prepped to allow for proper detection and quantification of specific 
metabolites. During chromatography, constituents of a mixture are separated - and in the 
case of HPLC, identified - based on chemical properties such as size and charge. For this 
purpose, there are many variables that can be adjusted, including the mobile phase (i.e. 
eluent), separation column and detector (e.g. UV or fluorescence), to cater to the needs of 
each compound of interest. However, separation of highly similar molecules remains 
difficult and as a result HPLC is less specific with regard to metabolite identification. This 
limitation can be overcome by the addition of mass spectrometry. During LC-MS/MS 
analysis, metabolites are identified using both the mass-to-charge ratio (m/z) and 
compound fragmentation, i.e. selected reaction monitoring (SRM) transitions, making 
LC-MS/MS very precise. In addition, for both HPLC and LC-MS/MS, quantification is 
performed using a calibration curve and both techniques have detection limits in the 
nano- or picomolar range. Yet, detection limits can vary widely, depending on which 
metabolite is studied. Taken together, there is a broad assortment of analytical tools that 
can be used to identify and quantify uremic solutes and each technique has its own 
merits, therefore, it is key to select the appropriate technique fitting to the avenue of 
research. An overview of the assets and drawbacks of the analytical techniques used for 
this thesis are provided in Tabel 1.  
Classification of uremic solutes
Uremic retention solutes are a heterogeneous group of molecules that, at present, are 
divided into three groups based on their physico-chemical properties affecting their 
elimination pattern during dialysis or other extracorporeal removal strategies [23]. The 
currently defined classes encompass (1) small water-soluble compounds (≤500 Da) that 
readily pass dialysis membranes; (2) middle molecules (>500 Da) for which filtration is 
limited due to their size; and (3) protein-bound solutes, which are very difficult to clear 
using current dialysis modalities. Interestingly, many uremic solutes arise from similar 
sources and an alternative classification has been proposed based on the source of 
origin, namely, endogenous metabolism (e.g. asymmetric dimethylarginine), microbial 
metabolism (e.g. p-cresyl sulfate) and exogenous intake (e.g. oxalate) [93]. This classification 
Table 1   Characteristics of analytical tools used to detect uremic solutes in  
body fluids
Proton NMR HPLC LC-MS/MS
Approach Untargeted Targeted Targeted*
Detection limit Micromolar Nanomolar Picomolar
Identification Chemical shift (++) Chromatogram (+) m/z, SRM transition (++) 
Quantification TSP reference Calibration curve Calibration curve
*LC-MS/MS can also be used for untargeted studies.
Specificity (i.e. correct metabolite identification) + ambiguous, ++ unequivocal.
m/z, mass-to-charge ratio; SRM, selected reaction monitoring;  
TSP, trimethylsilyl-2,2,3,3-tetradeuteropropionic acid. 
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values were below the reported maximal plasma concentrations, indicating that the 
tested uremic solutes impede kidney excretory function and can promote uremic toxin 
accumulation which may subsequently contribute to the progression of CKD. However, 
these studies did not confirm whether the toxins are also substrates for MRP4 and BCRP. In 
a follow-up study, using membrane vesicles isolated from HEK293 overexpressing either 
MRP4 or BCRP, we demonstrated that kynurenic acid is indeed actively transported by 
both pumps (Chapter 5 and Dankers et al. unpublished data). Moreover, as described in 
Chapter 5, LC-MS/MS analysis revealed that kynurenic acid levels are significantly elevated 
in the plasma of Mrp4 and Bcrp knockout mice, correlating loss of efflux transporter 
function with decreased uremic solute elimination. These findings provide essential 
information regarding the processes of renal uremic toxin handling, which might aid in 
developing novel therapeutic approaches to limit cellular toxicity and possibly mitigate 
CKD progression.
Intracellular fate of uremic solutes
Following transport across the plasma membrane, there are a multitude of intracellular 
targets that uremic solutes can affect to elicit biochemical and toxic responses, including 
the aryl hydrocarbon receptor (AhR), mitochondria and metabolizing enzymes. The AhR is 
a major transcription factor belonging to the superfamily of basic helix-loop-helix DNA 
binding proteins [236]. The inactive form is present in the cytosol as a multiprotein 
complex with the chaperones heat shock protein (Hsp)90, p23 and hepatitis B virus 
X-associated protein 2 (XAP2). Upon ligand binding, the AhR translocates to the nucleus 
where it forms a complex with AhR nuclear translocator (ARNT) which then binds to diox-
in-responsive elements resulting in gene transcription. To this date, most of the known 
AhR-ligands are exogenous chemicals such as the environmental pollutant 2,3,7,8-tetra-
chlorodibenzo-p-dioxin (TCDD), yet, an increasing number of endogenous metabolites 
have recently been identified as AhR agonists, including bilirubin [237,238]. Interestingly, 
several of these compounds are also well-known uremic retention solutes. At present, 
kynurenine, kynurenic acid, indole-3-acetic acid and indoxyl sulfate – all indolic products 
of tryptophan metabolism – have been demonstrated to bind to the AhR or induce the 
expression of AhR response genes, such as CYP1A1 [186-188,239-241]. Moreover, as 
depicted in Table 2, all four metabolites activate the AhR at concentrations either similar 
to the highest maximal plasma concentrations (Cmax) determined in dialysis patients (e.g 
indole-3-acetic acid) or at levels decisively lower than the Cmax, for instance indoxyl sulfate. 
As of yet, the clinical implications of AhR activation in the setting of CKD development 
and progression remain unclear, however, it has been postulated that uremic solutes 
might evoke ‘dioxin-like’ toxicity [240] leading to suppression of immune responses, 
induction of carcinogenesis and accelerating tumor growth, and promoting atherosclerosis 
[240,242-244]. 
[93,232]. Breakdown of tyrosine and phenylalanine results in the formation of phenylacetic 
acid, phenol and p-cresol, which is subsequently metabolized into p-cresyl sulfate and 
p -cresyl glucuronide [30,93]. On the other hand, bacterial metabolism of tryptophan 
results in the formation of indole, which can give rise to a myriad of indolic uremic solutes, 
including indoxyl sulfate and indole-3-acetic acid [93,125]. To glean information about the 
interplay between dietary protein and uremic solutes, we examined the impact of a high 
protein diet on the plasma concentration of a variety of uremic toxins. To this end, wild 
type (WT) Friend leukemia virus B (FVB) mice were provided either a control (21% crude 
protein; n = 10) diet or a high protein (HP; 45% crude protein; n = 10) diet for 21 days. Mice 
fed the HP diet showed significantly higher plasma levels of the phenol-derived 
metabolites phenylacetic acid (1.9 ± 0.3 µM), phenyl sulfate (3.9 ± 0.8 µM), phenyl 
glucuronide (0.20 ± 0.05 µM), p-cresyl glucuronide (1.6 ± 0.3 µM) and hippuric acid (0.10 ± 
0.01 µM) compared to mice provided with control diet (1.1 ± 0.1 µM, 1.4 ± 0.3 µM, 0.03 ± 
0.007 µM, 0.7 ± 0.1 µM and 0.040 ± 0.008 µM, respectively; Figure 1A). In addition, a 
reduction in tryptophan concentration (HP: 93 ± 11 µM vs. Control: 127 ± 5 µM; Figure 1B) 
was observed as well as an 1.2 fold increase in indoleamine 2,3-dioxygenase (IDO) activity 
(p = 0.0389; Figure 1C). Furthermore, in mice fed the HP diet, indoxyl sulfate levels 
significantly increased from 3.6 ± 0.7 µM (Control) to 7 ± 2 µM. In contrast, p-cresyl sulfate 
and kynurenic acid levels remained unaltered, and kynurenine and indole-3-acetic acid 
concentrations diminished. Taken together, a HP diet alters the metabolic status of mice 
consonant with changes observed in CKD patients [90,233]. In addition, mice on the HP 
diet developed significant polyuria (HP: 0.8 ± 0.2 mL/18 h vs. control: 0.30 ± 0.04 mL/18 h; 
Figure 1C), implying the presence of renal failure [234]. Therefore, it is important to manage 
the levels of dietary protein intake in CKD patients, since high protein intake will augment 
uremic toxin levels, whereas a restriction in dietary protein might cause protein-energy 
wasting [235]. One can see that dietary management, hampering colonic uptake and/or 
formation of uremic solutes and even engineering new food products might be extremely 
valuable tools to combat uremic illness.  
Efflux transporters involved in uremic toxin clearance
Next to reducing uptake and formation of uremic solutes, CKD treatment can gain ground 
by understanding and harnessing the capacity of efflux transporter to clear uremic solutes 
from the circulation. As delineated in Chapter 1, renal proximal tubule cells are well 
outfitted with a multitude of specialized transporters each mainly dealing with a specific 
set of substrates (e.g. anions or cations). In the last decades, small steps have been made 
in unraveling the contribution of uptake transporters in the extrusion of uremic solutes, 
whereas the identity of efflux transporters tasked with uremic solute clearance remained 
a mystery... until now. In Chapters 3-4, we observed that several uremic solutes, e.g. 
indoxyl sulfate, hippuric acid and p -cresyl sulfate, inhibited transport mediated by the 
apically expressed transporters MRP4 and BCRP. And for most toxins, the calculated Ki 
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It is well-documented that several uremic toxins can induce apoptosis in a variety of cell 
types, such as smooth muscle cells, neutrophils and proximal tubule cells [153,245-247]. 
However, only a few studies report a direct effect of uremic solutes on cell metabolism, 
including mitochondrial functioning. Mitochondria are best known for the production of 
ATP, the main source of cellular energy, via the oxidative phosphorylation (OXPHOS) 
system [248]. Next to their role in providing energy, mitochondria are also involved in 
other important cellular processes including ion homeostasis, production of reactive 
oxygen species and apoptosis [249-251]. As reported in Chapter 6 a myriad of uremic 
solutes decreased mitochondrial complex II (i.e. succinate dehydrogenase) activity in 
ciPTEC as shown by the MTT-assay. Especially, indole-3-acetic acid had a pronounced 
negative impact on MTT reduction, and high-resolution respirometry revealed that this 
solute diminished the maximum capacity of the electron transport system, signifying a 
reduction in the reserve capacity of the OXPHOS system (Chapter 6). In addition, Owada 
and coworkers demonstrated that indoxyl sulfate increases the production of superoxide 
and hydroxyl radicals in rat kidney mitochondria [217], and Dzurik et al., reported that 
hippuric acid reduces ammonia production by P-dependent mitochondrial glutaminase 
in kidney homogenates from rats, thereby shifting ammonia production from 
mitochondria to the lumen of proximal tubules [218]. Also, a reduced functioning of 
hepatic mitochondria following exposure to dialysate and  p-cresol have been reported 
previously [219,220]. These findings indicate that uremic toxins can cause mitochondrial 
dysfunction which is detrimental to normal cellular functioning.  
CKD is characterized by changes in drug disposition partially due to a reduction in 
glomerular filtration and active tubular secretion of xenobiotics, as well as mediated by a 
direct effect of uremic toxins on the expression level and activity of drug metabolism 
enzymes [48,49]. Most studies on the interaction between CKD and drug metabolism 
have focused on hepatic CYP expression and activity. Leblond et al, reported a reduction 
in CYP2C11, 3A1 and 3A2 expression, both on gene and protein level, in CRF rats which 
associated with a reduction in erythromycin and aminopyrine metabolism [223,224]. Also 
Figure 1   General characteristic and serum biochemistry of experimental groups. 
Mice were fed either control diet (white bars) or high protein diet (black bars) for 21 days. Plasma was 
collected at day 22 and, using LC-MS/MS, uremic toxin levels from different classes were determined: 
(A) phenolic compounds and (B) tryptophan and metabolites. (C) Urine flow was determined after 
a 18 h-period in metabolic cages at day 22. Statistical analysis was performed via an unpaired t test. 
Bars represent mean ± SEM of 10 mice per group. * indicates p < 0.05 compared to control (two- 
tailed), # indicates p < 0.05 compared to control (one-tailed).  HA, hippuric acid; I3A, indole-3-acetic 
acid; IDO, indoleamine 2,3-dioxygenase; IS, indoxyl sulfate; Kyn, kynurenine; KynA, kynurenic acid; 
pCG, p-cresyl glucuronide; pCS, p-cresyl sulfate; PhA, phenylacetic acid; PhS, phenyl sulfate; PhG, 
phenyl glucuronide; Tryp, tryptophan. 
Figure 1   Continued. 
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in CKD patients mitigation of CYP-mediated drug metabolism is demonstrated [252,253], 
including changes in bupropion, alprazolam and fexofenadine pharmacokinetics 
[254-256]. Moreover, it has been demonstrated both in vitro and in vivo that hemodialysis 
improves functional expression of hepatic CYP3A4 [257,258], implicating a role for uremic 
toxins in altering drug metabolism in CKD patients. This notion is supported by the study 
from Sun et al., showing that indoxyl sulfate and CMPF reduced erythromycin metabolism 
by CYP3A in rat liver microsomes [226]. In addition, CYP-mediated losartan metabolism 
can be inhibited by indoxyl sulfate, as demonstrated in human liver microsomes [259]. 
Furthermore, protein expression of CYP1A decreased in proximal tubule (i.e. HK-2) cells 
treated with serum from CRF rats, whereas CYP3A expression was unaffected [225]. With 
regard to phase II metabolism, it is shown that the pharmacokinetics of multiple drugs 
that are completely dependent on phase II enzymes for their clearance are changed in 
patients with CKD. For instance, acetylation of isoniazid is decreased as well as the 
 glucuronidation of morphine, p-aminobenzoic acid and metoclopramide [198,200-202]. 
Only a few studies investigated the direct effect of uremic toxins on phase II enzymes. 
Using primary rat hepatocytes, Simard et al., demonstrated that exposure of the cells to 
clinical relevant concentrations of parathyroid hormone results in a reduced gene and 
protein expression of N-acetyltransferase 2 [197]. Moreover, they observed a diminished 
N-acetylation of p-aminobenzoic acid in 5/6-nephrectomized rats [197]. In addition, we 
reported in Chapter 6 that over ten different uremic toxins, including indoxyl sulfate, 
kynurenic acid and phenylacetic acid, diminished UDP-glucuronosyltransferase activity in 
ciPTEC, as demonstrated by a reduction in glucuronidation of 7-hydroxycoumarin.       
Renal fibrosis is an integral process in the development and progression of CKD [260]. 
Moreover, it is a key event contributing to renal graft failure. The pathophysiological 
mechanism underlying renal fibrosis remains unclear and in recent years epithelial-to-mes-
enchymal transition (EMT) has emerged as a leading, yet highly debated, hypothesis for 
the origin of collagenous matrix-producing myofibroblasts which contribute to organ 
fibrosis [261,262]. EMT is a biologic process well known in embryogenesis. During early 
development, the epiblast gives rise to the primary mesenchyme via EMT which in turn 
further develops into secondary epithelia, this type of EMT is classified as type 1[263]. Type 
3 EMT is involved in carcinogenesis, more specifically in the acquisition of an invasive 
phenotype by cancer cells [263]. The transition of adult epithelial cells to fibroblasts 
following injury is called type 2 EMT, which is postulated to be involved in the development 
of tissue fibrosis [263]. Although the role of EMT in fibrogenesis is controversial, markers 
that demonstrate the loss of epithelial cell characteristics in the kidney, viz. increased 
expression of vimentin and the translocation of β-catenin into the cytoplasm, could be 
used to study nephrotoxicity. Of note, vimentin was reported to be a good marker of 
proximal tubule damage in rats [264]. Moreover, indoxyl sulfate is reported to be capable 
of inducing EMT in renal cell models from different species, such as murine PKSV-PRs, rat 
NRK-52E cells and human HK-2 cells [41,153,265]. These findings are in line with the results 
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inhibitors and/or angiotensin II receptor blockers (82%). Rapid progressors were more 
likely to be male, younger and have polycystic kidney disease; had higher blood pressure 
and proteinuria, and lower serum albumin and bicarbonate levels. Correlations between 
uremic toxin concentration and eGFR ranged between -0.58 to 0.07. Uremic toxins 
correlated poorly with other known risk factors. None of the uremic toxins were 
significantly associated to eGFR decline in neither univariate nor multivariate linear 
regression analysis. Figure 2 shows regression coefficients and 95% confidence intervals 
for the association between uremic toxins and the rate of eGFR decline adjusted for 
baseline eGFR, proteinuria, blood pressure, age and gender. In conclusion, baseline serum 
uremic toxin concentrations are not associated with eGFR decline in CKD patients (van 
den Brand et al., unpublished data). Taken together, uremic toxins could possibly be useful 
biomarkers to detect tubular (and possibly glomerular) damage, however, they seem to 
be poor predictors of disease progression. Nevertheless, more research is needed to 
elucidate their full biomarker potential.         
Future perspectives 
The findings described in this thesis have expanded our knowledge on the number of 
solutes retained in patients with a reduced kidney function. Furthermore, we have 
demonstrated the important role that the efflux transporters MRP4 and BCRP play in the 
described in Chapters 2 and 4, showing that the uremic solutes DMSO2, 2-HIBA and 
p-cresyl glucuronide increased vimentin expression and altered functionality of ciPTEC, 
suggesting a phenotypic transition. EMT can also be induced via an indirect pathway 
involving the induction of endoplasmic reticulum (ER) stress [266]. Several known nephro-
toxicants have been demonstrated to induce ER stress, including cadmium, cisplatin and 
cyclosporine A [267]. More interestingly, it is also reported that indoxyl sulfate can induce 
ER stress [268]. Thus, there is some evidence that uremic retention solutes initiate or 
directly contribute to renal fibrosis by means of EMT and ER stress. And the implementation 
of new experimental models, such as precision-cut tissue slices [269], will hopefully aid in 
unraveling the pathophysiological mechanism of CKD-associated renal fibrosis. Taken 
together, it is clear that uremic solutes can affect diverse intracellular targets and (patho)
physiological processes thereby hampering cellular functioning, illustrating the complex 
nature of uremic toxicity. 
Use of uremic solute levels as biomarkers for CKD
The glomerular filtration rate (GFR) is regarded as the best indicator for kidney function 
and is widely used to classify renal failure, however, direct measurement of this index is 
difficult to achieve [270,271]. Therefore, serum creatinine (SCr) is generally used as an 
estimate for GFR. Unfortunately, changes in SCr are insensitive to detect injury, since a 
relative large amount of injury can occur without affecting GFR, especially in patients with 
a renal reserve or during unilateral renal dysfunction [270,271]. Furthermore, GFR can drop 
with 50% before SCr levels increase [270,271]. The limitations of SCr as a marker for kidney 
failure is further supported by the fact that SCr concentrations do not only depend on 
GFR, but also on tubular secretion and systemic production of creatinine, which is for 
instance affected by muscle wasting [270]. Thus, SCr is subjected to high interindividual 
variability and is not suitable for early and site-specific detection of kidney injury. Reasoning 
from the notion that (1) CKD is synonymous with uremic retention solutes and (2) a 
number of studies, including the research described in Chapters 2-4, have demonstrated 
that plasma levels of multiple uremic toxins, e.g. indole-3-acetic acid, hippuric acid and 
indoxyl sulfate, are significantly elevated in non-dialysis CKD patients [96,272], we 
investigated in a preliminary study whether uremic toxins levels may predict the rate of 
eGFR decrease in CKD patients. To this end, we determined baseline concentrations of 
several uremic toxins, using HPLC and LC-MS/MS, in serum samples of patients that 
participated in the MASTERPLAN trial [273]. Cases were rapid progressors, i.e. patients with 
decline of eGFR > -4.5 ml/min/1.73m2/year, and as controls we selected patients with a 
lower rate of progression matched for baseline eGFR. In total, 27 cases and 65 controls 
were included, of whom 43 were slow progressors (decline 4.5 to 1.0 ml/min/1.73m2/year) 
and 22 stable patients (decline < 1 ml/min/1.73m2/year). Mean age in the selected patients 
was 59 ± 13 years and 67% was male. Most patients had moderate CKD with a mean eGFR 
of 37 ± 12 ml/min/1.73m2 and received blood pressure lowering drugs (96%), and ACE 
Figure 2    Absence of an association between baseline uremic toxin levels and eGFR 
decrease. 
A multiple adjusted linear regression analysis between uremic toxin concentration and change in 
eGFR was created. The model included baseline eGFR, proteinuria, blood pressure, age and gender. 
Dots represent regression coefficient (i.e. eGFR decline per unit of the solute) with the 95% 
confidence interval. HA, hippuric acid; I3A, indole-3-acetic acid; IS, indoxyl sulfate; Kyn, kynurenine; 
KynA, kynurenic acid; pCG, p-cresyl glucuronide; pCS, p-cresyl sulfate.
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reduce uremic retention solute levels. AST-120, an oral charcoal adsorbent, has been 
demonstrated to reduce plasma levels of uremic solutes, including p-cresyl sufate, indoxyl 
sulfate and hippuric acid [275], and is suggested to reduce a number of comorbidities 
associated with CKD such as atherosclerosis [276-279]. However, the beneficial impact of 
AST-120 still needs to be studied in large clinical trials. Other potential suppressive 
therapies include dietary and probiotic treatments. Several small intervention studies 
(n<30) have demonstrated that preparations with lactic acid bacilli and Bifidobacterium 
longum reduce serum levels of indoxyl sulfate with 9-30% [93,280-282]. Yet, studies on the 
impact of probiotics on hard clinical end points (e.g. mortality) in CKD patients have not 
been performed to date.  
Finally, there is much attention for the risk that CKD possess for cardiovascular mortality 
and morbidity [283], yet little effort is made to elucidate the kidney-brain axis [284]. Several 
known uremic toxins, e.g. kynurenic acid and quinolinic acid, have neuroactive properties 
and can modulate the activity of important receptors in the brain, including the α7-
nicotinic-acetylcholine (α7nAch)- and the N-methyl-d-aspartate (NMDA) receptor. 
Recently, we demonstrated that kynurenic acid concentration-dependently increased 
glucose uptake by malignant neuroblastoma (N2a) cells, and we unveiled a link between 
BCRP and kynurenic acid transport with brain energy metabolism, indicating that the 
efflux pump is an interesting therapeutic target to modulate cerebral glucose and 
kynurenic acid levels (Dankers et al. unpublished data). This exciting observation warrants 
further investigation into uremic toxin-induced neuronal dysfunction as well as 
CKD-associated cognitive impairment and neuropathy.
The results within this thesis expanded the currently known universe of uremic solutes by 
implementing and improving both targeted and untargeted analytical techniques. 
Furthermore, a multitude of uremic solutes, irrespective of the source of origin, were 
demonstrated to negatively influence numerous physiological processes and phenotypic 
characteristics that define the healthy renal proximal tubule cell. Moreover, we shed a light 
on the essential role of efflux transporters in the renal extrusion of uremic solutes, laying 
the foundation for future studies aiming to utilize these pumps to suppress or halt CKD 
progression and associated pathologies. 
renal handling of uremic solutes, and we demonstrated that inactivity of these ABC-trans-
porters directly results in accumulation of several potential toxic metabolites. In addition, 
the nephrotoxic actions of multiple uremic retention solutes were elucidated using a 
unique proximal tubular cell model, identifying diverse targets affected by these 
compounds, including mitochondria, drug metabolism enzymes and transporters.  Since 
dialysis is inapt in removing uremic solutes from the circulation, harnessing the ability of 
transporters to clear these metabolites might prove to be the long coveted therapeutic 
modality needed to improve clinical outcomes for CKD patients. Recently, Toyohara and 
coworkers demonstrated that statins could be used to increase the expression of OATP4C1 
and improve renal uremic toxin clearance [60]. However, ‘therapeutic manipulation’ of 
transporters, while intriguing, should be approached with caution. It is conceivable that 
upregulation of uptake transporter expression might ensue improved uremic toxin 
clearance. Yet, it could also result in increased renal proximal tubule cell death from toxic 
exposure. Therefore, it is key to simultaneously target both basolateral and apically 
expressed transporters in order to maintain the perfect, and delicate, balance between 
cellular uptake and efflux. An alternative might be employing “living dialysis membranes” 
consisting of bioreactors containing stem cell derived, and possibly patient specific, trans-
porter-expressing cells to better mimic normal renal function and improve therapy 
efficacy. In our lab, first steps have been undertaken to realize a bio-artificial kidney (BioKid) 
device using a unique and stable proximal tubule cell model, i.e. ciPTEC. This cell line has 
been established from cells exfoliated in the urine from a healthy volunteer. ciPTEC have 
been demonstrated to maintain proximal tubular characteristics, including expression of 
important in- and efflux transporters as well as megalin-mediated albumin uptake and 
sodium-dependent phosphate transport, over a prolonged period of cell culturing [98]. 
Moreover, ciPTEC can be used to study nephrotoxicity as shown by their sensitivity to 
gentamicin [101], and OCT-mediated organic cation transport [78]. Moreover, using a 
similar immortalization approach, our group was able to create ciPTEC from renal tissue 
(ciPTEC-T; Jansen et al., unpublished data). This novel model showed an analogous 
expression and activity profile as compared to ciPTEC. Of note, ciPTEC-T appeared to have 
retained the ability to create their own extracellular matrix, illustrated by increased gene 
expression levels of collagen I and –IV α1. Unfortunately, both ciPTEC and ciPTEC-T lack the 
important influx transporters OAT1 and OAT3 on gene, protein and functional level. 
Clearly, there is still much ground for the transporter field to cover, but the very fact that 
BioKid concepts are being discussed and practically achievable [274], foreshadows some 
exciting times to come.     
Progress can also be made in reducing the exogenous intake of uremic toxins as well as 
the diminishing the production of uremic solutes by the intestinal flora. Aronov et al. 
recently reported that in plasma of dialysis patients without a colon several uremic toxins 
were absent or present at lower concentrations compared to patients with a colon [92]. 
This finding underlines the notion that the gut is an important therapeutic target to 
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SUMMARY
A hallmark of chronic kidney disease (CKD) is the retention and subsequent accumulation 
of a myriad of chemically diverse metabolites that are normally cleared by the healthy 
kidney. These uremic retention solutes likely contribute to the complex pathophysiology 
that epitomizes uremic illness. In this thesis we strived to gain more insight on the 
multitude of uremic retention solutes along with the possible detrimental impact of these 
solutes on renal proximal tubule cells. 
To obtain more knowledge about the multitude of uremic solutes retained during CKD 
we studied the metabolic status of non-dialysis stage 3-4 CKD patients using non-targeted 
1H-nuclear magnetic resonance (NMR) spectroscopy, following three distinct deprotein-
ization strategies (e.g. ultrafiltration, protein precipitation via perchloric acid or via 
acetonitrile extraction). Our results demonstrated that both ultrafiltration and acetonitrile 
extraction are required as deproteinization methods to obtain a clear metabolome profile. 
Using this approach we revealed that a total of 14 metabolites accumulated in uremic 
plasma. Next to confirming the retention of several previously identified uremic toxins, 
including p-cresyl sulfate, two novel uremic retentions solutes were detected, namely 
dimethyl sulphone (DMSO2) and 2-hydroxyisobutyric acid (2-HIBA). Furthermore, we 
showed that exposure of the human renal proximal tubule cell line (ciPTEC) to either 
DMSO2 or 2-HIBA negatively impacted the epithelial characteristics of the cells, illustrated 
by an increased expression of the mesenchymal marker vimentin and a loss of glucuroni-
dation activity, without affecting cell viability. These results indicate that NMR is a useful 
tool in the search for CKD biomarkers and revealed new solutes that may contribute to the 
progression of renal disease. 
The renal proximal tubule is equipped with a multiplicity of transporters involved in the 
active clearance of endo- and xenobiotics, yet the contribution of this transport system to 
the secretion of uremic solutes is for a part still unknown. In chapter 3, we studied the 
interaction between several uremic toxins and two important efflux pumps present at the 
apical membrane of the proximal tubule, namely multidrug resistance protein 4 (MRP4) 
and breast cancer resistance protein (BCRP). Furthermore, the concentrations of various 
uremic toxins were determined in plasma of CKD patients, treated with dialysis, via high 
performance liquid chromatography and liquid chromatography/tandem mass 
spectrometry. Using membrane vesicles isolated from MRP4- or BCRP-overexpressing 
human embryonic kidney cells, we demonstrated that hippuric acid, indoxyl sulfate and 
kynurenic acid inhibited substrate specific uptake by both MRP4 and BCRP, whereas in-
dole-3-acetic acid and phenylacetic acid only reduced transport mediated by MRP4. 
Moreover, the calculated inhibition constant (Ki) values, i.e. the concentration needed to 
inhibit 50% of the transport activity, are in general lower than the maximal plasma 
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kynurenic acid, reduced UGT activity, as demonstrated by a diminished glucuronidation of 
7-hydroxycoumarin, without affecting UGT1A and UGT2B protein expression. In addition, 
several uremic toxins inhibited mitochondrial succinate dehydrogenase activity, and in-
dole-3-acetic acid reduced the reserve capacity of the energy-generating oxidative phos-
phorylation system. These results present a novel pathway via which uremic retention 
solutes affect the metabolic capacity of the kidney and are likely involved in altering drug 
metabolism during CKD.
Taken together, the results delineated in this thesis have improved our knowledge of the 
uremic metabolome and the nephrotoxic effects of multiple uremic retention solutes. 
This body of work provides essential and new insights required to advance our 
understanding of CKD, and paves the way for future research plus deliver leads for novel 
therapies. 
concentrations of the tested toxins in CKD patients. These results depict that uremic toxins 
can impede kidney excretory function and subsequently contribute to the accumulation 
of uremic solutes.
Recently, the two p-cresol metabolites, p-cresyl sulfate (pCS) and p-cresyl glucuronide 
(pCG), have gained much attention from the scientific community as key uremic toxins, 
yet how they are handled by the kidney and their nephrotoxic potential remain unknown. 
In chapter 4, we demonstrated that pCS inhibited both MRP4- and BCRP-mediated 
transport, whereas pCG solely mitigated transport by MRP4. In addition, exposure of 
ciPTEC to pCG had a pronounced effect on ciPTEC physiology as illustrated by an increased 
expression of vimentin, Bcl-2 and BCRP, while the expression of the organic anion 
transporting polypeptide 4C1 decreased. Of note, pCS did neither influence the protein 
expression of vimentin nor the gene expression of the studied transporters. Moreover, the 
biomarkers kidney injury molecule-1 and vanin-1 revealed that both pCS and pCG did not 
induce tubular damage. These findings indicate that MRP4 and BCRP are likely involved in 
the renal excretion of both solutes and that the two p -cresol conjugates have a different 
impact on renal proximal tubule cells. 
In chapter 5, we tried to unveil whether uremic retention solutes are solely a consequence 
of CKD or if they can instigate metabolite accumulation. Using the membrane vesicle 
transport assay, we revealed that the well-known uremic toxin, uric acid, inhibited 
BCRP-mediated transport at levels also reported in patients with hyperuricemia, as was 
previously shown for MRP4. In addition, we identified kynurenic acid as a novel substrate 
for MRP4 and BCRP. Moreover, using mouse models, we demonstrated that Mrp4- and 
Bcrp-deficiency as well as hyperuricemia, in the absence of renal failure, are associated 
with alterations in tryptophan metabolism and the retention of the widely biologically 
active compounds kynurenine and kynurenic acid. These results suggest that elevated 
uric acid levels impede MRP4 and BCRP functioning, thereby promoting the retention of 
other potentially harmful substrates, such as kynurenic acid. These findings underline the 
complex relation between hyperuricemia and its pathologies as well as hinting at the 
tantalizing notion that uremic solutes, by stimulating metabolite retention, might be one 
of the culprits in CKD development. 
 
Next to the accumulation of uremic solutes, CKD is also characterized by altered drug 
metabolism, partially due to a decline in glomerular filtration and tubular secretion. 
However, the direct impact of uremic solutes on the activity of drug metabolism enzymes 
is largely unknown. In chapter 6, we describe the interaction between a multiplicity of 
uremic solutes with an important class of phase II enzymes, namely UDP-glucuronosyl-
transferases (UGT), and the mitochondria. Our results demonstrated that a wide variety of 
uremic toxins, including indole-3-acetic acid, indoxyl sulfate, phenylacetic acid and 
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SAMENVATTING
Chronische nierinsufficiëntie (CKD) wordt gekenmerkt door een verminderde uitscheiding 
en dientengevolge stapeling van verscheidene metabolieten. Deze zogenoemde 
uremische toxines leveren hoogstwaarschijnlijk een belangrijke bijdrage aan het complexe 
ziektebeeld dat typerend is voor het uremisch syndroom. In dit proefschrift streefden wij 
ernaar om meer inzicht te verkrijgen in de grote verscheidenheid aan uremische toxines 
en de mogelijke schadelijke invloed van deze stoffen op de cellen van de proximale 
tubulus.     
Om de stapeling van metabolieten tijdens chronische nierinsufficiëntie beter te begrijpen, 
hebben wij met behulp van proton-nucleair-magnetische resonantie (NMR; of H-1-kern-
spinresonantie) spectroscopie de metabole status van stadium 3-4 chronische 
nierpatiënten bestudeerd. Hiervoor hebben we door middel van ultrafiltratie of door de 
toevoeging van perchloorzuur of acetonitril het plasma ontdaan van eiwitten. Onze 
resultaten wijzen uit dat zowel ultrafiltratie als acetonitrilextractie nodig zijn om een 
compleet metaboliet profiel te verkrijgen. Op deze wijze hebben wij aangetoond dat een 
totaal van 14 metabolieten stapelen gedurende uremie. Naast het detecteren van al 
bekende uremische toxines, zoals para-cresolsulfaat, hebben wij twee tot dan toe 
onbekende uremische toxines kunnen identificeren, te weten dimethylsulfon (DMSO2) en 
2-hydroxyisoboterzuur (2-HIBA). Bovendien hebben wij bewezen dat beide stoffen een 
negatieve invloed hadden op het fenotype en de functionaliteit van de humane proximale 
tubulus cellijn (ciPTEC), zonder celdood te induceren. Deze resultaten beschrijven dat 
NMR spectroscopie een zeer nuttige techniek is in de zoektocht naar nieuwe biomarkers 
van chronische nierinsufficiëntie alsmede in de ontdekking van nieuwe metabolieten die 
wellicht een bijdrage leveren aan het verslechteren van de nierfunctie.           
De proximale tubuluscel van de nier is uitgerust met een breed scala aan transporteiwit-
ten die zorgdragen voor de actieve uitscheiding van zowel lichaamseigen als lichaams-
vreemde stoffen in de urine. Toch is het aandeel van de verschillende transporteiwitten in 
de klaring van uremische toxines nog voor een groot deel onbekend. In hoofdstuk 3 laten 
we zien dat verscheidene uremische toxines een interactie aangaan met twee belangrijke 
effluxpompen, MRP4 en BCRP, die normaliter aanwezig zijn op de apicale membraan van 
de proximale tubulus. Daarnaast hebben we de concentratie van een aantal uremische 
toxines bepaald in het plasma van dialysepatiënten door middel van vloeistofchromato-
grafie onder hoge druk (HPLC) en een combinatie van vloeistofchromatografie en massa-
spectrometrie (LC-MS/MS). Door gebruik te maken van membraanvesikels, vervaardigd 
van cellen die MRP4 of BCRP tot overexpressie brachten, hebben we aangetoond dat 
hippuurzuur, indoxylsulfaat en kynureninezuur een remmend effect hebben op de 
activiteit van beide transporters. Daarentegen hadden indool-3-azijnzuur en fenylazijnzuur 
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ze de hypothese dat uremische toxines mogelijk ook een bijdrage kunnen leveren aan het 
ontstaan van chronische nierinsufficiëntie.    
   
Naast de stapeling van uremische toxines wordt chronische nierinsufficiëntie ook 
gekenmerkt door veranderingen in het metabolisme van medicijnen. Deels is dit te 
verklaren door een veranderde enzym expressie in de lever alsmede afname in 
glomerulaire filtratie en actieve tubulaire secretie. Maar het is goed voor te stellen dat 
uremische toxines ook een directe bijdrage kunnen leveren aan dit fenomeen, door de 
functionaliteit van enzymen, welke essentieel zijn voor afbraak van farmaca, te verstoren. 
Het onderzoek beschreven in hoofdstuk 6 geeft weer dat een veelvoud aan uremische 
toxines, waaronder indool-3-azijnzuur, indoxylsulfaat en kynureninezuur een remmend 
effect hebben op de activiteit van UDP-glucuronosyltransferases (UGT), een belangrijke 
groep van enzymen die fase II reacties, oftewel conjugatiereacties, katalyseren. Dit effect 
werd waargenomen zonder verandering in de UGT eiwitexpressie, hetgeen suggereert 
dat uremische toxines UGT activiteit op een indirecte manier beïnvloeden. Daarnaast 
hadden meerdere uremische toxines een negatief effect op de activiteit van mitochondri-
aal-succinaatdehydrogenase, en indool-3-azijnzuur verminderde de reservecapaciteit van 
de oxidatieve fosforylatie, essentiële onderdelen van de cellulaire energiehuishouding. 
Samengevat belichten deze resultaten een nieuwe wijze waarop uremische toxines het 
niermetabolisme kunnen ontregelen en op die manier de farmacokinetiek kunnen 
verstoren in chronische nierpatiënten.         
Concluderend draagt dit proefschrift bij aan het uitbreiden van onze kennis betreffende 
de metabolieten die accumuleren tijdens chronische nierinsufficiëntie en laat het zien op 
welke wijze uremische toxines schadelijk kunnen zijn voor nierpatiënten. Dit verhoogde 
inzicht in het uremisch syndroom legt een goede fundering voor toekomstig onderzoek 
naar chronische nierinsufficiëntie.   
alleen een remmende werking op de activiteit van MRP4. Bovendien zagen we dat het 
verslechteren van de transportfunctie al plaats vond bij concentraties van uremische 
toxines die te meten zijn in dialysepatiënten. Deze resultaten laten zien dat uremische 
toxines een direct effect hebben op de pompfunctie van MRP4 en BCRP die nodig is voor 
het ontgiften van bloed en zodoende een bijdrage kunnen leveren aan de progressieve, 
steeds ernstigere nierproblemen.        
Recentelijk hebben de twee metabolieten van para-cresol, para-cresolsulfaat (pCS) en 
para-cresolglucuronide (pCG), als prominente spelers in het uremisch syndroom veel 
aandacht gekregen van de wetenschappelijke gemeenschap. Desondanks is er nog niet 
veel bekend over de normale renale klaring van beide stoffen en ook de nefrotoxiciteit 
van pCS en pCG is tot op heden grotendeels onbekend. In hoofdstuk 4 beschrijven we dat 
pCS de activiteit van MRP4 en BCRP remt, terwijl pCG alleen een remmend effect heeft op 
MRP4-gemedieerd transport. Daarnaast bleek uit onze experimenten dat pCG een 
negatief effect had op de epitheliale kenmerken van ciPTEC, aangetoond door een 
toename in de expressie van vimentine (een eiwit kenmerkend voor fibroblasten maar 
niet voor epitheliale cellen, zoals ciPTEC), Bcl-2 (een anti-apoptose gen) en de pomp BCRP, 
en een verminderde expressie van de basolaterale transporteur OATP4C1. Dit in 
tegenstelling tot pCS, welke geheel geen invloed had op deze karakteristieken van ciPTEC. 
Voorts werd ook duidelijk dat beide metabolieten van para-cresol geen directe schade 
veroorzaakten aan ciPTEC. Samengevat suggereren deze bevindingen dat MRP4 en BCRP 
hoogstwaarschijnlijk betrokken zijn bij de uitscheiding van pCS en pCG in de nier en dat 
beiden een verschillend effect hebben op het fenotype van proximale tubuluscellen.  
In hoofdstuk 5, hebben we bestudeerd of uremische toxines slechts een product zijn van 
chronische nierinsufficiëntie of dat ze ook de accumulatie van metabolieten kunnen 
veroorzaken. Urinezuur, een afbraakproduct van purines, is een bekende uremische 
toxine maar de bloedspiegels van deze metaboliet zijn ook verhoogd in patiënten met 
hyperuricemie. Middels de eerder beschreven membraan vesikel transport test hebben 
we laten zien dat urinezuur de transportactiviteit van BCRP kan remmen. Dat gebeurt al 
bij concentraties die we ook waarnemen in patiënten met hyperuricemie. Hetzelfde is 
eerder al beschreven voor MRP4. Voorts maakten onze experimenten ook duidelijk dat 
kynureninezuur een substraat is voor zowel MRP4 als BCRP. Verder hebben we via 
muismodellen bewezen dat de afwezigheid van MRP4 of BCRP alsook hyperuricemie (in 
afwezigheid van nierschade) kan leiden tot veranderingen in tryptofaanmetabolisme en 
de accumulatie van kynurenine plus kynureninezuur. Deze bevindingen lijken erop te 
duiden dat verhoogde spiegels van urinezuur het functioneren van MRP4 en BCRP 
belemmert en zodoende de retentie van andere potentieel toxische stoffen, zoals 
bijvoorbeeld kynureninezuur, bevordert. Verder illustreren deze resultaten de complexe 
relatie tussen hyperuricemie en daarmee geassocieerde ziektebeelden, en ondersteunen 
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